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1 Summary 
 
 
Group 3 innate lymphoid cells (ILC3s) play decisive roles in mammalian physiology 
including lymphoid tissue development, tissue repair and immune regulation. So far, 
the functions of ILC3s in the adult immune system have been mainly linked to their 
capacity to release cytokines in response to microbial or inflammatory signals. It 
could be demonstrated that ILC3s are indispensable for protective immunity against 
the mouse intestinal pathogen Citrobacter rodentium by the early production of IL-22 
in response to IL-23 secreted mainly by dendritic cells (DCs) upon microbial 
exposure. However, whether ILC3s are able to directly sense and respond to the 
presence of pathogens thereby contributing to innate immunity is not yet known. 
Furthermore, whether these cells are capable to interact with cells of the adaptive 
immune system to meaningfully regulate adaptive immune responses has to be 
explored.  
In the present study, I could show that ILC3s directly responded to microbial products 
such as the Toll-like receptor (TLR) ligands CpG and Poly I:C in vitro. They up-
regulated the surface expression of the early activation marker CD69 and secreted 
IL-22, a cytokine known for its protective immune function in the mucosa. 
Additionally, I could demonstrate that in vivo challenge with TLR ligands CpG and 
LPS was able to induce ILC3 activation in vivo. Furthermore, ILC3s produced high 
amounts of IL-17 and IL-22 upon exposure to the pro-inflammatory cytokine IL-1β. IL-
1β emerged as a strong activator of ILC3s as its presence induced the production of 
a broad range of cytokines by ILC3s. Altogether, the response of ILC3s varied 
depending on the nature of innate stimuli. 
In addition, I could demonstrate that upon IL-1β exposure, peripheral ILC3s up-
regulated the expression of surface major histocompatibility complex class II (MHC 
II) molecules and expressed co-stimulatory molecules reminiscent of an antigen-
presenting cell-like phenotype. Further, I found that ILC3s could take up latex beads, 
process protein antigen (Ag) and consequently prime CD4+ T cell responses in vitro. 
The cognate interaction of ILC3s and CD4+ T cells led to T cell proliferation both in 
vitro and in vivo. By using a mouse model with MHC II deficiency exclusively in ILC3s 
I could demonstrate that the disruption of Ag-dependent interaction of ILC3s and 
CD4+ T cells impaired specific T cell and T-dependent B cell responses in vivo. In 
addition, I found that IL-1β-activated peripheral ILC3s were more efficient than non-
activated ILC3s in the induction of CD4+ T cell responses. ILC3-CD4+ T cell 
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interactions turned out to be bidirectional and led to the activation of ILC3s. The 
activating feedback loop of CD4+ T cells to ILC3s was most likely mediated by 
soluble factors produced by CD4+ T cells upon Ag encounter. Taken together, my 
data reveal an activation-dependent function of peripheral ILC3s in eliciting cognate 
CD4+ T cell immune responses, ascribing to them a novel function in adaptive 
immunity.  
Finally, I found that small intestinal ILC3s and peripheral ILC3s differed from each 
other in regard to their phenotype, responsiveness to IL-1β and immune function. In 
contrast to peripheral ILC3s, small intestinal ILC3s expressed high levels of CD69 on 
their surface suggesting an activated phenotype. I could show that CD69 expression 
was independent of TLR- and IL-1R signaling, the presence of T and B cells, or the 
microbiota as well as the availability of IL-23. In addition, small intestinal ILC3s were 
not able to increase the expression of MHC II molecules and to express co-
stimulatory molecules upon IL-1β exposure. Although they were able to take up latex 
beads and to process exogenous Ag, they were far less efficient in CD4+ T cell 
activation than peripheral ILC3s. However, they were capable to produce high 
amounts of IL-22 in response to IL-1β stimulation. Taken together, these data 
suggest that the immune functions of ILC3s are tissue specific and might be 
regulated by environmental factors and/or interactions with tissue-specific cells. 
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2 Introduction 
 
2.1 Innate and adaptive immunity 	  
Humans are daily exposed to a variety of bacteria, viruses, fungi and parasites. Our 
body has to be protected from all these infectious agents by the highly organized and 
regulated work of our immune system. To fulfill this difficult task, the immune system 
has established two different branches, first, the innate immunity and second, the 
adaptive immunity. The perfect interplay of both of these parts is required to get rid of 
invading pathogens and to clear ongoing infections.  
The innate immunity serves as a first line of defense. It is composed of soluble 
factors (e.g. complement system) and cells that express so-called pattern recognition 
receptors (PRRs). These germ-line encoded invariant PRRs are able to recognize 
molecules and regular patterns that are characteristic components of pathogenic 
microorganisms, known as pathogen associated molecular patterns (PAMPs). 
PAMPs are present in many microorganisms but not in the body`s own cells 
providing already an initial discrimination between self and non-self.   
The prototypes of PRRs are so-called Toll-like receptors (TLRs; see chapter 2.3.1 
TLR ligands induce early immune responses). The innate immune system mainly 
contains phagocytic cells like macrophages (MΦ) and neutrophils able to engulf 
pathogens, to digest and destroy them in intracellular vesicles by the production of 
degradative enzymes and antimicrobial substances. Natural killer (NK) cells are an 
additional tool of the innate branch of the immune system. These cells are able to 
recognize molecules on virus-infected and malignantly-transformed cells via germ-
line encoded receptors in order to kill these target cells. Upon recognition of the 
target cell, NK cells release cytotoxic granzymes and the pore forming protein 
perforin from their cytoplasmic granules penetrating the cell membrane of the target 
cell and inducing programmed-cell death (see chapter 2.2.1 Group 1 ILCs). In 
response to an infectious agent, innate immune cells produce a variety of cytokines 
and chemokines inducing a process known as inflammation. The induction of an 
inflammation can be beneficial, as released cytokines and chemokines attract 
additional effector molecules and immune cells from the blood to the site of infection.  
The response of the innate branch of the immune system is extremely fast (within 
hours) and immediately induced after the recognition of an infectious agent. 
However, innate defenses are not highly specific and cannot lead to immunological 
memory, a hallmark of the adaptive immunity. 
	   8 
In contrast to innate immune cells, cells of the adaptive immune system are able to 
recognize pathogens with high specificity by the expression of antigen (Ag)-specific 
receptors. Thereby, adaptive immune cells can eliminate those pathogens, which 
managed to overcome innate immunity. Furthermore, a unique feature of the 
adaptive immunity is the generation of immunological memory providing faster and 
enhanced protection against re-infections. The key components of the adaptive 
branch of the immune system are B and T lymphocytes, which develop in the primary 
lymphoid organs bone marrow (BM) and thymus, respectively. B cells recognize 
native Ags from the extracellular environment and consequently secrete antibodies 
(Abs) promoting the killing of extracellular pathogens (humoral immune response) 
while T cells are specialized to kill target cells infected with intracellular pathogens or 
viruses (cytotoxic T cells) and to support the humoral immune response (T helper 
(Th) cells). T cells only recognize Ag-derived peptides, which are presented to them 
in context of the major histocompatibility complex (MHC) expressed by Ag-presenting 
cells (APCs; see chapter 2.4.1 Processing and presentation of Ag to CD4+ T cells). 
Each lymphocyte of the adaptive immune system bears a unique variant of a 
receptor on its surface, which is generated by random recombination of variable 
receptor gene segments and the pairing of distinct variable chains. Thus, the whole 
population of lymphocytes expresses an enormous repertoire of different receptors 
with highly diverse Ag recognition sites allowing the specific recognition of a wide 
variety of different pathogens. Clonal selection and subsequent expansion of the 
lymphocyte carrying the specific Ag-receptor for the invading pathogen is required for 
complete elimination of the pathogen. Hence, the adaptive immunity is characterized 
by its high specificity but requires some time (up to days) to become fully 
established. Further, adaptive immunity is able to generate immunological memory.1,2 
 
2.2 The family of innate lymphoid cells  
 
Innate lymphoid cells (ILCs) are the most recently identified constituents of the innate 
immune system and represent a novel family of hematopoietic effector cells. In 
recent years, the family of ILCs has continuously grown and several different cell 
types with unique effector functions are identified. Previously, it was believed that 
innate lymphocytes are represented by a single lymphoid lineage, the natural killer 
(NK) cells. Nowadays, several different innate lymphocytes are described and 
referred in general to as innate lymphoid cells (ILCs).  
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All members of the ILC family are characterized by a classical lymphoid morphology 
and the lack of recombination activating gene (Rag)-dependent rearranged Ag 
receptors. In addition, all of them lack the expression of cell surface molecules that 
identify other immune cells and are therefore characterized as cell lineage marker 
negative (lin-) cells.3 Furthermore, all ILCs depend on the expression of the common 
cytokine receptor γ chain (γc chain) and the transcriptional repressor inhibitor of DNA 
binding 2 (Id2) for their development.3, 4 The different members of the ILC family are 
found to play crucial roles in the development of lymphoid tissues, tissue repair and 
wound healing after injury. They have been reported to regulate commensal bacterial 
communities, to promote inflammation, to contribute to the resistance to helminthes 
and bacterial pathogens and to be important for maintenance of organ homeostasis. 
Extensive research in the past few years has led to the discovery of an 
unprecedented complexity in the innate lymphocyte lineages collectively referred as 
ILCs. Therefore, three broad categories of ILCs have been defined based on the 
expression of different transcription factors and the distinct pattern of effector 
molecules these cells secrete; i) group 1 ILCs, ii) group 2 ILCs and iii) group 3 ILCs 
(Fig. 1).3  
Group 1 ILCs are composed of conventional NK cells and a second subset named 
ILC1s. Cells within the group 1 ILCs are characterized by their dependency on the T-
box transcription factor T-bet and the production of interferon (IFN)-γ, thereby 
resembling T helper type 1 (Th1) cells. Group 2 ILCs produce Th2 related cytokines 
such as interleukin (IL)-4, IL-5, and IL-13 and are involved in anti-helminth immunity 
and the development of allergic diseases such as asthma. So far, within the group 2 
ILCs only one cell type, the ILC2, is described. The development of ILC2s depends 
on the transcription factors retinoic acid related orphan receptor (ROR)-α and Gata3. 
Group 3 ILCs are identified as the producer of Th17-related cytokines IL-17A, IL17F 
and IL-22. All subsets within this group depend on the transcription factor RORγt. 
The group 3 ILCs are composed of the classical lymphoid tissue inducer cells (LTi 
cells) responsible for lymphoid organogenesis during embryogenesis and in 
neonates and two other populations with a similar phenotype discovered in adults. 
Adult ILC3s either express the natural cytotoxicity receptor (NCR) NKp46 or are 
negative for this molecule. NCR+ILC3s lack the expression of CD4 whereas within 
the NCR-ILC3s a CD4+ and CD4- subpopulation exists. NCR+ILC3s mainly produce 
IL-22 and contribute to immunity against intestinal bacteria. NCR-ILC3s lacking the 
expression of NKp46 are able to secrete IL-17 and IL-22, and under certain 
conditions also IFNγ.  
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Since, the transcriptional and effector program of the various ILC populations 
resembles those of T helper (Th) cells, ILCs are believed to be the innate 
counterparts of the adaptive Th cells. 
  
	  
Figure 1:	   Family of innate lymphoid cells. Simplified illustration of the members of the 
innate lymphoid cell family, their developmental requirements and cytokine production 
profiles. AhR: aryl hydrocarbon receptor; ROR: retinoic acid related orphan receptor; SCF: 
stem cell factor; TCF-1:  T cell factor 1; TSLP: thymic stromal lymphopoietin. Adapted from 
Spits et al., Nature Review (2013)3 and Artis et al., Nature (2015).5 
 
 Group 1 ILCs 2.2.1
 
Natural killer cells 
The first described subset of group 1 ILCs are NK cells. NK cells have been first 
identified in 1975 as innate effector lymphocytes exhibiting cytotoxic activity against 
tumor cells.6, 7 Later, NK cells have been found to be important during viral 
infections.8 Mature NK cells can be found in different tissues such as spleen, lymph 
nodes (LNs), liver, lung, skin and blood. They express several different germline 
encoded activating receptors such as NKp46 (also known as NCR1, natural 
cytotoxicity triggering receptor 1) and NK1.1 as well as inhibitory receptors (e.g. 
Ly49) on their surface. The cytotoxicity of NK cells is regulated by the net signaling of 
these activating and inhibitory receptors9 and the cytotoxic activity of NK cells is 
exhibited via a variety of effector molecules such as perforin, granzymes, Fas ligand 
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(FasL) and TNF-related apoptosis inducing ligand (TRAIL) inducing apoptosis.10, 11 
Hence NK cells are crucial for the defense against viral infections and tumors and the 
amplification of inflammatory responses through the induction of TNFα and high 
levels of IFNγ production. 
Conventional NK cells differentiate from the common lymphoid progenitor (CLP) in 
the BM and their development requires the transcription factor E4BP4 (also known 
as NFIL3, nuclear factor IL-3)12, 13 and the cytokine IL-15.14, 15, 16 NK cells co-express 
the T-box transcription factors eomesodermin (Eomes) and T-bet, which cooperate in 
the regulation of the development, maturation and function of NK cells.17 Although 
NK cells are the only cytotoxic innate lymphocytes of the ILC family, these cells are 
classified within the group 1 ILCs based on the expression of T-bet and the 
production of IFNγ.  
 
ILC1s 
So far, ILC1s within the group 1 ILCs are not well defined and characterized. To 
date, under the term ILC1 several different cell types are described. ILC1s are 
currently believed to be either intraepithelial ILC1s18 or so called “ex-RORγt+” 
ILC3s.19, 20, 21 Very recently, another distinct ILC1 cell type has been discovered in 
the small intestine.22  
Intraepithelial ILC1s are first discovered in human tonsils and small intestine as cells 
expressing transcription factors Eomes and T-bet, and NK cell surface molecule 
NKp44 whereas they lack expression of the transcription factors RORγt and aryl 
hydrocarbon receptor (AhR), which both are crucial for ILC3 development.18 In 
addition, intraepithelial ILC1s express intraepithelial lymphocyte markers CD103, 
CD101 and CD160 and a specific integrin repertoire (e.g. β7 integrin, CD49a) 
allowing their intraepithelial localization. Further, intraepithelial ILC1s produce IFNγ in 
response to IL-12 and IL-15 stimulation in vitro while lacking IL-22 production. These 
findings clearly separate intraepithelial ILC1s from ILC3s. Interestingly, some of the 
intraepithelial ILC1s contain intracellular perforin and granzyme and exhibit lytic 
activity in presence of a tumor cell line.18 The murine counterparts of human 
intraepithelial ILC1s have been identified as cells expressing NKp46 and NK1.1 as 
well as CD160 distinguishing them from murine splenic NK cells, which do not 
express CD160 at steady state. Murine intraepithelial ILC1s produce IFNγ in 
response to IL-12 and IL-15 in vitro mirroring the human ILC1 response.18 
Intraepithelial ILC1s are present in RORγt-deficient (RORγ-/-) and in AhR-deficient 
(AhR-/-) mice, both lacking ILC3s, but in contrast, they are absent in mice deficient in 
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T-bet or NFIL3, two transcription factors previously shown to be master regulators of 
NK cell development.17, 23 This suggests a developmental relationship rather between 
intraepithelial ILC1s and conventional NK cells than between ILC1s and ILC3s. 
However, analysis of IL-15-receptor-α-chain-deficient (IL-15Rα-/-) mice does not 
support this idea. IL-15Rα-/- mice show a complete absence of splenic NK cells24 
whereas intraepithelial ILC1s are minimally affected by the lack of IL-15Rα 
suggesting that intraepithelial ILC1s are a unique ILC1 cell subset distinct from 
conventional NK cells.18 
In RORγt-fate map mice, generated by crossing mice expressing Cre recombinase 
under the control of the Rorc promotor (Rorc(γt)-Cretg mice)25 with Rosa26-reporter 
mice (R26R-EYFP)26, all cells derived from RORγt+ precursors are heritably and 
permanently labeled by the enhanced yellow fluorescence protein (EYFP)-reporter, 
even when they loose RORγt expression over further development. By following 
small intestine-derived RORγt-fate map-positive (RORγtfm+) cells transferred into 
alymphoid mice, it could be shown that RORγt+NKp46+RORγtfm+ cells 
(RORγt+NKp46+ ILC3s) are able to develop into RORγt-NKp46+RORγtfm+ cells.19 
These RORγt-NKp46+RORγtfm+ cells have lost RORγt expression, however, they are 
originally derived from RORγt+ cells indicated by positive fate-map labeling 
(RORγtfm+). In vitro stimulation with different cytokine (e.g. IL-12 or IL-23) revealed 
that whereas RORγt+NKp46+RORγtfm+ ILC3s produce IL-22 and lack IFNγ production, 
the RORγt-NKp46+RORγtfm+ cells mainly secrete IFNγ while IL-22 production is 
missing.19 Therefore, RORγt-NKp46+RORγtfm+ cells are categorized as ILC1s but are 
most probably “ex-RORγt+” ILC3s. Additionally, these ex-RORγt+-ILC3-ILC1s have 
been suggested to be involved in the pathogenesis of anti-CD40 induced colitis by 
their massive production of IFNγ.19 
Another study has identified a cell type with ILC1 phenotype and high IFNγ 
production accumulating in the gut during dextran sodium sulfate (DSS) colitis in 
mice with a human immune system or in human patients with Crohn`s disease.20 
Originally, this ILC1 type of cell has been identified in human tonsils characterized by 
high levels of T-bet expression required for IFNγ production27 and low levels of 
RORγt expression suggesting that these cells are originally derived from ILC3s. 
Supporting this idea, it has been shown that these tonsil ILC1s are distinct from 
conventional NK cells as they lack perforin and granzyme B. In addition, they do not 
express NK cell markers CD94 and CD56 and lack the expression of the IL-15Rα 
chain of the IL-15R, which is essential for the development of NK cells.14 In patients 
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with Crohn`s disease the frequency of such ILC1s in the gut is significantly increased 
compared to controls without inflammatory bowel disease (IBD) and gut ILC1s 
express high levels of IFNγ.20 That these ILC1s might also be “ex-RORγt+” ILC3s is 
additionally supported by the fact that RORγt+ fetal gut-derived NKp44+ ILC3s are 
able to differentiate into ILC1s when cultured with IL-2 and IL-12 in vitro.  
The T-box transcription factor T-bet is a central regulator of type 1 immunity by 
controlling the expression of IFNγ.27, 28 Analysis of T-bet-deficient mice (Tbx21-/- 
mice)29 and adoptive transfer of RORγt+ ILCs into alymphoid mice could show that 
the acquisition of T-bet expression is required for RORγt+ ILCs to express NKp46 and 
to produce IFNγ.21 That T-bet expression is required for proper IFNγ production by 
ILCs has been as well described in a mouse model of ulcerative colitis (UC).30 In so-
called TRUC mice (Tbx21-/-Rag2-/- ulcerative colitis mice), which spontaneously 
develop IBD due to the lack of T-bet,31 ILCs mainly produce IL-17 promoting the 
disease whereas their IFNγ production is missing.30 A report from Klose et al. 
suggested that ex-RORγt+-ILC3-ILC1s develop from RORγt+ ILC3s, which expand 
after birth through AhR signals, up-regulate T-bet expression required for IFNγ 
production and simultaneously down-regulate RORγt expression.21 Such ex-RORγt+-
ILC3-ILC1s have been identified as the main IFNγ producer in an intestinal infection 
model of Salmonella typhimurium.21 IFNγ produced by these ILC1s in response to S. 
typhimurium infection has diverse roles. It has been shown to control the mucin 
release by goblet cells and thereby protecting the epithelial barrier, however, it is as 
well able to promote enterocolitis.21 
Recently, Klose et al. have identified another ILC1 cell type in the small intestine 
expressing the activating NK cell receptors NKp46 and NK1.1, and T-bet whereas 
the expression of Eomes and RORγt is absent.22 Studies using the RORγtfm mouse 
showed that these cells are RORγt-fate map negative (RORγtfm-) and therefore do not 
represent a subset of “ex-RORγt+” ILC3s.22 Transcriptome analysis of these ILC1s 
revealed that they have only low cytotoxic activity but, however, show high levels of 
IFNγ and TNF gene expression.22 In an intracellular infection model, in which mice 
are orally infected with the parasite Toxoplasma gondii, ILC1s have been identified 
as the main producer of IFNγ and TNF promoting the control of parasite replication. 
Furthermore, adoptive transfer of ILC1s into alymphoid mice after T. gondii infection 
resulted in the production of IFNγ and TNF and subsequently to a substantial 
reduction of Toxoplasma titers.22 These findings indicate that those recently 
discovered ILC1s are crucial during intracellular infections. Due to the fact that these 
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ILC1s lack the expression of Eomes and are RORγtfm- they develop independently of 
the NK cell as well as the ILC3 lineage suggesting that they are an individual ILC1 
lineage.22  
Collectively, several different cell types with different phenotypic and functional 
properties are described as ILC1s. In general, ILC1s are cells with a markedly 
production of IFNγ and the expression of T-bet mirroring Th1 type of cells. The 
plasticity between ILC1s and ILC3s is still under debate. Moreover, the relationship 
between ILC1s and conventional NK cells is not fully understood. Further research is 
required to identify precursor populations and developmental requirements of these 
cell types.  
 
 Group 2 ILCs 2.2.2
 
Innate lymphocytes capable to produce type 2 cytokines and thereby mirroring Th2 
cells are categorized within group 2 ILCs. The existence of innate lymphocytes 
dedicated to type 2 cytokine production is already reported in 2001. Fort et al. 
demonstrated that in vivo IL-25 administration induced the production of IL-5 and IL-
13 in Rag2-/- mice lacking conventional T and B cells.32 Subsequently a non-T/non-B 
FcεR1-negative (non-mast cell) cell population able to produce type 2 cytokines in 
response to IL-25 was identified and shown to be crucial at the onset of helminth 
infections.33 In 2010 three different groups independently of each other identified and 
further characterized such type 2 cytokine producing innate lymphocytes. These 
cells, identified by the different groups, have been referred to as natural helper 
cells,34 nuocytes35 and innate helper 2 cells (Ih2 cells).36 However, recently it has 
been agreed that these cells can collectively be referred to as ILC2s due to their 
common production of type 2 cytokines IL-4, IL-5 and IL-13.3, 34, 35, 36  
ILC2s can be found in mesenteric fat-associated lymphoid clusters (FALCs), a newly 
identified lymphoid structure associated with adipose tissue in the mouse peritoneal 
cavity.34 Additionally, ILC2s are present in mesenteric LNs, liver, spleen and 
intestine34, 35, 36 as well as in the airways. 37, 38, 39, 40, 41 
ILC2s can be found in Rag2-/- mice whereas they are absent in Rag2-/-γc-/- mice 
indicating their dependence on γc receptor signaling.34, 35, 36 Additionally, IL-7-deficient 
(IL-7-/-) or IL-7-receptor-α-chain-deficient (IL-7Rα-/-) mice as well as mice with 
mutations in either SCF or CD117 show reduced numbers or complete absence of 
ILC2s while the presence of IL-7 in in vitro cultures induces proliferation of ILC2s.34, 42 
These findings suggest a role for IL-7 and SCF in the development and maintenance 
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of ILC2s. Further, ILC2s are present in IL-15-deficient (IL-15-/-) mice lacking NK cells 
and in AhR-/- mice, which are diminished of ILC3s.43 In contrast to ILC3s, ILC2s 
develop independent of RORγt as RORγ-/- mice show normal ILC2 numbers.34 Hence, 
another member of the ROR family of transcription factors, RORα, plays an essential 
role in the development and function of ILC2s.42, 44 Studies with staggerer mice 
(RORαsg/sg mice),45 which have a spontaneous deletion in Rora, showed that ILC2s 
do not develop in absence of RORα.42, 44 Additionally, transplantation of total BM 
cells from RORαsg/sg mice into irradiated recipient mice fail to generate ILC2s and 
recipient mice show an impaired immunity to parasitic helminthes.42, 44 In addition to 
Id2, which is absolutely necessary for the development of all innate lymphocytes,4, 34 
the transcription factors Gata3 and TCF-1 (T cell-specific high-mobility group box 
transcription factor) have been shown to be required for the differentiation of ILC2s.42, 
43, 46, 47 The majority of ILC2s continuously express high levels of Gata3 and mice 
with a temporally deletion of Gata3 revealed that Gata3 expression is required for the 
differentiation of ILC2s from their precursors as well as the maintenance of ILC2s.43 
TCF-1-deficient mice (Tcf7-/- mice; Tcf7 is the gene encoding TCF-1) are not able to 
generate functional ILC2s46 probably due to the lack of immature ILC2 progenitors43, 
44 in the BM. Tcf7-/- mice are unable to mount an efficient immune response upon 
intranasal challenge with papain (inducing protease-mediated airway inflammation) 
or upon helminth infection with Nippostrongylus brasiliensis that are both infection 
models in which ILC2s have been demonstrated to promote protective immunity 
through their production of IL-5 and IL-13.44, 46 In both infection models, the transfer 
of WT ILC2s into Tcf7-/- mice is sufficient to restore ILC2 numbers in the lung and for 
worm clearance, respectively.46 Recently, it has been shown that the development of 
ILC2s also requires Notch signaling.42, 46 Notch signaling has been reported to 
support the development of ILC2s in vitro as it could be demonstrated that BM-
derived common lymphoid progenitors (CLPs) cultured on OP-9 stromal cells 
expressing the Notch ligand Delta-like 1 (OP9-DL1 cells) can give rise to ILC2 in the 
presence of IL-7 and IL-33.42 Normally, OP9-DL1 cells support T cell development 
from BM-derived CLPs in the presence of IL-7 and fms-like tyrosine kinase 3 ligand 
(FLT3L).48 Additionally, multipotent BM precursors in which dominant-negative 
Mastermind like-1 (dnMAML), a pan-Notch inhibitor is retrovirally induced, fail to 
differentiate into ILC2s in vivo.46 At the current state of research, ILC2s are 
phenotypically characterized as cells lacking markers of other lineages (lin-), and 
simultaneously expressing CD90, IL-7Rα, IL-25R (IL-17BR), IL-33R (T1/ST-2), 
KLRG1 and high levels of Sca-1 and Gata3.34, 35, 36 
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ILC2s as a prominent source of type 2 cytokines provide protective immunity against 
helminth infections.34, 35, 36, 43 ILC2s are able to expand at different anatomical sites in 
response to IL-25, IL-33 and thymic stromal lymphopoietin (TSLP) mainly produced 
by epithelial cells during infections. The production of IL-5 and IL-13 by ILC2s results 
in eosinophilia and goblet cell hyperplasia increasing mucus production. Additionally 
it has been reported that ILC2s through the production of IL-5 and IL-6 support the 
self-renewal of B1 B cells in vitro and in vivo.34 B1 B cells are most abundant in the 
peritoneal cavity and play a critical role in innate type immune responses by the 
production of natural antibodies.49 Further, ILC2s have been implicated in allergic 
airway inflammation as well as in lung epithelial tissue repair, thus, playing both 
damaging and tissue protective roles.37, 38, 39, 40, 41 A study showed that ILC2s are able 
to mediate virus-induced airway hyper-reactivity (AHR) through their responsiveness 
to IL-33, which is produced by alveolar MΦ accumulating during influenza-induced 
AHR in the lung. Depletion of ILC2s in influenza-infected mice significantly alleviated 
AHR whereas adoptive transfer of WT ILC2s into IL-13-/- mice, unable to establish 
AHR due to the lack of IL-13, is sufficient to induce AHR.39 In contrast, another study 
revealed that the depletion of ILC2s in mice infected with another influenza virus 
strain severely worsened virus-induced AHR. In this study, depletion of ILC2s or 
blocking of IL-33R signaling through administration of blocking IL-33R mAb, results in 
diminished lung function and impaired ability to generate hyperplastic epithelial cell 
responses. It could be shown that the tissue protective role of ILC2s during AHR 
reported in this study is mediated by the production of amphiregulin, a member of the 
epidermal growth factor family. Administration of recombinant amphiregulin into 
ILC2-depleted mice is able to restore airway epithelial integrity and lung function 
reducing AHR.41  
 
ILC2s and T cells 
Several reports showed that ILC2s play important roles in a variety of innate immune 
responses. They are crucial in immunity against helminthes, in allergy and asthma as 
well as in tissue repair and remodeling mediated via their production of various 
cytokines such as IL-5 and IL-13, and growth factors (e.g. amphiregulin). It could be 
shown that in the absence of T and B cells (Rag2-/- mice) ILC2s are able to expand 
and to produce type 2 cytokines upon N. brasiliensis infection, although not efficiently 
enough to expel the worm infection.34, 35 N. brasiliensis infection in Rag2-/- mice 
induce rapid expansion of ILC2s 4 days post infection. However, ILC2 numbers 
cannot be maintained in the absence of T and B cells.35 This finding suggests that 
expanded ILC2s are maintained by the presence of T cells (B cells have been show 
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to be dispensable for worm expulsion)50 and gives a first hint for a possible dialog 
between ILC2s and T cells. In fact, within the last year, several reports demonstrated 
that ILC2s and T cells interact with each other to promote immunity.51, 52, 53, 54 
In vitro studies showed that co-culture of ILC2s and CD4+ T cells, which are activated 
through anti-CD3/anti-CD28 coated on the plate, results in proliferation of ILC2s and 
enhances their production of Th2 cytokines.51 This effect is independent of cell-cell 
contact and occurs over soluble factors shown by the use of a transwell culture 
system in which ILC2s and CD4+ T cells have been separated by a culture insert.51 
IL-2 produced by activated CD4+ T cells has been reported to be responsible for the 
proliferation and increased type 2 cytokine production by ILC2s, since addition of 
neutralizing IL-2 mAb to co-cultures markedly impaired proliferation and cytokine 
secretion of ILC2s.51 The crucial role of IL-2 for ILC2 expansion and activation has 
been confirmed by the finding that Rag2-/- mice treated with IL-2/anti-IL-2 complexes 
are able to efficiently expel worms upon N. brasiliensis infection although CD4+ T 
cells are missing. The rapid worm expulsion correlates with elevated ILC2 numbers.54 
Therefore, the presence of activated CD4+ T cells producing IL-2 induces the 
expansion of ILC2s and enhances their type 2 cytokine production. Furthermore, it 
has been shown that the culture of naïve CD4+ T cells in the presence of plate-bound 
anti-CD3/anti-CD28 results in proliferation of CD4+ T cells and addition of ILC2s even 
increases the proliferation of CD4+ T cells and also enhances their production of type 
2 cytokines.51, 53 It has been reported that this effect is dependent on cell-cell contact 
via OX40-ligand (OX40L) expressed on ILC2s.53 Thus, the presence of ILC2s 
induces T cell proliferation and supports their differentiation into Th2 cells. These 
data could be confirmed in in vivo studies using two different mouse models with an 
ablation of ILC2s. Mice lacking ILC2s (iCOS-T or Rorαfl/sgIl7rCre mice) showed 
delayed worm expulsion upon N. brasiliensis infection and a dramatic reduction of IL-
5 and IL-13-producing CD4+ T cells.54 Furthermore, adoptive transfer of both CD4+ T 
cells and ILC2s into IL-7Rα-/- mice lacking ILC2s and T cells results in robust airway 
eosinophilia upon Ovalbumin (OVA) Ag plus bromelain (a cysteine protease) 
exposure. Transfer of either CD4+ T cells or ILC2s only shows minimal airway 
inflammation.53 Therefore, the in vivo interplay between ILC2s and CD4+ T cells is 
critical for the generation of Th2 cell immunity.  
ILC2s are shown to express major histocompatibility complex class II (MHC II) on 
their surface.35, 51, 54 This fact raised the question whether ILC2s can act as Ag-
presenting cells (APCs). Indeed, ILC2s have been reported to be able to induce 
CD4+ T cell proliferation in the presence of peptide-Ag in vitro and preferentially 
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induce the production of type 2 cytokines by CD4+ T cells.51, 54 Detailed analysis 
showed that ILC2s are able to endocytose soluble Ag and to degrade OVA-DQ, a 
self-quenched conjugate of Ovalbumin protein that fluoresces when cleaved.54 
Although ILC2s are able to process and present Ag on their surface, confirmed by 
the presence of E-alpha (Eα)-derived peptides in context with MHC II on the surface 
of ILC2s 20 h after incubation with the Eα-green fluorescent protein (GFP) fusion 
protein, ILC2s are not able to induce CD4+ T cell proliferation in the presence of 
whole protein-Ag in vitro.54 In addition to MHC II, a proportion of ILC2s are reported 
to express CD80 and CD86 on the surface. Blocking of CD80 and CD86 with 
neutralizing Abs in co-cultures of ILC2s and CD4+ T cells with peptide has been 
shown to decrease CD4+ T cell proliferation and production of type 2 cytokines 
suggesting another cell-cell contact-dependent way of T cell activation by ILC2s. In 
addition, in vivo models demonstrated that IL-13 production by ILC2s is most crucial 
for the generation of efficient Th2 responses. Intranasal administration of IL-13 or 
adoptive transfer of IL-13-producing WT ILC2s is sufficient to rescue Th2 
differentiation of CD4+ T cells in vivo.52 In this study, a role for ILC2-derived IL-13 in 
the migration of activated DCs to the lung draining LNs and the subsequent support 
of Th2 differentiation in the LNs is suggested.52 Collectively, ILC2s and CD4+ T cells 
are able to interact via soluble factors, surface molecules and Ag-MHC II complexes. 
The presence of both cell types and their interaction is required to increase ILC2- as 
well as CD4+ T cell-mediated Th2 immunity. The so far identified immune functions of 
ILC2s are summarized in figure 2 (Fig. 2). 
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Figure 2:	   Type 2 immunity and homeostasis mediated by ILC2s. Illustration of the 
different functions of ILC2s during type 2 immunity and tissue homeostasis. LN: lymph nodes; 
DC: dendritic cells; TCR: T cell receptor; TSLP: thymic stromal lymphopoietin; MHC II: major 
histocompatibility complex class II. Adapted from Mc Kenzie et al., Immunity (2014).55  
 
 Group 3 ILCs 2.2.3
 
Lymphoid tissue inducer cells  
The prototypes of the nowadays called ILC3s are lymphoid tissue inducer cells (LTi 
cells). LTi cells are first discovered in 1992 as a novel population of CD45+CD3-CD4+ 
cells accumulating in the LN during the first days of life.56 Additionally, these cells are 
found to be present in the spleen of neonates showing lymphoid size and 
morphology.  
Several years later, CD45+CD3-CD4+ cells were identified as the first cells colonizing 
the fetal LN anlagen, spleen (at embryonic day E13.5), small intestine, stomach and 
colon, however, they were found to be absent in the fetal liver (FL) and thymus.57, 58 
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CD45+CD3-CD4+ cells belong to the hematopoietic lineage (CD45+) and develop 
independently of the presence of spleen or thymus. A more detailed analysis of the 
phenotype of these cells revealed that they are negative for other lymphoid, myeloid 
and erythroid markers. T cell receptor (TCR) and B cell receptor (BCR) genes are 
found to be in germ line configuration and the mRNA for the recombination activating 
genes Rag1 and Rag2 are missing. However, these cells show expression of the 
common gamma (γc) chain (CD132, IL-2Rγ), CD25 (IL-2Rα), IL-7Rα, CD117, CD90 
and lymphotoxin (LT)-β.57 Additionally, CD45+CD3-CD4+ cells express the homing 
receptor integrin α4β7, which is a ligand for the mucosal vascular addressin cell 
adhesion molecule (MadCAM-1) that is exclusively expressed on high endothelial 
venules (HEV) in peripheral and mesenteric LNs until 24 hours after birth.59 
Therefore, α4β7 expression allows the selective entry of LTβ-expressing CD45+CD3-
CD4+ cells into the developing LN, a fact, which together with the finding that 
CD45+CD3-CD4+ cells are amongst the earliest hematopoietic cells colonizing fetal 
LN anlagen, the fetal spleen and intestine already suggests a role for these cells in 
lymphoid tissue development during ontogeny.57, 58 However, the contribution of 
CD45+CD3-CD4+ cells to lymphoid tissue development and the molecular and cellular 
events behind it, were still not known at that time.  
 
Origin and differentiation of LTi cells 
Two different groups independently of each other could identify a precursor 
population for LTi cells.60, 61 Mebius et al. found an IL-7Rα+Sca-1lowCD117low 
population in the FL at E12.5-E14.5 showing differentiation potential to CD45+CD3-
CD4+ cells.60 IL-7Rα+Sca-1lowCD117low cells, phenotypic analog to the CLP of the 
BM, additionally showed in vivo differentiation potential to B and T cells, NK cells and 
DCs whereas MΦ only developed from these precursors in in vitro studies.60 In 
addition, Yoshida et al. described a Lin-IL-7Rα+α4β7+ cell population present in the FL 
(E12.5) as precursor for CD45+CD3-CD4+ cells.61 Lin-IL-7Rα+α4β7+ cells have been 
reported to lack myeloid and B cell differentiation potential and to loose their T cell 
differentiation potential after migration to the embryonic intestine where they are 
suggested to be involved in the formation of Peyer`s Patches (PPs), organized  
lymphoid tissues containing mainly B lymphocytes. It has been demonstrated that IL-
7Rα-/- mice are not able to generate PPs and that the administration of an 
antagonistic IL-7Rα mAb to pregnant mice completely blocked the generation of 
PPs.62, 63 Since CD45+CD3-CD4+ cells express IL-7Rα, these findings suggested the 
involvement of CD45+CD3-CD4+ cells in the formation of PPs.  
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Role of LTi cells in lymphoid tissue development 
The identification of molecular and cellular requirements for the formation of 
lymphoid tissues started with the characterization of the LTα- deficient (LTα-/-) mice 
in 1994.64, 65 LTα-/- mice are unable to generate lymphoid tissues and completely lack 
LNs and PPs. LTα belongs to the tumor necrosis factor (TNF) superfamily and can 
form heterotrimers with LTβ consisting of one α-chain and two β-chains (LTα1β2). 
LTα1β2 binds to its own receptor, LTβ – receptor (LTβR).66, 67 The crucial role of LTβR 
triggering in the formation of lymphoid tissues has been shown by the fact that 
administration of soluble LTβR into pregnant WT mice blocked the formation of LNs 
and PPs in the offspring.68 In 1998 the LTβR-/- mice have been described and 
confirmed the requirement of LTβR triggering for the formation of lymphoid tissues.69  
The cellular requirements for lymphoid tissue formation are uncovered by studying 
two different mouse models, Id-2-/- mice4 and RORγt-/- mice,70 respectively. In the 
absence of either the helix-loop-helix inhibitor of DNA binding 2, Id2, or the orphan 
nuclear hormone receptor, RORγt, LN and PP development fails completely and 
subsequent analysis of these mice revealed that they lack CD45+CD3-CD4+ cells.  
Finally, two in vivo adoptive transfer experiments confirmed that CD45+CD3-CD4+ 
cells are indeed able to induce lymphoid tissue formation. First, Finke et al. have 
demonstrated that adoptive transfer of CD45+CD3-CD4+ cells isolated from the fetal 
spleen is able to induce PP development in CXCR5-/- mice and secondly, Fukuyama 
et al. adoptively transferred fetal intestinal CD45+CD3-CD4+ cells into Id-2-/- mice 
thereby inducing the formation of nasal-associated lymphoid tissue (NALT)-like 
structures.71, 72 Based on these findings CD45+CD3-CD4+ cells are renamed as 
lymphoid tissue inducer (LTi) cells.  
In general, the generation of lymphoid tissues such as LNs and PPs require the 
interaction of LTαβ-expressing hematopoietic cells and LTβR-expressing stromal 
cell.68 LTβR triggering on stromal cells induces the activation of the nuclear factor-κ-
B (NFκB) pathway resulting in the expression of the adhesion molecules vascular 
cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and 
mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) as well as the 
production of the chemokines CXCL12, CXCL13, CCL19 and CCL21. These 
chemokines are required for the recruitment and retention of additional hematopoietic 
cells at putative sites for LN or PP development (Fig. 3).73  
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Figure 3: Illustration of lymphoid tissue organogenesis mediated by LTi cells. LTi: 
lymphoid tissue inducer; LTαβ: lymphotoxin αβ; VCAM-1: vascular cell adhesion molecule-1. 
Adapted from Mebius, Nature Reviews (2003).74 
 
Lymph node organogenesis 
LN development starts with the formation of the lymphatic system by the 
development of the lymph sac at approximately E10.5. Prox1, a homeobox gene, is 
crucial for the budding and sprouting of lymphatic endothelium to form the lymph 
sacs.75 Subsequently, from these early lymph sacs lymphatic vessels sprout into 
tissues and reconnect with other lymphatic vessels. At E15.5 a complete network is 
formed.75 At E12.5 – E13.5 the earliest LN anlagen are formed by the colonization 
with LTi cells that cluster with VCAM-1+ stromal cells. LTα1β2 expression on LTi cells 
was shown to be induced through IL-7R- and TNF-related activation-induced 
cytokine receptor (TRANCER)- signaling76 and allows the cells to interact with LTβR-
expressing stromal cells activating their NFκB pathway.73 Signaling through LTβR on 
stromal cells interacting with LTαβ-expressing LTi cells is absolutely crucial for LN 
organogenesis.68 NFκB pathway activation induces the expression of VCAM-1, 
ICAM-1 and MAdCAM-1 on the stromal cells amplifying their interaction with LTi cells 
expressing the corresponding receptors α4β1 and α4β7, respectively.57 On the other 
hand, activation of the NFκB pathway of stromal cells triggers secretion of several 
chemokines including CXCL13 and CCL21 that attract and retain additional LTi cells 
expressing the respective chemokine receptors CXCR5 and CCR7.57 The crucial role 
for NFκB signaling in lymphoid organogenesis has been confirmed by the finding that 
NFκB-inducing kinase (NIK)-deficient mice fail to develop LNs.77 Further, interaction 
of LTi cells and stromal cells via LTαβ and LTβR has been reported to induce the 
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secretion of IL-7 and TRANCE by the stromal cells.78 Both IL-7 and TRANCE are 
able to induce LTαβ expression on newly arriving LTi cells resulting in enhanced 
LTβR triggering on stromal cells generating a positive feedback loop.78 
 
Peyer`s patch organogenesis 
For PP development three distinctive stages are described starting with the first at 
E15.5 involving clustering of VCAM-1+ and ICAM-1+ cells.58 VCAM-1+ICAM-1+ 
stromal cells in the developing PP express LTβR and upon LTβR triggering produce 
the homeostatic chemokines CXCL13, CCL19 and CCL21, which are potent 
chemoattractants for LTi cells.79 Thus, subsequently LTi cells colonize these first 
stromal cell clusters and co-localize with VCAM-1+ICAM-1+ stromal cells in the 
intestine (E16.5 – E17.5, stage 2).79 The third stage involves the recruitment of and 
further colonization by T and B lymphocytes. In addition to the requirement of VCAM-
1+ICAM-1+ stromal cells and LTi cells for the development of PPs, another lymphoid 
cell type has been described to be essential. The so-called lymphoid tissue initiating 
cell (LTin) is found in the embryonic gut from day E15.5 – E16.5 on and expresses 
CD11c and CD117 while lacking CD4, CD3 and IL-7Rα expression.80 In the absence 
of LTin cells, PP development has been reported to be significantly reduced.80  
As described for LN development, PP development depends as well on signaling 
through the LTαβ-LTβR axis. Mice deficient for LTβR, LTα or LTβ are unable to 
generate PPs.64, 69, 81 The chemokine CXCL13 is produced by stromal cells in the 
fetal intestine and is known to direct B cells to lymphoid follicles.79, 82 Through 
signaling via CXCR5 expressed on LTi cells, CXCL13 can trigger β1 integrin 
activation. β1 integrin expression on LTi cells allows the interaction with VCAM-1 
expressing stromal cells.71 The activation of the β1-VCAM-1 axis induces augmented 
expression of CXCL13 which signals via CXCR5 resulting in the induction of LTαβ 
expression on LTi cells. Thus, a feedback loop for PP formation is generated via the 
β1-integrin – VCAM-1 axis.71 Moreover, signaling via the receptor tyrosine kinase 
RET is required for the formation of PP anlagen. Despite normal numbers of LTi 
cells, the lack of RET disrupts the cell cluster aggregation.80  
 
Different requirements for LN and PP development 
LN and PP organogenesis shows many similarities such as the requirement for the 
LTαβ-LTβR signaling axis. However, some factors involved in the developmental 
program differ for LNs and PPs. TRANCE-/- mice are shown to lack LNs whereas PPs 
develop normally.83 Therefore, TRANCE-TRANCER signaling axis is an additional 
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example of TNF/TNFR family members crucial for LN development.  LTi cells 
express both TRANCE and TRANCER and the TRANCE/TRANCER signaling axis is 
required for survival of LTi cells and their clustering at putative sites of LN formation 
as TRANCE overexpression in TRANCE-/- mice is able to rescue LTi cell numbers 
and LN development.84 However, TRANCE overexpression in LTα-/- mice does not 
result in rescued LN development suggesting different roles for the 
TRANCE/TRANCER and the LTαβ/LTβR signaling axis.84 Moreover, the role of IL-
7Rα signaling in PP and LN development differs. While PP development is 
completely dependent on IL-7Rα-signaling displayed by the lack of PPs in mice with 
a IL-7Rα deficiency,62, 85, 86 LN organogenesis does only partially depend on IL-7Rα 
signaling.87 As lymphocyte-deficient Rag1-/- mice generate LNs normally, the 
absence of some LNs in IL-7Rα-/- mice is not due to the role of IL-7R signaling in 
lymphocyte development.87 Further, the cytokines IL-7 and SCF (Kit Ligand) 
differentially regulate LN and PP development. Both IL-7 and SCF are shown to be 
growth factors for LTi cells and their FL precursors in vitro and in vivo.88, 89 However, 
IL-7-/- mice show defects in LN generation, whereas PP development is not 
perturbed.88 In contrast, PP development is highly reduced in mice with a deficiency 
in Kit signaling while all LNs develop normally.89 In line with this, it could be 
demonstrated that stromal cells isolated from LNs show high IL-7 and low SCF 
expression while stromal cells of PPs are characterized by high SCF and low IL-7 
expression.89 
Transgenic overexpression of IL-7 in mice revealed that IL-7 is a survival factor for 
both LTi cells and their FL precursor by increasing cell survival rather than 
proliferation. Increased IL-7 availability in these mice induces de novo generation of 
VCAM-1+ PP anlagen resulting in increased numbers of PPs in the intestine of adult 
mice. Furthermore, ectopic lymphoid tissues so-called tertiary lymphoid tissues are 
formed. The generation of additional PPs and LNs has been reported to depend on 
the availability of IL-7, LTi cells and LTαβ signaling.88 Since IL-7-/- mice are unable to 
form LNs and IL-7 regulates the size of the LTi cell pool in vivo it has been suggested 
that low numbers of LTi cells in IL-7-/- mice are responsible for the defects in LN 
organogenesis.88 IL-7 and TSLP have been reported to exhibit overlapping biological 
functions.90 Transgenic overexpression of TSLP in IL-7-/- mice is able to restore LN 
development due to the induction of an increase in LTi cell numbers. The same is 
found when TSLP is transgenetically overexpressed in Rag2-/-γc-/- mice demonstrating 
that peripheral lymphocytes are not required for LN formation.91 Altogether, IL-7, 
TSLP and SCF have been shown to regulate the size of the LTi cell pool by 
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increasing the generation and survival rather than the proliferation of these cells. LN 
and PP development is clearly regulated by the number of LTi cells, the availability of 
region-specific cytokines and signaling via LTβR.  
 
LTi cells persist after birth 
Beside the existence of fetal LTi cells playing an essential role in lymphoid tissue 
formation during embryogenesis, several studies showed that LTi-like cells could be 
found after birth.  
RORγt has been described to be essential for the generation of fetal LTi cells and 
consequently for the formation of lymphoid tissues.70, 92 In a transgenic mouse model, 
in which the enhanced green fluorescent protein (EGFP) was used as a reporter 
gene inserted into the gene encoding RORγt (Rorc(γt)+/GFP mouse), it could be shown 
that RORγt is an exclusive marker for LTi cells during fetal life.93 Additionally, further 
analysis of Rorc(γt)+/GFP mice revealed that RORγt+ cells could be found in the gut of 
adult mice.25 They have been identified within cryptopatches (CPs), isolated 
lymphoid follicles (ILFs) and PPs, all organized structures in the gut. These RORγt+ 
cells additionally express IL-7Rα and CD117 and lack the expression of lineage 
markers suggesting that they are the adult counterparts of the fetal LTi cells.25 In 
RORγt-deficient mice, reached by breeding Rorc(γt)+/GFP mice to homozygosity 
(Rorc(γt)GFP/GFP mice), intestinal RORγt+ cells are absent and CPs as well as ILFs do 
not develop.25 Thus, adult RORγt+ cells identified in the adult gut share 
developmental requirements, phenotype and function with fetal LTi cells and are 
therefore thought to be the adult equivalents of the fetal LTi cells.  
Moreover, Lane et al. identified a cell type in the spleen of adult mice with a 
phenotype closely resembling them of fetal LTi cells. These CD3-CD4+CD11c- cells 
are found in the spleen mainly in and around B cell follicles as well as at the T:B cell 
interface in close proximity to T cells. Detailed analysis revealed that compared to 
embryonic and neonatal LTi cells these cells express high levels of the T cell co-
stimulatory molecules CD30-ligand (CD30L) and OX40L.94 The receptors for CD30L 
and OX40L, CD30 and OX40, are only expressed by primed but not by naïve T cells. 
Therefore, it has been suggested that adult CD3-CD4+CD11c- splenic LTi-like cells 
are potential candidates for providing co-stimulatory signals to T cells.94 Indeed, mice 
with a deficiency in CD30 and OX40 (CD30-/-OX40-/- mice) are shown to lack proper 
memory antibody responses due to a failure in the survival of primed CD4+ T cells.95 
It could be shown that this failure was due to the inability of primed CD4+ T cells to 
interact with CD30L- and OX40L-expressing splenic LTi-like cells.95 The lack of 
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CD30L and OX40L revealed as the only difference between embryonic/neonatal LTi 
cells and adult splenic LTi-like cells. Otherwise embryonic/neonatal LTi cells and 
CD3-CD4+CD11c- splenic LTi-like cells share a genetic fingerprint, which clearly 
separates these cells from other lineages.96  
LTα-/- mice show a disruption of B and T cell segregation in the spleen, which could 
not be rescued by the transfer of total WT splenocytes.97 However, the transfer of 
LTα-/- splenocytes into Rag-/- mice was able to rescue the spleen organization, 
thereby suggesting a non-T and non-B cell type to be responsible for proper B/T 
segregation.98 Indeed, it could be shown that the transfer of either fetal LTi cells or 
adult LTi-like cells, both expressing high levels of LTαβ, is able to restore B/T cell 
segregation in the spleen of LTα-/- mice within 10 days whereas the transfer of either 
lymphocytes or DCs fails to restore a correct organization in the spleen.98 Thus, adult 
LTi-like cells are important for a correct T and B cell segregation in the adult mouse 
spleen.98 
The infection with lymphocytic choriomeningitis virus (LCMV) is characterized by 
cytotoxic CD8+ T cell-mediated destruction of the T cell zone stromal cell network.99 It 
has been shown that the fibroblastic reticular cell (FRC) network is mainly affected by 
the LCMV infection and consequently hosts are not able any more to mount proper 
immune responses and loose their immunocompetence. The rebuilding of a correct 
lymphoid microarchitecture is required to regain immune responsiveness. At the 
peak of LCMV-mediated tissue destruction, increased numbers of CD45+IL-7Rα+lin- 
cells are found in LNs and spleen, most probably through a proliferative 
accumulation of these cells.99 These CD45+IL-7Rα+lin- cells bear a phenotype similar 
to embryonic LTi cells and could be shown to be able to fully restore the T cell zone 
stromal network through LTαβ-LTβR-mediated FRC stimulation.99 In the absence of 
CD45+IL-7Rα+lin- cells, the reorganization of the spleen is delayed whereas adoptive 
transfer of LTi cells into RORγt-/- chimeras has been shown to accelerate the 
restoration of the splenic architecture after LCMV caused destruction.99 These data 
indicate that adult LTi-like cells are important for restoration and reorganization of 
destroyed tissue after birth thereby following the same program as during fetal life. 
Moreover, LTi cells have been described to play a role in the generation of T- 
independent IgA in the gut.100 T- independent IgA is produced in mainly B cell 
containing ILFs, which only develop in presence of LTi cells, their LTαβ-LTβR-
dependent interaction with stromal cells, and signals from bacteria that enhance the 
interaction of these two cell types.100, 101 
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As already described for fetal LTi cells and their progenitors,88, 89 it could be 
demonstrated that the size of the adult splenic LTi-like cell pool depends on the 
availability of IL-7. Adult IL-7-/-, IL-7Rα-/- and mice lacking the γc chain (γc-/- mice) show 
reduced numbers of splenic LTi-like cells whereas mice with a transgenic 
overexpression of IL-7 show increased numbers of LTi-like cells in the spleen.102, 103 
Additionally, the treatment of adult IL-7-/- mice with IL-7/anti-IL7 complexes104 has 
been shown to be able to rescue numbers of splenic LTi-like cells in adult mice.103  
Moreover, the transfer of adult splenic LTi-like cells into newborn CXCR5-/- mice has 
been demonstrated to result in the appearance of PP anlagen.103 This revealed for 
the first time that adult splenic LTi-like cells are bona fide LTi cells able to induce the 
de novo formation of lymphoid tissue. However, compared to fetal LTi cells, adult 
LTi-like cells have been shown to be less efficient in the induction of PP anlagen.   
 
Development of LTi-like cells found after birth 
Whether fetal LTi cells persist or adult LTi cells are newly generated from BM 
precursors is not fully understood. Fetal LTi cells, which are transferred into adult 
mice, could be recovered in the spleen expressing CD30L and OX40L.94, 96 This 
finding supported the idea that adult LTi cells might develop from fetal LTi cells. Fetal 
LTi cells have been reported to develop from precursors of the FL.60, 61 After birth, the 
BM is the major site of hematopoiesis. Whether a precursor for adult LTi cells exists 
in the BM was not known. The transfer of total FL cells or total BM cells into IL-7Rα-/- 
mice revealed that LTi cells are able to develop either from FL or from BM cells.103 
However, the successful and efficient generation of adult LTi cells from BM cells 
requires exogenous IL-7.103 Another study supported the idea that the BM might be 
the source of adult LTi cells. In this study, the transfer of total BM cells into RORγt-/- 
mice results in the generation of CP and ILFs.100 
Collectively, several reports showed that cells with an extremely similar phenotype to 
fetal LTi cells exist after birth. These cells are called at the time of its discovery LTi-
like cells and could be shown to achieve numerous functions. Some of the functions 
of LTi-like cells after birth are related to their original function as lymphoid tissue 
inducer,25, 99, 103 however, LTi-like cells also contribute within several ways to 
immunity.94, 95, 100  
 
NKp46- and NKp46+ ILC3s 
In general, the group 3 ILCs are defined as RORγt+ IL-17 and/or IL-22-producing 
cells, thus resembling Th17 cells. The group 3 ILCs are divided into LTi cells 
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(extensively described before) and a heterogeneous population of RORγt+ ILC3s. 
This heterogeneous population of RORγt+ ILC3s consists of RORγt+ ILC3s, which 
additionally express the natural cytotoxicity receptor NKp46 on their surface, here 
referred to as NCR+ILC3s, and RORγt+ ILC3s lacking NKp46 expression, so-called 
NCR-ILC3s. NCR-ILC3s are characterized by the expression of IL-17 and IL-22,105, 106 
and under inflammatory circumstances as well IFNγ107 while NCR+ILC3s exclusively 
express IL-22 and predominantly exist in the intestine.108, 109, 110  
The term NCR-ILC3s for adult RORγt+ ILC3s lacking NKp46 was introduced by the 
new nomenclature of the ILC family3 and most probably the LTi-like cells (see 
chapter 2.2.3 Group 3 ILCs, LTi cells persist after birth), which exist after birth 
exhibiting several functions in tissue organogenesis25, 99, 103 and immunity,94, 95, 100, 105 
are equivalent to these nowadays called NCR-ILC3s. 
The development of NCR- and NCR+ILC3s depends on the expression of Id2 and 
RORγt as these cells are missing in Id2-/- mice4 and RORγtGFP/GFP mice.19, 93, 108, 109, 110 
The aryl hydrocarbon receptor (AhR), a ligand-dependent transcription factor, plays a 
crucial role in the expansion of NCR- and NCR+ILC3s after birth.111, 112 It has been 
reported that AhR-/- mice or mice, which only lack AhR on RORγt+ ILCs and T cells 
(AhrΔLTi, T mice) are not able to generate CPs and consequently also ILFs are 
missing, while their prenatal formation of secondary lymphoid tissues is not 
affected.111, 112 It could be shown, that ligand binding to AhR inducing AhR signaling 
is required for the postnatal expansion of ILC3s, which subsequently are able to 
generate CPs that develop under the influence of signals from the microbiota into 
ILFs.111 In contrast, AhR signaling is dispensable for LTi cell development and 
function during embryogenesis additionally reflected by the presence of PPs in the 
gut.112 Kiss et al. could show that AhR signaling induces the transcription of Kit 
(SCF), which has been previously reported to be crucial for ILC3 expansion, survival 
and maintenance.89 Therefore, Kiss et al. suggested that the postnatal expansion of 
ILC3s is mediated via the AhR-Kit axis.111 Furthermore, due to the lack of post-natal 
occurring IL22- producing ILC3s, AhR-/- mice are unable to mount protective 
immunity against C. rodentium infection, an intestinal mouse pathogen that requires 
IL-22-producing cells for its clearance.111, 112, 113 AhR is not only responsible for the 
expansion and maintenance of IL-22-producing ILC3s after birth as it could be 
demonstrated that AhR influences the IL-22 production on a per cell basis reflected 
by reduced IL-22 production of remaining ILC3s in AhR-/- mice.114 
A recent study showed that Tbx21-/- mice lack NCR+ILC3s while NCR-ILC3s develop 
normally suggesting that T-bet expression is only required for NCR+ILC3 but not for 
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NCR-ILC3 development.22 Further research is required to uncover the precise role for 
T-bet in the development and function of ILC3s.  
The contribution of the microbiota and its microbial signals to the development and 
maintenance of NCR- and NCR+ILC3s in the intestine is not fully understood and 
several reports noted different findings.108, 109, 112, 115 By the analysis of germfree mice 
two groups reported that the numbers of RORγt+ NCR+ILC3s are extremely reduced 
whereas numbers of RORγt+ NCR-ILC3s (or LTi-like cells) and conventional NK cells 
are normally represented in the intestine.108, 109 Additionally, the remaining 
NCR+ILC3s in germfree mice produce lower levels of IL-22. However, it could be 
shown that the recolonization of germfree mice with normal microbiota is able to 
rescue the numbers of NCR+ILC3s.109 In contrast, two other groups reported that the 
numbers of RORγt+ NCR+ILC3s are not changed in the intestine of either germfree 
mice or mice treated with antibiotics efficiently eradicating intestinal bacteria.112, 115 
Furthermore, it has been shown that compared to NCR+ILC3s of adult germfree or 
antibiotic-treated mice, NCR+ILC3s from normal mice produce lower levels of IL-22, 
suggesting that the presence of the microbiota represses the IL-22 production of 
NCR+ILC3s. Indeed, it could be demonstrated that the presence of the microbiota 
induces IL-25 production by epithelial cells, which in turn activates DCs that 
subsequently inhibit IL-22 production by NCR+ILC3s in a cell-cell contact dependent 
manner.115  
RORγt+ ILC3s expressing NKp46 on the surface (NCR+ILC3s) have been discovered 
by several research groups independently.108, 109, 110 Up to that time, NKp46 was 
believed to be highly and specifically expressed by conventional NK cells.116, 117 In 
contrast to NK cells, NCR+ILC3s have been reported to develop independent on IL-
15 and do not produce perforin or granzymes, therefore lack cytotoxicity.108, 109, 110 
However, NCR+ILC3s have been identified as important producers of IL-22,108, 109, 110 
a cytokine, which is crucial during the infection with the attaching and effacing 
bacterial pathogen C. rodentium.113 IL-22-deficient (IL-22-/-) mice infected with C. 
rodentium show increased epithelial damage followed by bacterial dissemination and 
a high systemic bacterial burden.113 It could be shown that IL-22 plays a crucial role 
in the early phase of host defense against C. rodentium infection, as administration 
of neutralizing IL-22 Ab118 to WT mice at day 0 after inoculation with C. rodentium 
results in weight loss, bacterial dissemination and increased mortality whereas WT 
mice, which received the neutralizing IL-22 Ab at day 8 after C. rodentium inoculation 
are able to fully recover from the infection.113 The receptor of IL-22 (IL-22R) is 
exclusively expressed by epithelial cells119 and epithelial cells are able to produce 
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many anti-microbial proteins such as RegIIIβ and RegIIIγ promoting epithelial cell 
integrity thereby limiting bacterial dissemination.113 In addition to the crucial role of 
NCR+ILC3s during C. rodentium infection in vivo, another study showed that NCR-
ILC3s (or LTi-like cells) contribute substantially to protective immunity against C. 
rodentium.106 Sonnenberg et al., could show that NCR-ILC3s are able to expand and 
to produce increased levels of IL-22 upon C. rodentium infection in an IL-23-
dependent manner.106 NCR-ILC3s are the main source of IL-22 at early time points of 
the infection and absolutely required to survive the first days until the adaptive 
immunity starts to work.106 Thus, NCR- and NCR+ILC3s are shown to be the main 
producers of IL-22 early after infection with C. rodentium and are thus indispensable 
for the clearance of the infection.106, 108, 109 Another study identified a crucial role for 
NCR-ILC3s (or LTi-like cells) in innate immunity mediated by their ability to produce 
high amounts of IL-17 in response to microbial products.105 Takatori et al. reported 
that NCR-ILC3s are able to produce IL-17, a major mediator of inflammation, in 
response to the yeast cell wall product zymosan in vivo.105 They could show that 
NCR-ILC3s found in the spleen of zymosan-treated Rag2-/- mice produce high levels 
of IL-17 and also IL-22.  Zymosan treatment induces IL-23 production by DCs, which 
in turn has been suggested to activate NCR-ILC3s expressing high levels of IL-
23R.105 In line with this, it has been proposed that the protective response of NCR- 
and NCR+ILC3s during C. rodentium infection depends on IL-23 as mice lacking IL-
23 (IL-23p19-/- mice) are not able to recover from C. rodentium infection.106, 113 
Indeed, it could be shown that IL-22 production by ILC3s is induced by IL-23 
secreted by DCs and simultaneously ILC3s enhance the IL-23 production by DCs 
through activation of LTβR in a positive feedback loop.120 Accordingly, several in vitro 
studies confirmed that ex vivo isolated ILC3s are able to produce IL-22 in response 
to IL-23 supporting the importance of the IL-23-IL-22 axis.105, 106, 108 
 
ILC3s in adaptive immunity 
In addition to their crucial role as cytokine-producing cells in innate immunity, NCR- 
and NCR+ILC3s have been reported to be involved in adaptive immunity.  
Granulocyte-macrophage colony-stimulating factor (GMCSF) has been shown to be 
essential for the induction and maintenance intestinal tissue-resident DCs,121 which 
are implicated, together with MΦ, in the induction and expansion of regulatory T cells 
(Tregs).122, 123 Tregs itself have been reported to regulate intestinal tolerance.124 Thus, 
provision of GMCSF is important for the conversion of T cells into Tregs in the intestine 
to balance the intestinal immune response. In addition to epithelial cells, which are 
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believed to be the source of GMCSF in the gut,125 a GMCSF-producing cell 
population expressing RORγt has been found in the small and large intestine of mice 
at steady state. This cell population contains NCR- and NCR+ILC3s and significantly 
reduced levels of GMCSF in the gut of RORγt-/- mice lacking NCR- and NCR+ ILC3s 
confirmed these cells as important GMCSF producer.126 Since GMCSF is not 
detectable in newborns but increases with age, commensal bacteria-driven signals 
have been suggested to induce GMCSF production by ILC3s in the intestine. Indeed, 
intestinal MΦ could be identified as main source of IL-1β in response to microbial 
products, which in turn activates ILC3s to produce GMCSF.126 The importance of IL-
1β and IL-1R1 signaling has been confirmed by the fact that ILC3s from IL-1R1-/- 
mice are unable to produce GMCSF. In addition, adoptive transfer of ILC3s from 
either GMCSF-sufficient (Csf2+/+) or GMCSF-deficient (Csf2-/-) mice into Rag2-/-γc-/- 
mice revealed that only mice, which received GMCSF-sufficient ILC3s are able to 
produce GMCSF and to convert T cells into Tregs upon T cell transfer and 
immunization.126 Thus, IL-1β-responsive GMCSF-producing ILC3s are the primary 
source of GMCSF in the intestine crucial for the induction of Tregs mediating intestinal 
immune tolerance.  
ILC3s are also able to interact with B cells. A recent study showed that ILC3s in the 
spleen are capable to enhance Ag production of marginal zone B cells (MZB cells).127 
NCR+ILC3s can be found in the marginal zone (MZ) and perifollicular zone areas of 
the spleen where they are able to interact with marginal reticular cells (MRCs), a MZ 
subset of stromal cells.127 The interaction of NCR+ILC3s with MRCs has been shown 
to be bidirectional as MRCs promote the survival of NCR+ILC3s through the release 
of chemokines and cytokines while NCR+ILC3s induce up-regulation of ICAM-1 and 
VCAM-1 on MRCs.127 In addition to the activation of MRCs, mouse splenic ILC3s 
express APRIL, a B cell activating factor (BAFF)-related molecule shown to enhance 
plasma cell survival.128 Furthermore, ILC3s have been shown to produce GMCSF, 
which allows the recruitment of neutrophils resulting in enhanced T- independent (TI) 
production of Abs.127 In line with this, adoptive transfer of GMCSF-sufficient, but not 
GMCSF-deficient ILC3s, is able to increase the abundance of splenic neutrophils in 
Rag1-/-γc-/- mice.127 Another study could show that intestinal ILC3s promote the IgA 
production by B cells either through membrane bound lymphotoxin αβ (LTα1β2) or 
secreted soluble lymphotoxin α (sLTα3).129 It has been reported that intestinal ILC3s 
interact with CD11c+ DCs via membrane bound LTα1β2 triggering LTβ receptor 
(LTβR) expressed on DCs. This interaction controls the expression of inducible nitric 
oxide synthase (iNOs) by DCs, which is known to be critical for IgA induction.130, 131 
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DCs isolated from mice lacking LTβ expression on ILC3s and T cells (LTβ ΔILC,T mice) 
are shown to be less potent in inducing IgA in vitro when cultured with IgM+ B 
cells.129 Furthermore, in contrast to LTβ ΔILC,T mice, mice with a deficiency of LTα 
expression on ILC3s and T cells (LTα ΔILC,T mice) are not able to produce soluble 
LTα3 and consequently show highly reduced numbers of CD40L-expressing T cells 
and reduced IgA levels in the intestine.129 It could be shown that the provision of 
CD40L-sufficient, but not CD40L-deficient T cells results in increased IgA levels 
assuming a crucial role for sLTα3 in promoting the recruitment of T cells to the 
intestinal lamina propria.129 Thus, the production of membrane bound LTα1β2 by 
ILC3s regulates TI IgA induction via controlling iNOS induction by DCs whereas the 
production of sLTα3 by ILC3s regulates the induction of T-dependent (TD) IgA 
induction via recruitment of T cells to the gut.129  
MHC II expression on ILC3s has been reported already some time ago.57, 93 
However, only recently a study suggested that ILC3s regulate CD4+ T cell responses 
in the intestine most probably through the presentation of commensal bacteria-
derived peptides as ILC3s could be shown to produce the Ag-processing machinery 
for class II presentation.132 Genome wide transcriptional profiling revealed that ILC3s 
are highly enriched in transcripts involved in MHC II Ag processing and presentation 
pathways such as Cd74, H2-Ab1, H2-Aa, H2-DMb2 and H2-DMa.132 It could be 
shown that MHC II protein is expressed at highest level on NCR-ILC3s whereas 
NCR+ILC3s only showed minimal expression of MHC II.132 In vitro studies 
demonstrated that NCR-ILC3s are able to process exogenous Ag and to present 
peptide on the cell surface approved by detection of GFP-Eα protein derived 
peptides (GFP- Eα protein; see chapter 2.2.2 Group 2 ILCs). However, OVA-pulsed 
ILC3s failed to induce OVA-specific CD4+ T cell proliferation in vitro most probably 
due to the lack of co-stimulatory molecules CD40, CD80 and CD86.132 As Ag 
presentation in the absence of co-stimulation has been proposed to limit T cell 
responses,133 ILC3s have been suggested to negatively regulate CD4+ T cell 
responses. Indeed, in a mouse model in which MHC II is exclusively deleted on 
ILC3s (MHCIIΔILC mice) spontaneous inflammation in the intestine as well as 
significantly increased levels of proliferating T cells with a memory effector 
phenotype could be observed.132 The authors of this study claimed that due to the 
lack of MHC II on ILC3s CD4+ T cell responses to commensal bacteria are 
dysregulated promoting intestinal inflammation.132 Some functions of NCR- and 
NCR+ILC3s in innate and adaptive immunity are summarized in figure 4 (Fig. 4).  
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Figure 4:	  ILC3s in innate and adaptive immunity. A and B) ILC3-mediated innate (A) and 
adaptive (B) immunity. DC: dendritic cell; MHC II: major histocompatibility complex class II; 
TD: T-dependent; TI: T-independent; sLTα3: soluble lymphotoxin α3; LTα1β2: lymphotoxin 
α1β2; IgA: immunoglobulin type A. Adapted from Mc Kenzie et al., Immunity (2014)55 and 
Magri et al., Current Opinion in Immunology (2015).134  
 
Origin and developmental requirements of ILC2s and ILC3s  
During fetal development, LTi cells arise from lin-IL-7Rα+α4β7+ precursor found in the 
FL.60, 61 In adults, ILC2s and ILC3s have been reported to develop from CLPs in the 
BM.42, 46, 135 A recent study showed, that for ILC2s a more committed precursor, 
which is called immature ILC2 (iILC2), exists in the BM.43 In contrast to CLPs, iILC2s 
express Id2 as well as high levels of Gata3 and show a close relationship to adult 
mature ILC2s in genome-wide analysis. It could be shown that iILC2s are able to 
differentiate successfully into fully functional ILC2s in vitro and in vivo.43 Another 
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research group reported the so-called common helper innate lymphoid progenitor 
(CHILP; lin-Id2+IL-7Rα+CD25-α4β7+), which can be found in the FL as well as in the 
BM. The CHILP, which is assumed to arise from the CLP, is able to differentiate in 
vitro and in vivo into all helper-like ILCs including ILC1s, ILC2s and ILC3s but not into 
conventional NK cells that are cytotoxic ILCs.22 
In addition to the expression of the transcriptional repressor Id2, which is required for 
the development of ILC2s and ILC3s (including LTi cells), Notch signaling has been 
reported to contribute to ILC2 and ILC3 development.42, 46, 135, 136 It has been shown 
that active Notch signaling is required for the development of ILC2s in vitro and in 
vivo,42, 46 whereas the role of Notch signaling in ILC3 development is not completely 
clear. The development of ILC3s from their precursor appears to depend on Notch 
signaling that is differentially regulated in fetal and adult precursors.135 One report 
claimed, that active Notch signaling is important at very early steps of ILC3 
development, but has to be switched off for further differentiation into adult ILC3s.136  
The development of ILC2s and ILC3s (including LTi cells) requires the cytokine IL-
7.34, 42, 88, 89 Other cytokines such as SCF and TSLP have been reported to play as 
well a crucial role in the development of LTi cells.89, 91 Not surprisingly, fetal as well 
as adult ILC precursors express the respective receptors for the cytokines IL-7 and 
SCF.60, 61, 137 Additionally to IL-7Rα (for IL-7) and CD117 (for SCF), they express the 
cytokine receptor fms-like tyrosine kinase 3 (flt3 also known as CD135).135, 138, 139 The 
ligand binding to flt3 is FLT3L, and is a cytokine known to be important for the 
development of several hematopoietic lineages.140, 141 The role of FLT3L in the 
development of ILCs is not yet understood. The effect of FLT3L on ILC precursors, 
on LTi cells in fetal and neonatal mice as well as on adult ILC populations (including 
ILC2 and ILC3s) is discussed in the manuscript: “FLT3L regulates the development 
of innate lymphoid cells in fetal and adult mice” attached in the appendix. By the use 
of FLT3L-deficient mice (flt3l-/- mice)141 and mice with a transgenic overexpression of 
FLT3L under the control of human β-actin promotor (flt3l-tg mice)142 as well as an 
approach in which recombinant FLT3L is administrated to adult mice, the role of 
FLT3L on fetal and adult ILCs and on the development of lymphoid tissues such as 
PPs has been investigated.   
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2.3 Activators of immune cells: Toll-like receptor (TLR) ligands 
and IL-1β  
 
The initiation of an immune response starts with the recognition of the pathogen 
invading the body. Innate immunity serves as the first line of defense and acts mainly 
via innate immune cells expressing germ-line encoded pattern-recognition receptors 
(PRRs) recognizing highly conserved molecular structures of pathogens. Pathogen 
recognition can induce a variety of effector functions by the innate immune system 
such as phagocytosis and subsequent digestion of pathogens or the release of 
cytokines inducing an inflammation. Some pathogens are able to overcome the 
defense mechanisms of the innate immunity. In this case, the adaptive immunity, the 
second arm of the immune system, is required for efficient defense against them. A 
well-orchestrated interplay between the innate and the adaptive immunity is 
indispensable to mount an efficient immune response. Signals derived from the 
innate branch have to be integrated by the adaptive branch to fulfill this task. Some 
of the activators of innate immune cells are described in the following sections. 
 
 TLR ligands induce early immune responses 2.3.1
 
Toll-like receptors (TLRs) are the prototypes of PRRs in mammals able to recognize 
molecular structures broadly shared by pathogens, the so-called pathogen-
associated molecular patterns (PAMPs). Thus, innate immune cells expressing TLRs 
play an essential role in the early recognition of microbial components and 
integration of such signals thereby representing an efficient first line defense. TLRs 
represent an evolutionary ancient host defense system.143 Nowadays, in mice, 13 
different TLRs are identified and each of them recognizes a distinct set of molecular 
patterns that are not found on healthy host cells allowing the discrimination between 
self and non-self in a limited way.144 TLRs are able to recognize various components 
of the bacteria cell wall such as lipopolysaccharide (LPS) of Gram-negative bacteria, 
which is exclusively recognized by TLR4.145, 146 TLR2 is able, together with TLR1 or 
TLR6, to sense peptidoglycan, lipoproteins and lipopeptides of Gram-positive 
bacteria.147, 148, 149, 150, 151 Flagellin, a protein subunit from the bacterial flagella, is 
recognized by TLR5.152 TLR3 has been found to recognize double stranded RNA, a 
major component of many viruses.153 Additionally, TLR7 is identified as an antiviral 
TLR, as it senses the synthetic chemical imiquimod, which is known to stimulate 
antiviral responses.154 Subsequently, TLR7 and the related TLR8 are shown to 
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recognize single stranded viral RNA.155, 156, 157 DNA with unmethylated repeats of the 
dinucleotide CpG, which are frequent in bacteria but rare in vertebrates, is 
recognized by TLR9.158 Furthermore, mouse TLR13 is able to recognize bacterial 
ribosomal RNA.159, 160, 161 Thus, the expression of several distinct TLRs allows the 
recognition of a wide range of different pathogens and viruses. TLRs are either 
expressed on the surface of the cell (TLR1, TLR2, TLR4, TLR5 and TLR6) and 
largely recognize microbes on the basis of microbial membrane components in the 
extracellular space, or they are located within intracellular vesicles (TLR3, TLR7, 
TLR8 and TLR9) and mainly recognize nucleic acids.162 TLR engagement activates 
signaling pathways that provide specific immune responses corresponding to the 
recognized PAMP. The recruitment of one or a combination of Toll/IL-1R (TIR)-
domain containing adaptor proteins (e.g. MyD88, TIRAP, TRIF or TRAM) initiates the 
specific response.163 The adaptor molecule, myeloid differentiation primary response 
protein 88 (MyD88) is used by all TLRs, except by TLR3, which requires TIR-domain 
containing adaptor inducing interferon beta (TRIF) for downstream signaling. TLR 
signaling is mediated via the activation of NFκB, mitogen activated protein (MAP) 
kinases and in case of TLR3 and TLR4 the interferon regulatory transcription factor 3 
(IRF3).163 TLR downstream signaling events culminate in the secretion of 
inflammatory cytokines, type I IFNs, chemokines as well as antimicrobial peptides 
leading to activation of MΦ, recruitment of neutrophils and IFN-inducible gene 
expression.163 One prominent pro-inflammatory cytokine, which is involved in a 
variety of effects mediating innate immunity and host responses, is IL-1β described in 
the next paragraph. 
 
 IL-1β  production and pro-inflammatory function 2.3.2
 
IL-1β production and release are mainly initiated through invading microorganisms 
recognized as PAMPs (described before) or the presence of damage-associated 
molecular pattern molecules (DAMPs), such as uric acid crystals released by dying 
cells. Monocytes, MΦ and DCs are the main cell types producing and secreting IL-1β 
within inflammatory conditions.164, 165, 166, 167 IL-1β is first synthesized as an inactive 
form, the so-called pro-IL-1β, and requires its cleavage into a biological active form, 
IL-1β.168 This cleavage is mediated by a cysteine protease called caspase-1. 
Caspase-1 activation requires the assembly and activation of the inflammasome, a 
multiprotein complex.168 Subsequently, the biological active form of IL-1β is released 
into the extracellular milieu. The receptor for IL-1 contains extracellular 
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immunoglobulin domains and a TIR-domain in the cytoplasmic portion. Signaling via 
IL-1R starts with the binding of IL-1β to the primary receptor subunit, IL-1R1, which 
subsequently allows the recruitment of the second receptor subunit, the IL-1R 
accessory protein (IL-1RAP). The formation of the heterodimer induces the 
recruitment of signaling intermediates such as MyD88 resulting in the activation of 
NFκB and MAP kinase (MAPK) pathways.169 IL-1β released upon microbial triggers 
or other factors induces a variety of processes in other immune cells. MΦ enhance 
their cytokine production and phagocytic ability in response to IL-1β.170 Furthermore, 
by the induction of the transcription factor IFN regulatory factor 4 (IRF4) IL-1 
contributes to the development of Th17 cells, secreting IL-17 and IL-22.171, 172  
Integration of microbial signals directly via TLRs or indirectly via inflammatory 
cytokines  (e.g. via IL-1β) induces the maturation of immature DCs (iDCs) into 
mature DCs, which are able to present peptides derived from ingested pathogens to 
T cells of the adaptive immune system. Before maturation, iDCs are highly 
phagocytic cells of the innate immune system able to recognize microbial products 
via TLRs and to ingest pathogens. DC maturation includes up-regulation of MHC II 
and co-stimulatory molecule (CD40, CD80 and CD86) expression thereby changing 
from a preferentially phagocytic cell to a professional APC able to activate T cells 
inducing T cell effector functions.173, 174 Thus, DCs can be placed at the interface of 
innate and adaptive immunity, capable of integrating “danger” signals and 
transmitting them resulting in the induction of a protective adaptive immune 
response. Ag processing and presentation to CD4+ T cells via MHC II, the role of co-
stimulatory molecules and the effector T cell responses, which can be subsequently 
initiated are described in the following paragraphs.  
 
2.4 Activation of CD4+ T cell responses 
 
 Processing and presentation of Ag to CD4+ T cells  2.4.1
 
T cell-mediated immune responses rely on the recognition of pathogen-derived 
peptides, which are presented via MHC I or II molecules. Peptides presented via 
MHC II molecules are recognized by CD4+ T cells whereas peptides presented in 
context of MHC I molecules are recognized by CD8+ T cells. MHC I molecules are 
specialized to present intracellular Ags, such as viruses or tumor Ags, while Ags from 
extracellular sources, such as bacterial Ags, are presented via MHC II.175 In contrast 
to MHC I molecules, which are constitutively expressed on almost all nucleated cells, 
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expression of MHC II molecules is restricted to professional APCs including DCs, MΦ 
and B cells.  
MHC II molecules consist of two transmembrane chains, α- and β-chain, which are 
synthesized in the endoplasmic reticulum (ER). Stable assembly of the MHC II αβ 
heterodimer in the ER relies on a specialized type II transmembrane chaperone 
protein, the invariant chain (Ii, also known as CD74).176, 177, 178 Ii binds in the MHC II-
peptide binding groove, thereby acts like a surrogate peptide, stabilizes the MHC II 
protein and prevents premature loading of antigenic peptides. The Ii-MHC II 
heterotrimer is transported via the Golgi apparatus into an endolysosomal 
compartment, termed MHC II compartment (MIIC). In the MIIC, Ii is degraded by a 
series of proteolytic cleavage events mediated by the proteases cathepsin S and 
cathepsin L and a residual class-II associated Ii peptide (CLIP) is left in the peptide-
binding groove of the MHC II heterodimer.179 The CLIP bound to each MHC II 
heterodimer has to be replaced by peptides arrived in the MIIC via endosomal 
pathway from the extracellular milieu. Once endocytosed, exogenous proteins are 
degraded by proteases, the CLIP is replaced by such peptides and MHC II molecules 
loaded with the specific peptide are transported to the cell surface where they are 
able to present their loaded peptide to CD4+ T cells.180 HLA-DM (or in mouse H2-DM) 
accelerates the exchange of the CLIP with peptides within MIIC.181, 182, 183 
MHC II expression is mainly restricted to professional APCs like DCs, MΦ and B cells 
as mentioned before. However, MHC II expression can be induced in non-
hematopoietic cell types following the exposure to cytokines, whereby IFNγ is the 
most potent inducer.184 For the transcription of MHC II genes the class II 
transactivator, CIITA, is absolutely required. CIITA is the master regulator of 
constitutive and inducible expression of all MHC II genes as well as their accessory 
genes (e.g. the invariant chain Ii).185, 186, 187 CIITA is recruited to a multiprotein 
complex referred to as MHC II enhanceosome consisting of several factors 
(regulatory factor X (RFX), nuclear factor Y (NFY) and cyclic AMP response element 
binding protein (CREB)) required for MHC II gene expression.186 The MHC II 
enhanceosome serves as a “landing pad” for CIITA subsequently inducing the 
transcription of MHC II genes.186, 188 In contrast to the components of the MHC II 
enhanceosome, which are produced in many cell types, the synthesis of CIITA is 
highly controlled. In mouse, the expression of the gene encoding for CIITA 
(MHC2TA) is regulated by three different promotors (pI, pIII and pIV), which can 
individually be activated in a cell type- as well as stimulus-specific manner.189 This 
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restricted expression of CIITA can act as a molecular switch that controls the specific 
expression of MHC II.  
Before extracellular Ags can be presented via MHC II to CD4+ T cells, these Ags 
have to be taken up by phagocytic cells. Neutrophils, MΦ and immature DCs are 
efficient phagocytic cells. Whereas neutrophils and MΦ mainly destroy phagocytosed 
particles, DCs show reduced degradation and consequently increased conservation 
of antigenic peptides. Moreover, DCs are the key players in presentation of such 
antigenic peptides via MHC II and subsequent activation of CD4+ T cells. Immature 
DCs are known to take up Ag via different types of endocytosis namely phagocytosis 
or macropinocytosis.190 Phagocytosis is triggered by the attachment of extracellular 
particles to surface receptors, such as complement receptors, Fc receptors and 
mannose receptors.191 Macropinocytosis is a non-specific process, where large 
volumes of surrounding fluid containing extracellular Ags are engulfed. Endocytosed 
extracellular Ags are placed into membrane-delimited compartments, known as 
phagosomes. Phagosomes finally fuse with lysosomes to form the phagolysosome in 
which the Ag is degraded by lysosomal proteases. Degraded Ag are loaded on MHC 
II molecules within the phagolysosome and transported to the cell surface.  
 As already mentioned before, DCs express TLRs through which they can recognize 
pathogens and become activated. Exposure to pathogens induces remarkable 
transformation in DCs.  Immature DCs undergo a maturation process and develop 
from highly endocytic cells into professional APCs. DC activation by stimulation with 
either TLR ligands or inflammatory cytokines results in migration of DCs to lymphoid 
organs, redistribution of MHC II molecules from MIIC to the cell surface and 
expression of co-stimulatory molecules.192, 193 Although Ag uptake is transiently 
increased in response to TLR signaling endocytosis is decreased in mature DCs.194 
Furthermore, TLR signaling increases the efficiency of Ag presentation by DCs 
through phagosome maturation.195 
 
 CD4+ T cell activation and effector function 2.4.2
 
The priming of naïve CD4+ T cells to become effector CD4+ T cells carrying out 
different effector functions requires three distinct signals. The first signal is delivered 
by the APCs presenting the Ag via MHC II complex to the CD4+ T cells, which 
recognize the peptide-MHC II complex via its T cell receptor (TCR) inducing TCR 
downstream signaling. Subsequently the second signal, the co-stimulation, has to be 
delivered. APCs express co-stimulatory molecules on their surface, which interact 
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with the corresponding receptors expressed by CD4+ T cells. Finally, the third signal 
is mediated through cytokines produced by the activated APCs and secreted into the 
immunological synapse.196  
CD4+ T cells proliferate and start to produce cytokines when they interact via TCR 
with APCs presenting their specific Ag in context of MHC II and providing the 
additional co-stimulation via binding of co-stimulatory molecules to the corresponding 
receptors on the CD4+ T cells.197, 198, 199, 200, 201 CD69, a C-type lectin receptor, is one 
of the earliest glycoproteins acquired during lymphocyte activation.202 CD69 
expression is induced on the surface of T cells upon TCR engagement.202, 203 The 
induction of CD69 expression is extremely rapid (within hours) and requires de novo 
synthesis.204, 205, 206 Thus, T cell proliferation and CD69 up-regulation on the surface 
of T cells are two parameters to measure early T cell activation upon interaction with 
the cognate Ag presented by APCs.  
APCs are the main drivers of T cell activation and differentiation in lymphoid organs. 
DC are known as professional APCs and are absolutely crucial for the regulation of T 
cell activation, the differentiation into a certain T helper subset, and the T cell effector 
function and survival. In response to microbial simulation, recognized through TLRs, 
or to inflammatory cytokines, DCs undergo maturation, allowing them to migrate into 
lymphoid organs where they can interact with T cells, and inducing the expression of 
the co-stimulatory molecules CD80 and CD86 (also known as B7-1 and B7-2) on 
their surface.207 Via CD80 and CD86, DCs are able to deliver the co-stimulation to 
CD4+ T cells expressing the corresponding receptor, CD28, on the surface.208, 209 The 
CD80/CD86 – CD28 co-stimulation pathway is suggested to deliver the most efficient 
signal, as it could be shown that CD28-deficient cells fail to proliferate in the 
presence of APCs.210 CD28 engagement on T cells has several distinct effects. It 
stimulates the proliferation of T cells and induces up-regulation of high levels of IL-2 
secreted by the T cells.211 Further it promotes T cell survival by enhancing Bcl-XL 
expression.212 Those effects have been shown to depend on the engagement of 
downstream signaling via phosphoinositide-3 kinase (PI3K), NFκB and protein 
kinase B (PKB).213 TCR and CD28 triggering induces several signaling cascades, 
including NFκB, NFAT (nuclear factor of activated T cells), JNK (c-Jun N-terminal 
kinase) and ERK (extracellular regulated kinase), resulting in the expression of IL-
2.214 IL-2 secretion and IL-2 receptor expression by T cells is increased upon 
activation thereby IL-2 achieves an autocrine effect and supports the survival of T 
cells.215 The main elements of this co-stimulatory pathway, CD80216 and CD28217 
were already discovered a long time ago and the absolute requirement for co-
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stimulation to induce activation and proliferation of T cells could be demonstrated by 
the fact that T cells were unresponsive upon TCR engagement in the absence of co-
stimulation.218 T cell activation through TCR triggering in the absence of CD80/86-
CD28 co-stimulation leads to a state of anergy characterized by severely reduced 
production of IL-2 and other effector cytokines.219 CD40, another co-stimulatory 
molecule, mediates APC-T cell dialog and is expressed on DCs. CD40 can be ligated 
by its corresponding ligand, CD40L, expressed on T cells. This results in the 
activation of the NFκB pathway220 inducing increased DC survival221 and DC 
maturation including up-regulation of the co-stimulatory molecules CD80 and 
CD86.222  
DCs can provide all three signals required for efficient CD4+ T cell activation. They 
are able to prime naïve CD4+ T cells inducing activation (signal 1), survival (signal 2) 
and differentiation (signal 3) into different CD4+ T cell effector subsets. CD4+ T cells 
are categorized within these Th cell subsets based on the secretion of a distinct set 
of effector cytokines. Nowadays the following Th subsets are described: Th1 cells, 
Th2 cells, Th17 cells, T follicular helper cells (Tfh) and inducible regulatory T cells 
(iTregs).223, 224 The plasticity between the distinct Th subsets as well as the lineage 
commitment and differentiation into these subsets, and the categorization based on 
the effector cytokine repertoire is still under debate.224 Th1 and Th2 cells, 
characterized by the expression of IFNγ and IL-4, respectively, have been already 
identified in 1986.225 Further research revealed that Th1 cell development depends 
on the expression of the transcription factor T-bet and the presence of IL-12 and IFNγ 
produced by other immune cells (e.g. DCs and NK cells, respectively). By the 
production of IFNγ, Th1 cells are able to promote immunity to intracellular 
microorganism.223, 226, 227 Additionally to IL-4 production, Th2 cells are capable to 
secrete IL-5, IL-9, IL-10, IL-13, IL-25 and amphiregulin thereby contributing to 
immunity against extracellular parasites and to the induction and persistence of 
asthma and allergies. Th2 differentiation requires the transcription factor Gata-3 and 
the cytokines IL-2 and IL-4 whereby IL-4 is a positive feedback loop cytokine in Th2 
differentiation produced by the Th2 cell itself.223, 228, 229, 230 Th17 cells require RORγt 
and the presence of transforming growth factor (TGF)-β for their development.231, 232, 
233, 234 They are characterized as IL-17 and IL-22 producing cells thereby promoting 
immunity against extracellular bacteria and fungi.223, 235 iTreg development depends on 
the transcription factor FoxP3 and the cytokine TGFβ.236, 237 Survival of iTregs is 
mediated via IL-2 as these cells express high levels of CD25, the high affinity 
receptor for IL-2.238 iTregs are involved in the regulation and suppression of immune 
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responses.238 The cytokines IL-6 and IL-21 are the main cytokines involved in the 
differentiation of Tfh cells.239, 240 Recently the transcription factor Bcl-6, which is 
selectively expressed by Tfh cells, has been identified to play an important role in Tfh 
cell differentiation.241 Tfh cells are located in follicular areas of lymphoid tissue and 
participate in the development of Ag-specific B cell immunity.242, 243 They are able to 
interact with Ag-primed B cells in special structures called germinal centers inducing 
the differentiation of B cells into Ig-producing plasma cells and the development of 
long-lived memory B cells.244 Thereby Tfh cells play a significant role in mediating 
humoral immune responses through the interaction with B cells.  
Collectively, DCs are professional APCs and play crucial roles in the induction of 
adaptive immunity. They are able to integrate innate signals and thereby modulate 
the outcome of an immune response. They induce the differentiation of CD4+ T cells 
into distinct helper subsets and promote their survival. Thus, they are able to initiate 
a pathogen-dependent fine-tuned immune response by the induction of the correct T 
cell effector subset. 
  
	   43 
3 Aim of the project 
 
 
Group 3 innate lymphoid cells (ILC3s) were initially described as key players for the 
induction of lymphoid tissue formation and organization during embryogenesis. 
These cells are also found after birth, mainly present at mucosal surfaces in the 
gastrointestinal tract as well as in peripheral secondary lymphoid organs. An innate 
immune function has been attributed to ILC3s in the mucosa of adult mice based on 
their ability to release effector cytokines in response to soluble factors secreted by 
other cells such as dendritic cells (DCs). However, whether ILC3s are able to directly 
sense microbial products is not yet known. Additionally, whether ILC3s possess the 
ability to directly interact with cells of the adaptive immune system and thereby 
contribute to adaptive immune responses is not fully understood. Finally, the tissue-
specific properties of ILC3s have not been investigated until now. 
 
The first aim of the present study was to investigate whether ILC3s are able to 
directly sense and to respond to innate stimulation. To address this question, I tested 
the response of ILC3s to different microbial products and inflammatory cytokines. 
The response of ILC3s to innate challenge was monitored by the examination of 
changes in the phenotype and cytokine production.  
 
The finding that fetal/neonatal ILC3s can express major histocompatibility complex 
class II (MHC II) on their surface57 suggested that ILC3s might be able to interact 
with CD4+ T cells. Therefore, the second aim of the present study was to uncover the 
role of ILC3s in T cell and T-dependent B cell responses. To address this question, I 
tested, whether ILC3s are able to take up antigen (Ag), to process and to present it 
via MHC II to CD4+ T cells. Subsequently, I investigated whether ILC3s are capable 
to promote CD4+ T cell responses in vitro.  To examine the role of ILC3s in CD4+ T 
cell-mediated immunity in vivo, I generated a mouse model with a deficiency of MHC 
II exclusively in ILC3s, and tested Ag-specific CD4+ T cell and T-dependent B cell 
responses. 
Finally, to uncover tissue-related and environment-dependent ILC3 functions, I 
compared the phenotype as well as the ability of peripheral spleen-derived ILC3s 
and small intestine-derived ILC3s to respond to innate challenge and to induce CD4+ 
T cell responses. 
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4 Materials and methods 
 
4.1 Materials 
 
 Reagents and chemicals 4.1.1
 
2-mercaptoethanol      Gibco 
2-propanol (CH3CH(OH)CH3) Merck KgaA 
2x SensiMix SYBR Hi-ROX     Bioline 
Albumin from bovine serum (BSA)    Sigma-Aldrich 
Alum (Aluminium potassium sulphate, AlK(SO4)2)  Sigma-Aldrich  
Ammonium chloride (NH4Cl)     Sigma-Aldrich 
Anti-CD3 soluble Ab (clone 2cll) A. Rolink, University of 
Basel 
Anti-CD4 microbeads      Miltenyi Biotec 
Anti-PE microbeads      Miltenyi Biotec 
Brefeldin A (BFA)      Sigma-Aldrich 
Carboxyfluorescein succinimidyl ester (CFSE)  Molecular Probes 
Ciproxine       Bayer  
Collagenase D      Roche 
Cytochalasin D (CytD)  AppliChem 
D (+) – glucose monohydrate (C6H12O6 x H2O) Merck KgaA 
Deoxyadenosine triphosphate (dATP) Sigma-Aldrich 
Deoxycytidine triphosphate (dCTP) Sigma-Aldrich 
Deoxyguanosine triphosphate (dGTP) Sigma-Aldrich 
Deoxythymidine triphosphate (dTTP) Sigma-Aldrich 
Di-ethanolamine (C4H11NO2) Sigma-Aldrich 
Di-nitrophenyl phosphate (dNPP) Sigma-Aldrich 
Di-potassium hydrogen phosphate (K2HPO4) Merck KgaA 
Di-sodium hydrogen phosphate (Na2HPO4 x 2 H2O) Merck KgaA 
DMEM (1x) GlutaMaxTM-I Gibco 
DNase I Roche 
EDTA disodium salt dihydrate AppliChem 
Ethanol (C2H5OH) Merck KgaA 
Fetal calf serum (FCS, heat-inactivated) Gibco 
FluoSpheres® carboxylate-modified microspheres  Molecular Probes 
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Hoechst 33342 Invitrogen 
Hypoxanthine-aminopterin-thymidine (HAT) supplement  Gibco 
Intracellular (IC) fixation buffer eBioscience 
Insulin Transferrin Selenium Gibco 
Iscove`s modified Dulbecco`s medium (IMDM) Sigma-Aldrich 
Kanamycin Sigma-Aldrich 
L929 Sigma-Aldrich 
Magnesium chloride (MgCl2) Roche 
Magnesium chloride hexahydrate (MgCl2 x 6 H2O) AppliChem 
Non-essential amino acids (NEAA) Gibco  
Oligo dT  Promega 
Phosphate buffered saline (PBS) Biochrom AG 
Penicillin Streptomycin (Pen Strep) Gibco 
Percoll GE Healthcare 
Polyethylene Glycol (PEG) 1500 Roche 
Potassium bicarbonate (KHCO3) Sigma-Aldrich 
Potassium chloride (KCl) AppliChem 
Primatone Sigma-Aldrich 
Propidium iodide (PI) Sigma-Aldrich 
Proteinase K Roche 
Random hexamers Sigma-Aldrich 
Sodium acide (NaN3) Merck KgaA 
Sodium chloride (NaCl) AppliChem 
Sodium dodecyl sulfate (SDS, C12H25NaO4S) BioRad 
Sodium hydrogen carbonate (NaHCO3)  Merck KgaA 
Sodium hydroxide (NaOH) Merck KgaA 
SuperScriptTM III Reverse Transcriptase   Invitrogen 
Taq Polymerase homemade 
Tris (C4H11NO3) Carl Roth GmbH 
Tween-20 AppliChem 
 
 Buffers, solutions and media 4.1.2
 
1x PBS      137 mM NaCl 
       2.7 mM KCl 
       10 mM Na2HPO4 x 2 H2O 
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       2 mM KH2PO4 
       in dH2O 
 
1x TE buffer      10 mM Tris 
       1 mM EDTA 
       in dH2O 
 
BMDC medium     IMDM (SF) 
       5 % FCS 
       200 ng/ml FLT3L 
 
BMMΦ medium     DMEM (1x) GlutaMaxTM-I 
       L929 
 
BW-OTII medium     IMDM (SF) 
       5 % FCS    
 
DMEM (1x) GlutaMaxTM-I    (+) 4.5 g/L D-Glucose 
       (-) Pyruvate 
 
dNTP mix      10 mM dATP 
       10 mM dCTP 
       10 mM dGTP 
       10 mM dTTP 
       in nuclease-free H2O 
 
ELISA buffer (NP-OVA ELISA)   1 % BSA  
       0.2 % Tween-20 
       in 1x PBS 
 
ELISA wash buffer (NP-OVA ELISA)   0.1 % Tween-20 
       in H2O 
 
Erythrolysis buffer     0.15 M NH4Cl 
       10 mM KHCO3 
       0.1 mM EDTA 
       in dH2O (pH 7.2 – 7.4) 
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FACS buffer      1x PBS 
       3 % FCS 
       2 mM EDTA 
 
HAT medium      IMDM (powder) 
       3.02 g NaHCO3 
       2 % FCS 
       2 % IL-6 supernatant 
       1x HAT supplement 
       0.5 % Ciproxine 
 
IMDM (SF)      IMDM (powder) 
       3.02 g NaHCO3 
       1 % PenStrep 
       1 % Ciproxine 
       0.1 % Kanamycin 
       1 % Insulin Transferrin  
       Selenium 
       0.3 % Primatone 
       1 % NEAA 
       0.1 % 2-mercaptoethanol 
 
IMDM 2 % FCS     IMDM (SF) 
       2 % FCS 
 
IMDM 5 % FCS     IMDM (SF) 
       5 % FCS 
 
IMDM 10 % FCS     IMDM (SF) 
       10 % FCS 
 
lysis buffer       1 mM Tris (pH 8.0) 
(for DNA isolation from mouse biopsies)  100 mM NaCl   
10 mM EDTA (pH 8.0) 
0.5 % SDS   
 in dH2O  
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substrate buffer (NP-OVA ELISA)   0.1 g MgCl2 x 6 H2O 
       10 mM NaN3 
       10 % C4H11NO2 
in 1 l dH2O (pH 9.8)   
 
 Cytokines, TLR ligands, peptides, proteins 4.1.3
 
FMS-like tyrosine kinase ligand (FLT3L)  A. Rolink, University of Basel 
IL-1β, recombinant     Biovision 
IL-6, supernatant (clone X63)    A. Rolink, University of Basel 
IL-7, recombinant     Peprotech 
IL-23, recombinant     eBioscience 
SCF, recombinant     Peprotech 
TNFα, recombinant     R&D systems 
IFNβ, recombinant     Sigma-Aldrich   
IFNγ, recombinant     R&D systems 
 
CpG (class B) Trilink Biotechnologies (CpG-
ODN1826 InvivoGen) 
Flagellin (Flag) InvivoGen 
Imiquimod (Imiqui) InvivoGen 
Lipopolysaccharide (LPS) Sigma-Aldrich 
Pam3Cys (P3C) InvivoGen 
Poly I:C InvivoGen  
Zymosan (Zym) InvivoGen 
 
Ovalbumin323 - 339 (OVA323 - 339) peptide AnaSpec 
OVA protein (Imject Ovalbumin) Thermo Fisher Scientific Inc. 
4-hydroxy-3-nitrophenylacetyl NP- (18)-OVAL  Biosearch Technologies Inc. 
  
	   49 
 Antibodies (Abs) 4.1.4
 
Abs used for flow cytometry analysis (directed against murine proteins) 
specificity      clone 
CD3ε        17A2, 145-2C11  
CD4        RM4-4, RM4-5 and GK1.5  
CD8α        53-6.7 
CD11b       M1/70 
CD11c       117310, N418  
CD19        6D5 
CD21       7G6 
CD23        B3B4 
CD25  (IL-2Rα)     PC61, 7D4  
CD29  (β1 integrin)     HMb1-1 
CD40       1C10, HM40-3  
CD44        IM7 
CD45R (B220)     RA3-6B2 
CD54  (ICAM-1)     3E2 
CD62L       MEL-14  
CD69        H1.2F3  
CD80        16-10A1  
CD86        GL1  
CD90.2 (Thy1.2)     30-H12 
CD117 (ckit)      2B8 
CD127 (IL-7Rα)      A7R34  
CD132 (γc chain)     TUGm2 
CD184 (CXCR4)     2B11  
CD185 (CXCR5)     2G8  
CD196 (CCR6)     29-2L17 
CD197 (CCR7)     4B12 
CD275 (ICOSL)     HK5.3 
CD278 (ICOS)     C398.4A 
α4β7        DATK32 
F4/80        BM8 
Gr-1        RB6-8C5 
IFNγ        XMG1.2 
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MHC II       M5/114.15.2, 25/09/2017 
NKp46       29A1.4 
NK1.1        PK136 
RORγt       AFKJS-9, B2D 
TCRβ        H57-597  
TCRγδ       UC7-13D5 
 
All reagents were purchased from BD Bioscience, eBioscience or Biolegend (all San 
Diego, CA). Primary monoclonal Abs (mAbs) were conjugated to either fluorescein 
isothiocyanate (FITC), phycoerythrin (PE), allophycocyanin (APC), brilliant violet 421 
(BV421TM) or the tandem dyes phycoerythrin cyanine 7 (PECy7), peridinin chlorophyll 
(PerCP)-eFluor 710 and allophycocyanin cyanine 7 (APCCy7).  
Biotin-conjugated primary mAbs were detected using secondary anti-rat polyclonal 
Abs conjugated either to Streptavidin/PECy7, Streptavidin/APCCy7 or 
Streptavidin/BV421TM (Biolegend). 
Blocking of Fc receptors was performed using anti-mouse FcγRII/III mAb (clone 
2.4G2, purified supernatant, home made). 
 
Abs used for Lymphotoxinαβ  staining 
LTβ-R Fc (human)     J. Browning, Biogen 
Biotin-conjugated goat anti-human IgG  Jackson Immunosearch 
 
Abs used for ELISA (NP - OVA) 
For coating of plates: 
Purified anti-mouse IgM (unlabeled) M41 (A. Rolink, University of 
Basel)  
Purified anti-mouse IgG3 (unlabeled)  R2-38, BD Bioscience 
 
For detection: 
Biotin-conjugated goat anti-mouse IgM M41 (A. Rolink, University of 
Basel) 
Biotin-conjugated goat anti-mouse IgG  Caltag Laboratories 
Biotin-conjugated goat anti-mouse IgG1  Caltag Laboratories 
Biotin-conjugated goat anti-mouse IgG2a  Caltag Laboratories 
Biotin-conjugated goat anti-mouse IgG2b  Caltag Laboratories 
Biotin-conjugated goat anti-mouse IgG3  Caltag Laboratories 
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Alkaline phosphatase (AKP) – Streptavidin  Roche 
AKP- anti-mouse IgG3    R40-82, BD Bioscience 
 
 Primers for real time quantitative PCR (RT qPCR) 4.1.5
 
β-actin: 
Fwd: 5’ CAATAGTGATGACCTGGCCGT 3’ 
Rev: 5’ AGAGGGAAATCGTGCGTGAC 3’ 
IL-1β: 
Fwd: 5’ GACCCCAAAAGATGAAGGGCT 3’   
Rev: 5’ ATGTGCTGCTGCGAGATTTG 3’ 
TNFα: 
Fwd: 5’ CCAAGTACTTAGACTTTGCGG 3’ 
Rev: 5’ CTGAGGAGTAGACAATAAAGGG 3’ 
IFNγ: 
Fwd: 5’ CTGAGACAATGAACGCTACAC 3’ 
Rev: 5’ TTTCTTCCACATCTATGCCAC 3’ 
 
 Kits 4.1.6
 
Experion RNA HighSens Analysis Kit   BioRad 
Foxp3 staining buffer set      eBioscience 
LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit   Molecular Probes 
mouse IL-17 ELISA MAXTM Standard Set    Biolegend 
mouse IL-22 ELISA MAXTM Deluxe Set    Biolegend  
RNeasy Micro Kit       Qiagen  
RNeasy Mini Kit       Qiagen 
SensiMix SYBR Hi-ROX Kit     Bioline 
SuperScriptTM III Reverse Transcriptase   Invitrogen 
Zombie AquaTM Fixable Viability Kit     Biolegend 
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 Tools and instruments 4.1.7
 
BD Microtainer SST tubes      BD Bioscience 
Cell counter CASY INNOVATIS    Roche 
Cell strainer (70 µm / 100 µm)    Falcon 
CO2 - incubator       Binder 
Confocal microscope LSM 510 Meta    Zeiss 
Cs-137 radiator      Gammacell 
Eppendorf centrifuge 5810 R, 5415 R, 5417 R  Eppendorf 
Eppendorf Thermomixer Comfort    Eppendorf 
Eppendorf Mastercycler Gradient    Eppendorf 
ELISA plate reader      ASYS Expert Plus 
FastPrep-24 instrument      MP Biomedicals 
Flow cytometer BD FACSAria Ilu    BD Bioscience 
Flow cytometer BD FACSCalibur    BD Bioscience 
Flow cytometer BD FACSCanto II    BD Bioscience 
MACS® multi stand (magnetic column holder)  Miltenyi Biotec 
MACS® separation columns MS/LS Miltenyi Biotec 
MAXI sorb 96 well plates     Nunc 
Micro tubes PP (1.5 ml)      Sarstedt 
Luminex 100 (LX100) analyzer     Invitrogen 
Nanodrop 2000c      Thermo Scientific 
Rotorgene RT PCR machine (RG-3000A)   Corbett Research 
Shaker Polymax 1040     Heidolph 
Syringes 1 ml BD MicroFine+     BD Bioscience 
Thermocyler Biometra (PCR)     BIOLABO 
Vortex Genie       Scientific Industries 
Waterbath       GFL 
Zirconia beads       BioSpec Products 
 
 Software 4.1.8
 
Program  Application    Provider 
FlowJo   FACS analysis   Tree Star Inc., USA 
Prism   Graphs, calculations   GraphPad Software  
        Inc., USA 
ImageJ  Image analysis   NIH, USA  
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 Mice 4.1.9
 
C57BL/6 (WT) mice were purchased from Janvier (Saint Berthevin Cedex, France). 
RORγ-/-,70 MHCIIΔ/Δ (here referred to as I-ab-/-),245 Rag2-/- (provided by G. Hollaender, 
University of Basel, Switzerland and Jesus College Oxford, UK),246 OT-IItg (provided 
by A. Rolink, University of Basel, Switzerland),247 I-abneo (provided by E. Palmer, 
University of Basel, Switzerland),248 RORc(γt)-Cretg mice (provided by A. Diefenbach, 
University of Mainz, Germany),25 MyD88fl,249 MyD88-/- (provided by M. Donath, 
University Hospital, Basel, Switzerland),250 MyD88-/-Trif-/- (crossing between MyD88-/- 
and Trif-/-  mice,251 provided by B. Holzmann, Technische Universität München, 
Munich, Germany), IL-1R1-/- (provided by M. Manz, University of Zurich, 
Switzerland),252 IL-23p19-/- (provided by B. Becher, University of Zurich, 
Switzerland),253 I-abΔILC3 (MHC II deficiency exclusively in RORγt+ ILCs) and 
MyD88ΔILC3/T mice (MyD88 deficiency exclusively in RORγt+ cells) were kept under 
specific-pathogen free (SPF) conditions. The animal experiments received the 
approval of the Cantonal Veterinary Office of the city of Basel, Switzerland. 
 
4.2 Methods 
 
 Time mating 4.2.1
 
For timed pregnancies two females and one male were placed in the same cage in 
the late afternoon. The next morning (approx. 15 h later), male and females were 
separated again. Females were checked for vaginal plugs. Plug positive females 
were assumed to be at gestational age 0.5 days.  
 
 Generation of I-abΔILC3 and MyD88ΔILC3/T mice 4.2.2
 
I-abΔILC3 mice were generated by crossing I-abneo mice, which contain a floxed H2-
Ab1 allele, with RORc(γt)-Cretg mice. F1 generations were backcrossed to I-abneo 
mice. I-abΔILC3 mice are homozygous for the floxed H2-Ab1 allele and carry one copy 
of the Cre transgene.  
MyD88ΔILC3/T mice were generated by crossing MyD88fl mice, which contain a floxed 
MyD88 allele, with RORc(γt)-Cretg mice. F1 generations were backcrossed to 
MyD88fl mice. MyD88ΔILC3/T mice are homozygous for the floxed MyD88 allele and 
carry one copy of the Cre transgene. 
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 Genotyping of I-abΔILC3 and MyD88ΔILC3/T mice 4.2.3
 
Isolation of DNA 
For isolation of genomic DNA, biopsies were digested in lysis buffer containing 300 
µg/ml Proteinase K (at least 3 h at 56 °C while shaking at 700 rpm on a heat block). 
Saturated NaCl (6 M) was added for 10 min at 4 °C to remove membrane lipids. After 
centrifugation, supernatant was collected and DNA was precipitated by addition of 2-
propanol for 15 min at RT. DNA was recovered in 1x TE buffer and stored at 4 ºC. 
 
Reaction mix for PCR 
1. Cre - PCR 
Primer Cre Fwd:  5’ CGTACTGACGGTGGGAGAAT 3’ 
Primer Cre Rev:  5’ TGCATGATCTCCGGTATTGA 3’ 
 
PCR reaction mix: 
2.5 µl  10x buffer  
0.5 µl  Cre Fwd primer (10 µM) 
0.5 µl  Cre Rev primer (10 µM) 
0.5 µl  dNTPs (10 mM)   
0.1 µl    Taq Polymerase (homemade) 
 1 µl  genomic DNA 
fill up to 25 µl final volume with H2O 
 
PCR program for amplification:  
step 1  94 ºC  5 min 
step 2  94 ºC  30 sec 
step 3  58 ºC  30 sec 
step 4  72 ºC  90 sec  step 2 - 4 33 x 
step 5  72 ºC  10 min 
step 6  10 ºC  hold 
 
product length:   
Cre: ~420 base pairs (bp) 
 
2. MyD88fl - PCR 
Primer MyD88 Fwd:   5’ GTT GTG TGT GTC CGA CCG T 3’ 
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Primer MyD88 Rev:   5’ GTC AGA AAC AAC CAC CAC CAT GC 3’ 
 
PCR reaction mix: 
1.2 µl  10x buffer  
1.2 µl  MyD88 Fwd primer (10 µM) 
1.2 µl  MyD88 Rev primer (10 µM) 
 0.24 µl dNTPs (10 mM)   
 0.96 µl MgCl2 
 1 µl    Taq Polymerase (homemade) 
 1 µl  genomic DNA 
fill up to 12 µl final volume with H2O 
 
PCR program for amplification:  
step 1  94 ºC  3 min 
step 2  94 ºC  30 sec 
step 3  66 ºC  1 min 
step 4  72 ºC  1 min  step 2 - 4 35 x 
step 5  72 ºC  2 min 
step 6  10 ºC  hold 
 
product length:  
homozygote: 353 bp 
heterozygote: 266 bp and 353 bp 
wild type: 266 bp 
 
3. I-abneo -PCR 
Primer common Fwd:  5’ CTC TAC ACC CCC AAC ACA CC 3’ 
Primer WT Rev:   5’ AGT GAG CGA GCA CAG ACA AG 3’ 
Primer I-ab Rev:   5’ TCG CCT TCT TGA CGA GTT CT 3’ 
 
PCR reaction mix: 
1.2 µl  10x buffer  
1.2 µl  common Fwd primer (10 µM) 
1.2 µl  WT Rev primer (10 µM) 
1.2 µl  I-ab Rev primer (10 µM) 
0.24 µl  dNTPs (10 mM)   
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0.96 µl  MgCl2 
1 µl    Taq Polymerase (homemade) 
1 µl  genomic DNA 
fill up to 12 µl final volume with H2O 
 
PCR program for amplification:  
step 1  94 ºC  3 min 
step 2  94 ºC  30 sec 
step 3  62 ºC  30 sec 
step 4  72 ºC  30 sec  step 2 - 4 35 x 
step 5  72 ºC  2 min 
step 6  10 ºC  hold 
 
product length:  
homozygote: 199 bp 
heterozygote: 199 bp and 295 bp 
wild type: 295 bp 
 
 Flow cytometry and cell sorting 4.2.4
 
Cells derived from various organs were stained with mAbs using standard 
protocols.88 Briefly, cells were resuspended in FACS buffer and stained with 
biotinylated or fluorochrome-conjugated Abs (30 min, 4 ºC). Fc receptors were 
blocked by incubation of the cells with anti-mouse FcγRII/III mAb (clone 2.4G2). 
Fluorochrome-conjugated streptavidin was added as a second incubation step (20 
min, 4 ºC) for stainings including biotinylated Abs.  
Intracellular RORγt staining was carried out using Foxp3 staining buffer set 
(eBioscience) according to manufacturer`s protocol. For intracellular cytokine 
staining (IFNγ), IC fixation buffer (eBioscience) was used and cells were incubated 
with 10 µg/ml Brefeldin A (BFA) for 4 h at 37 °C before analysis. 
Dead cells were identified using LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit 
(Molecular Probes), Zombie AquaTM Fixable Viability Kit (Biolegend) or in case of 
non-fixed cells propidium iodide (PI) solution (Sigma-Aldrich).  
Lymphotoxinαβ (LTαβ) staining was performed as previously described.87 Briefly, 
cells were treated with anti-FcγRII/III mAb (clone 2.4G2) and 0.5 % mouse and rat 
serum. LTβR-Fc (J. Browning, Biogen, Cambridge) was added and detected using 
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biotin-conjugated goat anti-human IgG (Jackson Immunoresearch) pretreated for 30 
min with 4 % rat and mouse serum. Finally, fluorochrome-conjugated streptavidin 
and surface Abs were added. 
Data acquisition was realized using FACSCalibur (four color staining) or FACSCanto 
II (eight color staining). Data were analyzed using FlowJo software (Tree Star). 
Cell sorting was done using FACSAria Ilu (BD Bioscience, >98 % purity). 
Absolute numbers of cells derived from various organs were determined by counting 
cells with the cell counter CASY INNOVATIS (Roche). 
 
 Cell isolation and culture 4.2.5
 
For in vitro generation of FL-derived NCR-ILC3s, total FL cells were isolated from 
14.5 days post coitum (dpc) WT embryos, stained with PE-conjugated anti-α4β7 Ab 
(DATK32) and purified with magnetic associated cell sorting (MACS®, Miltenyi 
Biotec). MACS® - enriched FL-derived α4β7+ ILC3 precursors were cultured for 5 days 
in supplemented Iscove’s modified Dulbecco’s medium containing 2 % FCS (IMDM 2 
% FCS) in the presence of 20 ng/ml IL-7 (Peprotech) and 20 ng/ml SCF (Peprotech) 
at 37 ºC and 10 % CO2 as described before.89 Total cells were harvested from 
cultures and in vitro generated NCR-ILC3s were sorted based on CD90.2, CD117 
and CD4 expression. 
Splenic and small intestinal lamina propria (LP) NCR-ILC3s were isolated from spleen 
and small intestine (SI) of adult mice. Briefly, SI was opened longitudinally, feces 
were removed, and SI was cut into small pieces, which were incubated in 1x PBS 
containing 30 mM EDTA for 30 min at 4 ºC (tubes were laid down horizontally on 
ice). Afterwards, tissue pieces were washed several times in 1x PBS by vigorous 
shaking and then incubated in Dulbecco modified eagle’s minimal essential medium 
(DMEM, Gibco) containing 0.025 mg/ml DNAseI (Roche) and 1 mg/ml Collagenase D 
(Roche) for total 1 h at 37 ºC. Every 15 min, tissue pieces in medium were pipetted 
up and down 20 times and afterwards the supernatant was collected (by passing 
through a 100 µm filter). The remaining tissue pieces were re-incubated with fresh 
pre-warmed medium containing DNAseI and Collagenase D. Cell suspension was 
pelleted, resuspended in 5 ml 40 % Percoll (GE Healthcare), underlaid with 3 ml 80 
% Percoll and centrifuged for 30 min at 20 ºC (1800 rpm, acceleration 4, brake 1). 
Cells of the interphase were collected (total LP lymphocytes).  
Spleens were cut into pieces, washed in 1x PBS by vigorous shaking and digested 
with DNaseI and Collagenase D as described for SI tissue pieces.  After digestion, 
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spleen cells were pelleted, washed and red blood cells were lysed using erythrolysis 
buffer (2 min at room temperature (RT)).  
Ex vivo isolated splenic or small intestinal LP ILC3s were sorted based on the 
expression of CD117 or CD90.2 and the lack of the lineage marker CD3ε, CD8α, 
CD11c, CD19, B220, Gr-1, TCRβ, TCRγδ, NK1.1 and NKp46.  
Naïve CD4+ T cells from spleen and LNs of OT-IItg mice were magnetically purified by 
using CD4-beads (LTR4, Miltenyi Biotec) following manufacturer’s instruction. 
Additionally, MACS® - enriched CD4+ T cells were sort-purified based on CD4 
expression and the lack of CD11c to reach >98 % CD4+ T cell purity.  
BMDCs and BMMΦ were generated as described elsewhere.254, 255 In brief, femurs 
and tibias of WT mice were collected and the BM was recovered by crushing the 
bones. Red blood cells were lysed using erythrolysis buffer (2 min at RT). For 
BMDCs, total BM cells were cultured in a 6 well plate (Nunc) in supplemented IMDM 
containing 5 % FCS (IMDM 5 % FCS) in the presence of 200 ng/ml FLT3L (A. Rolink, 
University of Basel) at 37 ºC and 10 % CO2. For BMMΦ, total BM cells were cultured 
in a 10 cm petridish (Sarstedt) in DMEM (Gibco) supplemented with L929 (Sigma 
Aldrich) at 37 ºC and 10 % CO2. Cells were harvested after 7 days in culture.  
 
 Generation of BW - OTII cells 4.2.6
 
BW-OTII cells were generated as already described.256 Briefly, total splenocytes of 
an OT-IItg mouse were cultured for 2 days in supplemented IMDM containing 10 % 
FCS (IMDM 10 % FCS) in the presence of 5 µg/ml soluble anti-CD3 Ab (clone 2cll, A. 
Rolink, University of Basel). Activated OT-IItg splenocytes were fused with the 
TCRαβ- BW5147 NFAT-EGFP fusion partner using pre-heated PEG 1500 solution. 
Cells were plated out at limiting dilution in the presence of HAT (hypoxanthine-
aminopterin-thymidine) medium. Grown BW-OTII clones were tested in vitro in the 
presence of irradiated WT splenocytes and OVA323-339  peptide.   
 
 ILC3 stimulation and Ag presentation assay in vitro 4.2.7
 
Sort-purified in vitro generated NCR-ILC3s or ex vivo isolated splenic and LP NCR-
ILC3s were cultured in a 96-well plate (Costar, Corning Inc.) in the presence of either 
TLR ligands (100 ng/ml Pam3Cys, 25 µg/ml Poly I:C, 1 µg/ml Flagellin, 1 µg/ml 
Imiquimod, 10 µg/ml Zymosan, 1 µg/ml LPS, 1 µM CpG), pro-inflammatory cytokines 
(20 or 100 ng/ml IL-1β, 20 ng/ml IL-23) or in medium alone for 48 h.  
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To test Ag presentation and CD4+ T cell activation, 5 x 104 sort-purified stimulated 
(20 ng/ml IL-1β, 24 h) NCR-ILC3s were co-cultured with either 1.5 x 105 ex vivo 
isolated and sort-purified OT-IItg CD4+ T cells or 1 x 105 cultured BW-OTII cells in the 
presence of either OVA323-339 peptide (5 µg/ml), OVA protein (100 µg/ml) or medium 
alone (w/o Ag) for 48 - 72 h or 12 - 15 h, respectively.  
 
 CFSE labeling and fluorescent latex bead uptake 4.2.8
 
To follow up proliferation of CD4+ T cells upon antigen (Ag) challenge, OTIItg CD4+ T 
cells were labeled with 7.5 µM carboxyfluorescein succinimidyl ester (CFSE) in 1x 
PBS for 10 min at 37 °C. The reaction was stopped by addition of 1x PBS containing 
80 % FCS. 
Fluorescent latex bead uptake was performed as previously described with some 
adaptations.257 Briefly, in vitro generated NCR-ILC3s or ex vivo isolated splenic and 
LP NCR-ILC3s were cultured in a 96-well plate flat bottom over night (o/n) to allow 
the cells to settle down. Latex beads (FluoSpheres® carboxylate-modified 
microspheres, 1 µm, red fluorescent (580/605)) were added for 6 h at 37 ºC and 4 
ºC. To examine the specificity of bead uptake, ILC3s were pre-incubated for 1 h in 
the presence of 0.5 µM Cytochalasin D, washed and afterwards incubated with latex 
beads for 6 h at 37 ºC. To compare bead uptake of BMMΦ and NCR-ILC3s, cells 
were harvested after 2 h or 24 h. Bead internalization was analyzed by flow 
cytometry and immunofluorescence microscopy. For immunofluorescence 
microscopy, in vitro generated NCR-ILC3s were stained with FITC-conjugated anti-
CD90.2 (30-H12, 30 min at 4 °C) and HOECHST dye (Hoechst 33342, 30 min at 37 
°C) after incubation with beads. Bead uptake was monitored using a confocal laser-
scanning microscope (Zeiss LSM 510 Meta). Images were analyzed with ImageJ (W. 
Rasband, NIH). An adjustment of brightness and contrast was performed. 
 
 Adoptive cell transfer and immunization 4.2.9
 
To investigate CD4+ T cell proliferation in vivo, 3 x 106 OT-IItg CD4+ T cells (CFSE+) 
were intravenously (i.v.) injected into WT, I-abΔILC3 and I-ab-/- recipient mice, which 
additionally were i.v. immunized with OVA323-339 peptide (20 µg), OVA protein (100 
µg) and CpG (50 µM). 48 h later, OT-IItg CD4+ T cell proliferation was examined in 
the spleen by flow cytometry.  
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To examine T- dependent (TD) B cell responses in vivo, 2 x 106 OT-IItg CD4+ T cells 
plus CpG (25 µM) were i.v. injected into WT, I-abΔILC3 and RORγ-/- mice. Mice were 
immunized intraperitoneally (i.p.) with 100 µg alum-precipitated NP-OVA (NP (18)-
OVAL) at day 0. Sera were collected 1 day before (day -1) and at day 5 and 14 after 
NP-OVA immunization and CD4+ T cell transfer. 
To monitor CD4+ T cell – NCR-ILC3 interaction in vivo, APCs (either BMDCs or in 
vitro generated NCR-ILC3s) were i.v. injected into I-ab-/- mice. 24 h later, OT-IItg CD4+ 
T cells were adoptively transferred (i.v.) and mice were immunized. Different 
immunization strategies were used; i) alum-precipitated NP-OVA (100 µg), ii) OVA 
peptide (20 µg) and OVA protein (100 µg), iii) OVA peptide (20 µg), OVA protein (100 
µg) and CpG (50 µM). CD4+ T cell proliferation was monitored 48 h after 
immunization in the spleen, the inguinal LNs and the mesenteric LNs. In a second 
approach, APCs were injected into the foot pad (f.p.) of I-ab-/- mice in a maximal 
volume of 50 µl and monitored after different time points (3 - 24 h) in the draining LNs 
(popliteal LNs).  
To investigate activation state of NCR-ILC3s upon innate challenge in vivo, WT or 
Rag2-/- mice were injected i.p. with 100 µM CpG (CpG-ODN1826) or 100 µg LPS. 
The phenotype of splenic NCR-ILC3s was assessed 6 h later by flow cytometry. To 
perform RT qPCR analysis of spleen tissue, a small tissue piece was immediately 
frozen in liquid nitrogen (N2). 
 
 Antibody and cytokine detection by ELISA and Luminex assay 4.2.10
 
To detect NP-OVA-specific Abs in the serum of immunized mice, NUNC 
immunoplate Maxisorb F96 plates were coated with 5 µg/ml NP-OVA (Biosearch 
Technologies Inc.) in 1x PBS at 4 ºC o/n. Sera were incubated for 1.5 h at RT and 
after washing (H2O, 0.1 % Tween-20) biotin-conjugated goat anti-mouse IgG, IgG1, 
IgG2a, IgG2b or IgG3 (Caltag Laboratories, 1.5 h, RT) were added and detected by 
alkaline-phosphatase (AKP)-conjugated Streptavidin (Roche, 45 min, RT). Plates 
were developed with dinitrophenyl phosphate (dNPP, 1 mg/ml, Sigma) in substrate 
buffer. The reaction was stopped with 1 M NaOH (Fluka). The optical density (OD) 
was determined at 405 nm with an ELISA reader (ASYS Expert plus).  
To detect total IgM and IgG3 levels in the serum of non-immunized mice, NUNC 
immunoplate Maxisorb F96 plates were coated with either 5 µg/ml purified anti-
mouse-IgM (unlabeled, clone M41) or purified anti-mouse IgG3 (clone R2-38) in 1x 
PBS at 4 ºC o/n. Sera were incubated for 1.5 h at RT and after washing biotin-
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conjugated goat anti-mouse IgM was added to IgM coated plates (1.5 h, RT) and 
detected by AKP-conjugated Streptavidin (45 min, RT). AKP-conjugated anti-mouse 
IgG3 (R2-38) was added to IgG3 coated plates (1.5 h, RT). Plates were developed 
and OD at 405 nm was determined as described before.  
IL-17 and IL-22 were determined in the cell culture supernatants of NCR-ILC3s by 
either using mouse IL-17 ELISA MAXTM Standard Set (Biolegend) or mouse IL-22 
ELISA MAXTM Deluxe Set (Biolegend) according to manufacturer’s instructions. OD 
was determined at 450 nm with an ELISA reader (ASYS Expert plus).  
In addition, cytokines in cell culture supernatants of in vitro generated NCR-ILC3s 
were quantified using a multiplex-bead based Luminex assay (mouse cytokine 20-
plex panel, Invitrogen, Life technologies) according to manufacturer’s protocol. 
Analysis was performed with a Luminex 100 (LX100) analyzer (Invitrogen, Life 
technologies). 
 
 RNA isolation, cDNA synthesis and RT qPCR 4.2.11
 
For RNA isolation from whole spleen tissue, a small tissue piece was immediately 
frozen in liquid N2 in a 1.5 ml Micro tube PP (Sarstedt) containing Zirconia beads 
(BioSpec Products). Whole tissue was homogenized using FastPrep-24 instrument 
(MP Biomedicals) for 1 min at 6.5 m/sec. Afterwards, RNA was isolated with the 
RNeasy Mini Kit (Qiagen) according to manufacturer’s protocol. RNA quantification 
and quality assessment were performed on a Nanodrop 2000c (Thermo Scientific 
Inc.).  
First-strand cDNA synthesis was carried out using Oligo dT (Promega), dNTPs 
(Roche), random hexamers (Sigma-Aldrich) and Superscript III Reverse 
Transcriptase (Invitrogen) according to manufacturer’s instructions. Real-time qPCR 
for quantitative expression analysis was performed on a Rotor-Gene RG-3000A 
(Corbett research) using SensiMix SYBR Hi-Rox Kit (Bioline). The results were 
normalized to the housekeeping gene β-actin using the comparative threshold cycle 
method (ΔCT) for relative quantification. 
 
 DNA microarray analysis 4.2.12
 
The gene expression profiles of in vitro generated CD4+ and CD4- NCR-ILC3s were 
assessed using Affymetrix Gene 2.0 ST Array (Affymetrix, Santa Clara, CA). 
Microarray data were generated by analysis of only one specimen per experimental 
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condition; i) naïve CD4+ NCR-ILC3s, ii) naïve CD4- NCR-ILC3s, iii) IL-1β-activated 
CD4+ NCR-ILC3s and iiii) IL-1β-activated CD4- NCR-ILC3s. The activation of cells 
with IL-1β was carried out in in vitro cultures for 1 h at 37 °C. RNA from sort-purified 
in vitro generated CD4+ and CD4- NCR-ILC3s (2 x 105 – 1 x 106 cells) was isolated 
using the RNeasy Micro Kit (Qiagen) according to manufacturer’s protocol. High 
quality of RNA was confirmed with the Experion RNA HighSens Analysis Kit 
(BioRad). RNA target synthesis starting with 258.7 ng RNA was performed using WT 
Expression Kit (Ambion).  Fragmentation and labeling of amplified cDNA were 
carried out using GeneChip® WT Terminal Labeling Kit (Affymetrix). DNA was 
loaded on Mouse Gene 2.0 ST Array (Affymetrix), hybridized for 17 h and afterwards 
washed and stained using Affymetrix protocol FS450_0007. The GeneChips were 
processed with an Affymetrix GeneChip® Scanner 3000 7G and DAT images (raw 
image data from chip scanner) as well as CEL files (intensity values) of the 
microarray were generated using Affymetrix GeneChip® Command Control® 
Software (AGCC, version 3.0.0.1214). Affymetrix CEL files were normalized based 
on the RMA (Robust Multiarray Average)258 and data were log2-transformed using 
Partek® Genomics Suite (version 6.12.0907) software (Partek Inc. St. Louis, MO).  
 
 Statistical analysis 4.2.13
 
Statistical analysis was performed using Mann Whitney U test, unpaired Students t-
test and Wilcoxon test with Prism software (GraphPad Software, Inc.). 
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5 Results 
 
5.1 In vitro generation of natural cytotoxicity receptor-negative 
(NCR–) ILC3s. 
 
 Fetal liver-derived α4β7+ cells can give rise to CD4+ and CD4- 5.1.1
NCR- group 3 innate lymphoid cells in vitro.  
 
To study the immune response of natural cytotoxicity receptor (NCR)- group 3 innate 
lymphoid cells (NCR-ILC3s) toward innate stimuli in vitro, these cells were either in 
vitro generated from α4β7+ ILC3 precursors or ex vivo isolated from different organs 
of adult mice. The α4β7+ ILC3 precursors could be found in the fetal liver (FL) of WT 
embryos 14.5 dpc and were known to give rise to NCR-ILC3s in vitro.60, 61 Therefore, 
for in vitro generation of NCR-ILC3s, I cultured FL-derived α4β7+ ILC3 precursors for 5 
days in the presence of IL-7 and SCF. These two factors were known to be essential 
for the survival and maintenance of NCR-ILC3s in vitro and in vivo.88, 89, 91, 103 By the 
use of these culture conditions the majority of α4β7+ ILC3 precursors differentiated 
into FL- derived NCR-ILC3s expressing characteristic phenotypic markers of NCR-
ILC3s like CD90.2, CD127 (IL-7Rα) and CD117 (Fig. 5 A).  
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Figure 5:	   In vitro generation of NCR-ILC3s from α4β7+ ILC3 precursors isolated from the FL of 
14.5 dpc WT embryos. A) Phenotype of α4β7+ cells isolated from the FL of 14.5 dpc WT embryos 1, 4 
and 5 days in culture with IL-7 and SCF. Representative dot plots are shown. Numbers in dot plots show 
the percentage of cells in each gate. 
 
Phenotypic analysis of in vitro generated NCR-ILC3s revealed that within the 
CD90.2+CD117+ population of NCR-ILC3s two different subpopulations of cells 
existed (Fig. 6 A). One subpopulation showed CD4 expression on the surface (CD4+ 
NCR-ILC3s, approximately 30 % of total NCR-ILC3s), whereas the other lacked the 
expression of CD4 (CD4- NCR-ILC3s, approximately 70 % of total NCR-ILC3s) (Fig. 6 
A). To examine whether differences in the phenotype of these two subpopulations 
exist, I performed a detailed analysis of in vitro generated NCR-ILC3s. 
The retinoic acid related orphan receptor RORγt is a transcription factor, which is 
absolutely required for the development of all ILC3 subsets.70, 93 In line with this, both 
in vitro generated CD4+ and CD4- NCR-ILC3s expressed comparable high levels of 
RORγt (Fig. 6 B). Since IL-7 and SCF are both important cytokines required for the 
survival and maintenance of ILC3s and their precursors,88, 89, 91, 103 I investigated the 
expression of their according receptors on in vitro generated NCR-ILC3s. Both CD4+ 
and CD4- NCR-ILC3s showed high expression of the γc chain, which builds together 
with the IL-7Rα chain the receptor for IL-7 (Fig. 6 B).259 The IL-7Rα chain was as well 
expressed on both CD4+ and CD4- NCR-ILC3s (Fig. 5 A). Additionally, high 
expression levels for CD117, the receptor for SCF, could be detected on both 
subsets of in vitro generated NCR-ILC3s (Fig. 6 B). During embryogenesis, ILC3s 
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play a crucial role in lymphoid tissue formation and organization.4, 70, 71, 72 This 
process involves the interaction of LTαβ-expressing ILC3s and LTβR-expressing 
stromal cells.68, 260 In line with this, both CD4+ and CD4- NCR-ILC3 subsets 
expressed comparable high levels of LTαβ (Fig. 6 B). In addition to LTαβ-LTβR 
signaling, several integrins and adhesion molecules (α4β7 and β1 integrin, ICAM-1) 
as well as chemokine and cytokine receptors (CXCR4, CXCR5, CCR6 and CCR7) 
are involved in the process of lymphoid tissue formation mediated by ILC3s.73, 79 In 
accordance, both CD4+ and CD4- NCR-ILC3 subsets expressed α4β7 and β1 integrin 
as well as ICAM-1 (Fig. 6 B). Further, CXCR4, CXCR5, CCR6 and CCR7 were 
expressed on CD4+ and CD4- NCR-ILC3s (Fig. 6 B). Additionally, CD4+ and CD4- 
NCR-ILC3s expressed comparable high levels of CD44 whereas they both lacked the 
expression of CD62L and NKp46 (Fig. 6 B). The expression of NK1.1 and CD69 was 
low on both subpopulations of in vitro generated NCR-ILC3s (Fig. 6 B). Altogether, 
these data demonstrated that in vitro generated NCR-ILC3s display a characteristic 
NCR-ILC3 phenotype already described in 1997.57 Furthermore, the in vitro 
generated CD4+ and CD4- NCR-ILC3 subsets show an equal phenotype.  
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Figure 6:	  Phenotype of in vitro generated NCR-ILC3s. A) Phenotype of in vitro generated NCR-ILC3s 
derived from α4β7+ ILC3 precursors. First dot plot shows total cells differentiated from α4β7+ ILC3 
precursors after 5 days in culture. Second dot plot shows CD4+ and CD4- subsets within the 
CD90.2+CD117+ NCR-ILC3 population. Representative dot plots are shown. B) Representative 
histograms of intracellular RORγt expression and the expression of several surface molecules (indicated 
in the figure) by CD4+ and CD4-NCR-ILC3 subsets.  
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5.2 In vitro generated NCR-ILC3s produce cytokines and show an 
activated phenotype after innate stimulation in vitro. 
 
 Innate stimulation of in vitro generated NCR-ILC3s induces 5.2.1
cytokine secretion. 
 
Innate immunity is mainly mediated by immune cells directly recognizing microbial 
products through pattern recognition receptors (PRRs), such as Toll-like receptors 
(TLRs) and nucleotide-binding oligomerization domain (NOD)-like receptors.  
To examine whether in vitro generated NCR-ILC3s were either able to directly sense 
the presence of pathogens or to respond to inflammatory cytokines produced by 
other immune cells, I cultured NCR-ILC3s for 48 h in the presence of several different 
pro-inflammatory cytokines or TLR ligands. Cytokines and TLR ligands were used at 
concentrations already described for in vitro stimulation.30, 261, 262  
IL-22 is a cytokine, which is able to directly induce antimicrobial host defense. It 
stimulates epithelial cells to produce antimicrobial peptides and contributes to 
epithelial cell integrity.113 Therefore, I measured whether innate stimulation of NCR-
ILC3s was able to induce IL-22 production. Upon stimulation with the pro-
inflammatory cytokine IL-1β, in vitro generated NCR-ILC3s produced high levels of 
IL-22 whereas non-stimulated naïve NCR-ILC3s did not show IL-22 secretion (Fig. 7 
A). IL-22 secretion upon IL-1β stimulation even exceeded those induced in response 
to IL-23 stimulation, a factor which was already reported to induce IL-22 production 
by ILC3s (Fig. 7 A).105, 106, 108, 120 Both CD4+ and CD4- NCR-ILC3 subpopulations 
produced comparable levels of IL-22 in response to IL-1β stimulation (Fig. 7 A).  
IL-17 is a major mediator of inflammation and plays a critical role in host defense 
against extracellular bacteria and fungi.263, 264 Therefore, I additionally measured 
whether in vitro generated NCR-ILC3s were able to produce IL-17 in response to 
innate stimulation. Indeed, in vitro generated NCR-ILC3s produced IL-17 upon 
exposure to IL-1β, although at lower levels than IL-22 (Fig. 7 B). In vitro IL-23 
stimulation did not induce IL-17 production by in vitro generated NCR-ILC3s although 
it was previously reported that IL-17 production of ILC3s upon Candida albicans 
infection depends on IL-23 (Fig. 7 B).265  
Furthermore, I measured cytokine production of NCR-ILC3s after 48 h in vitro 
stimulation with TLR ligands. In response to Poly I:C, the TLR ligand for TLR3, NCR-
ILC3s secreted significantly higher amounts of IL-22 compared to naïve NCR-ILC3s. 
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Other TLR ligands such as Imiquimod and CpG only led to low or negligible 
production of IL-22 (Fig. 7 C). The addition of TLR ligands to in vitro cultures was 
unable to induce IL-17 secretion by in vitro generated NCR-ILC3s (Fig. 7 C). Notably, 
IL-1β was an extremely strong inducer of IL-17 and IL-22 production by NCR-ILC3s. 
Basal and IL-23-induced IL-22 production by ILC3s was reported to be dependent on 
IL-1R1,266, 267, 268 but whether ILC3s release other cytokines in response to IL-1β was 
not known so far. Therefore, I screened for additional cytokines produced by in vitro 
generated NCR-ILC3s after 48 h IL-1β exposure. IL-1β-exposed NCR-ILC3s secreted 
IL-2, IL-6, MIP-1α, IFNγ and TNFα, all known for their capacity to promote T cell 
responses (Fig. 7 D). In addition, IL-1β induced NCR-ILC3s to secrete interferon-
induced protein of 10 kDa (IP-10), a chemoattractant for mononuclear cells and 
CXCR3+ effector T cells (Fig. 7 D).268 Reminiscent of its RORγt-dependent 
expression in T cells,269 GMCSF was already produced by naïve NCR-ILC3s and its 
secretion was enhanced upon IL-1β exposure (Fig. 7 D).  
Collectively, these data demonstrated that the response of NCR-ILC3s to innate 
stimulation differed dependent on the nature of the stimuli. IL-1β acted as a strong 
activator of NCR-ILC3s inducing the production of a wide range of cytokines, many of 
which were known to alter T cell behavior. Moreover, NCR-ILC3s responded directly 
to TLR3 stimulation with IL-22 secretion. 
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Figure 7: Cytokine secretion of activated NCR-ILC3s. A) IL-22 secretion by in vitro generated total 
NCR-ILC3s upon 48 h exposure to IL-1β, IL-23 or medium alone (unstim) and by CD4+ and CD4-NCR-
ILC3 subsets upon 48 h exposure to IL-1β. Data are shown as mean values + SD (n = 3 - 7, 3 
independent experiments; *P < 0.05). B) IL-17 secretion by in vitro generated total NCR-ILC3s upon 48 
h exposure to IL-1β, IL-23 or medium alone (unstim). Data are shown as mean values + SD (n = 3 - 6, 2 
independent experiments; n.s. = not significant; *P < 0.05; **P < 0.01). C) IL-22 and IL-17 secretion by 
in vitro generated total NCR-ILC3s upon 48 h exposure to TLR ligands (indicated in the figure) or 
medium alone (unstim). Data are shown as mean values + SD (n = 3 - 7, at least 2 independent 
experiments; **P < 0.01). D) Cytokine production by in vitro generated NCR-ILC3s after 48 h exposure 
to IL-1β or medium alone. Results are shown as mean values + SD. 
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 In vitro generated NCR-ILC3s show an activated phenotype 5.2.2
upon innate stimulation.  
 
Based on the findings that in vitro generated NCR-ILC3s were able to respond to 
innate stimulation with the production of cytokines, I next investigated, whether 
stimulation with microbial products or inflammatory cytokines induces changes in the 
phenotype of NCR-ILC3s. How dendritic cells (DCs) undergo maturation and 
activation upon exposure to signals associated with infection and inflammation is well 
documented.173 However, the mechanism by which NCR-ILC3s undergo activation 
and change in phenotype and function was still not known. I therefore tested pro-
inflammatory cytokines and TLR ligands for their ability to induce phenotypical 
changes resembling activation of NCR-ILC3s. 
CD69 is known as the earliest inducible cell surface glycoprotein acquired during 
lymphocyte activation.202 Thus, I screened for CD69 expression on NCR-ILC3s 
cultured in the presence of either pro-inflammatory cytokines or TLR ligands. Indeed, 
IL-1β, Poly I:C and CpG were able to induce surface CD69 expression on NCR-ILC3s 
indicating their activation (Fig. 8 A).  
MHC class II (MHC II) expression is required for Ag presentation to CD4+ T cells. 
Additionally, the expression of co-stimulatory molecules such as CD80/CD86 and 
CD40 on professional APCs, like DCs, provide accessory signals to CD4+ T cells, 
which are required for complete CD4+ T cell activation, proliferation and increased 
survival.207 Therefore, I asked whether, analog to DCs, activated NCR-ILC3s 
expressed co-stimulatory molecules and up-regulated MHC II molecule expression 
on the surface. When cultured in medium alone, in vitro generated sort-purified CD4+ 
NCR-ILC3s showed a naïve phenotype displayed by the absence of CD69 and co-
stimulatory molecules (Fig. 8 B). Upon exposure to IL-1β for 48 h, sort-purified in 
vitro generated CD4+ NCR-ILC3s expressed the co-stimulatory molecules CD80 and 
CD86 and up-regulated the expression of CD40, CD69 and MHC II (Fig. 8 B). Hence, 
upon IL-1β stimulation, in vitro generated NCR-ILC3s acquired an APC-like 
phenotype, reminiscent of activated DCs.  
Further, I determined the gene expression profile of CD4+ and CD4- NCR-ILC3s by 
performing a whole transcript array (Affymetrix Mouse Gene 2.0 ST Array). First, 
sort-purified in vitro generated naïve and activated CD4+ and CD4- NCR-ILC3s were 
analyzed for the expression of genes related to their phenotype. It has to be noted 
that CD4+ and CD4- NCR-ILC3s were activated in vitro only for 1 h in the presence of 
IL-1β. Genes related to the phenotype of NCR-ILC3s such as Cd4, Rorc, Cd90, 
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Cd117 and Il1r1 were highly expressed by CD4+ and CD4- NCR-ILC3s shown by an 
expression value of around 12.0 (log2 values of signal intensity measured in the 
array; Fig. 8 C). Expression values around 5.0 were measured for genes like Cd3 
and Cd19, which are related to T and B cells, respectively (Fig. 8 C). Based on these 
findings, I assumed that genes with an expression value below or around 5.0 were 
not expressed by NCR-ILC3s while genes with an expression level of around 12.0 
were highly expressed by these cells. Therefore, both naïve and IL-1β-activated 
CD4+ and CD4- NCR-ILC3s showed expression of genes related to their phenotype 
at high levels (Fig. 8 C). No differences in genes related to the phenotype of NCR-
ILC3s were found when naïve and IL-1β-activated NCR-ILC3s were compared (Fig. 8 
C). The expression value of Cd4 in naïve and IL-1β-activated CD4+ NCR-ILC3s was 
12.8 and 12.7, respectively. CD4- NCR-ILC3s showed Cd4 expression values clearly 
lower than that of CD4+ NCR-ILC3s (8.4 and 8.0; Fig. 8 C). The fact that in vitro 
generated NCR-ILC3s expressed an APC-like phenotype upon IL-1β exposure 
indicated, that these cells might be involved in Ag presentation. Therefore, I 
examined the expression of genes related to MHC II-dependent Ag-presentation in 
CD4+ and CD4- NCR-ILC3s. Genes related to Ag-presentation such as Cd74, H2-Ab1 
and H2-Aa were expressed by both naïve and IL-1β-activated CD4+ and CD4- NCR-
ILC3s at high levels (expression values in the range of 9.3 – 11.7; Fig. 8 C). Other 
genes related to Ag-presentation like H2-DMb2 and H2-DMa were expressed at 
slightly lower levels (7.7 – 8.6; Fig. 8 C). No differences in transcript levels of genes 
related to Ag-presentation could be observed when naïve NCR-ILC3s were 
compared to IL-1β-activated NCR-ILC3s (Fig. 8 C).  
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Figure 8: Innate stimulation of in vitro generated NCR-ILC3s induces changes in the expression 
of surface molecules. A) Representative histograms of CD69 expression on in vitro generated NCR-
ILC3s after 48 h stimulation with IL-1β, Poly I:C, CpG or medium alone. B) Expression of CD69, CD80, 
CD86, CD40 and MHC II on sort-purified in vitro generated CD4+ NCR-ILC3s cultured for 48 h with IL-
1β or medium alone as indicated in the figure. Numbers in contour plots show the percentage of cells in 
each quadrant. Data are representative of 3 independent experiments. C) Expression levels of individual 
genes expressed in naïve and IL-1β-activated (1 h) CD4+ and CD4- NCR-ILC3s. The expression values 
are shown as log2 transformed values of signal intensities measured in the array. Expression values are 
depicted as numbers (5.0 = negative or low expression; 13.0 = positive or high expression) and in a 
color code (white = neg. or low expression; blue = pos. or high expression). Genes were clustered as i) 
genes related to the phenotype of NCR-ILC3s, ii) genes related to Ag-presentation, and iii) genes 
related to T and B cell phenotype. Data shown were generated by the analysis of DNA isolated from one 
individual specimen of two independent rounds of in vitro NCR-ILC3 generation. 90 - 120 embryos 
collected from 13 - 15 pregnant female WT mice were used to isolate α4β7+ ILC3 precursors 
differentiating into NCR-ILC3 in vitro.  
 
Altogether, I could show that α4β7+ ILC3 precursors isolated from the FL of WT 
embryos could give rise to NCR-ILC3s in vitro. CD4+ and CD4- NCR-ILC3s, sharing 
an identical phenotype, were both able to respond to innate stimulation. They 
produced IL-17 and IL-22 upon exposure to the pro-inflammatory cytokine IL-1β. 
Additionally, remarkable IL-22 secretion by NCR-ILC3s could be induced in the 
presence of the cytokine IL-23 and the TLR ligand Poly I:C. Furthermore, the TLR 
ligands CpG and Poly I:C as well as the pro-inflammatory cytokine IL-1β induced the 
up-regulation of the early activation marker CD69 on NCR-ILC3s indicating that NCR-
ILC3s are able to directly respond to innate stimuli. Finally, IL-1β turned out to be a 
remarkable strong activator of in vitro generated NCR-ILC3s, capable to induce the 
production of a broad repertoire of cytokines and the expression of co-stimulatory 
molecules and MHC II molecules. All findings observed by in vitro stimulation of in 
vitro generated NCR-ILC3s are summarized in Table 1. 	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Table 1: Summary: Innate stimulation of in vitro generated NCR-ILC3s induces cytokine 
secretion and changes in the phenotype. Summary of changes in in vitro generated NCR-ILC3s in 
response to innate stimulation with different TLR ligands and pro-inflammatory cytokines as indicated. 
Red: up-regulation of cytokine production or surface marker expression; yellow: no changes observed; 
n.a: not available. 	  
5.3 Splenic NCR-ILC3s can become activated through innate 
stimulation in vivo and acquire an APC-like phenotype upon 
IL-1β  exposure in vitro. 
 
 Stimulation with TLR ligands induces activation of splenic 5.3.1
NCR-ILC3s in vivo. 
 
Our research group and others have previously shown that FL-derived and adult 
ILC3s share phenotypic and functional properties such as lymphotoxin β-dependent 
formation of lymphoid tissues and its organization.96, 103 I could show that FL-derived 
NCR-ILC3s produced cytokines and changed their phenotype upon in vitro exposure 
to either microbial products or pro-inflammatory cytokines. However, whether adult 
NCR-ILC3s in vivo were able to sense innate stimulation was not known.  
In vivo, NCR-ILC3s could be identified in the spleen of adult mice by the lack of all 
lymphoid lineage markers (lin-) and the expression of CD90.2 and CD117 at high 
levels (Fig. 9 A). The lineage cocktail used to distinguish lineage positive (lin+) and 
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lineage negative (lin-) cells contained antibodies against CD3ε, CD8α, CD11c, CD19, 
B220, Gr-1, TCRβ, TCRγδ, NK1.1 and NKp46. Similar to in vitro generated NCR-
ILC3s, ex vivo isolated splenic NCR-ILC3s could be subdivided into two 
subpopulations, CD4+ and CD4- NCR-ILC3s, respectively (Fig. 9 A). Approximately 
70 % of all NCR-ILC3s expressed CD4 whereas approximately 30 % lacked CD4 
expression (Fig. 9 A). Both subpopulations expressed comparable high levels of the 
transcription factor RORγt (Fig. 9 A). Hence, considering phenotypic markers that are 
characteristic for NCR-ILC3s, ex vivo isolated splenic and in vitro generated NCR-
ILC3s were identical (Fig. 9 A). For identification and phenotypic characterization of 
splenic NCR-ILC3s, I used Rag2-/- mice since these mice harbor increased numbers 
of NCR-ILC3s compared to WT mice. The phenotype of splenic NCR-ILC3s of Rag2-/- 
mice did not differ from that of WT mice.  
In order to test whether in vivo exposure to innate stimuli was able to induce 
activation of splenic NCR-ILC3s, WT mice were injected intraperitoneally (i.p.) with a 
single dose of 100 µM CpG, the ligand for TLR9. Control mice were injected with a 
single dose of PBS. First of all, I monitored the effects of in vivo CpG treatment on 
the whole splenic tissue of WT mice. 6 h after CpG injection the relative expression 
of the pro-inflammatory cytokines IL-1β, TNFα and IFNγ was significantly increased 
compared to PBS treated mice (Fig. 9 B). Thus, CpG was able to generate an 
inflammatory milieu in the spleen of treated WT mice including elevated levels of IL-
1β, a factor, which was shown to act as a strong activator of in vitro generated NCR-
ILC3s.  
Therefore, I next investigated the phenotype of NCR-ILC3s ex vivo isolated from the 
spleen of either CpG or PBS treated mice. Indeed, i.p. injection of CpG induced 
activation of splenic NCR-ILC3s displayed by high surface expression of CD69 in 
CpG compared to PBS treated WT mice (Fig. 9 C) consistent with the data observed 
for in vitro generated NCR-ILC3s after CpG stimulation in vitro (Fig. 8 A, Table 1). 
Whether splenic NCR-ILC3 activation resulted from a direct effect of CpG or indirectly 
through the established inflammatory milieu (e.g. IL-1β) could not be determined. 
Microbial products as well as sterile host-derived danger molecules released upon 
injury are able to induce the inflammasome complex, which promotes the cleavage of 
pro-IL-1β into bioactive IL-1β.270, 271 One of these microbial products is 
Lipopolysaccharide (LPS), the component of the outer membrane of gram-negative 
bacteria. LPS, the ligand of TLR 4, is known to induce IL-1β production upon in vivo 
challenge.167 Therefore, I additionally tested whether in vivo treatment with LPS was 
able to induce activation of splenic NCR-ILC3s in adult mice. Injection of 100 µg LPS 
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resulted in high expression of CD69 and up-regulation of MHC II expression on 
splenic CD4+ NCR-ILC3s examined 6 h after treatment (Fig. 9 D). In vivo LPS 
treatment did not affect the amount of splenic NCR-ILC3s nor the ratio between CD4+ 
and CD4- NCR-ILC3s (Fig. 9 D). Whether activation of NCR-ILC3s was mediated 
directly by LPS or by LPS-induced IL-1β has to be explored.  
Collectively these data demonstrated that in vivo treatment of adult mice with TLR 
ligands CpG or LPS resulted in activation of splenic NCR-ILC3s monitored by 
increased CD69 and MHC II expression. However, from these experiments it could 
not be revealed whether the TLR ligands acted directly on the cells or indirectly by 
generating an inflammatory environment.  
 
	   77 
	  
 
Figure 9:	   In vivo treatment with TLR ligands induces an inflammatory milieu in the spleen and 
activates splenic NCR-ILC3s. A) Phenotype of NCR-ILC3s ex vivo isolated from the spleen of adult 
Rag2-/- mice. Numbers in dot plots show the percentage of cells in each gate. Representative dot plots 
and histogram are depicted. B) qRT-PCR of IL-1β, TNFα and IFNγ transcripts in total spleen tissue from 
WT mice 6 h after i.p. injection of either PBS or CpG. Expression is shown relative to the house keeping 
gene β-actin. Data are representative for 1 of 2 independent experiments (n = 5; mean values + SD; *P 
< 0.05; **P < 0.01). C) CD69 expression of splenic CD4+ NCR-ILC3s of WT mice 6 h after i.p. injection of 
PBS or CpG as indicated in the figure. Representative dot plots and a histogram of 3 independent 
experiments is shown. D) CD69 and MHC II expression of splenic NCR-ILC3s of Rag2-/- mice 6 h after 
i.p. injection of PBS or LPS as indicated in the figure. First dot plots represent live cells. Histograms 
show CD4+ and CD4- subsets within the lin-CD90.2+CD117+RORγt+ population. Dot plots are 
additionally gated on CD4+ NCR-ILC3s. Numbers show the percentage of cells in each gate. Data are 
representative of at least 3 independent experiments. 	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 IL-1β activates splenic NCR-ILC3s and induces up-regulation 5.3.2
of MHC II and co-stimulatory molecule expression.  
 
My previous findings showed that in vitro generated NCR-ILC3s were able to respond 
to innate stimulation in vitro. Further, in vivo challenge of adult mice with TLR ligands 
induced activation of splenic NCR-ILC3s. However, whether splenic NCR-ILC3s 
isolated from adult mice were able to express co-stimulatory molecules and MHC II 
upon IL-1β exposure, as it has been demonstrated for in vitro generated NCR-ILC3s 
(Fig. 8 B), remained to be determined. To test this, I isolated NCR-ILC3s from the 
spleen of adult Rag2-/- mice. As mentioned before, Rag2-/- mice harbor increased 
numbers of ILC3s compared to WT mice while lacking T and B cells. Therefore, the 
usage of Rag2-/- mice facilitated the enrichment of a high number of ILC3s without 
contaminating T or B cells. Ex vivo isolated splenic NCR-ILC3s of Rag2-/- mice were 
sort-purified based on the expression of CD90.2/CD117 and the lack of lineage 
markers (lin-). 48 h after IL-1β exposure, splenic NCR-ILC3s up-regulated the 
expression of CD69 and co-stimulatory molecules (Fig. 10 A). Interestingly, 
compared to naïve in vitro generated NCR-ILC3s, which lacked MHC II expression 
(Fig. 8 B), ex vivo isolated NCR-ILC3s already expressed MHC II on their surface in 
the absence of innate stimulation. Furthermore, MHC II expression was increased 
upon IL-1β exposure and exceeded those of IL-β-activated in vitro generated NCR-
ILC3s (Fig. 10 A and Fig. 8 B). Altogether, ex vivo isolated splenic NCR-ILC3s were 
able to respond to IL-1β stimulation thereby acquiring an APC-like phenotype.  
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
 
Figure 10:	  IL-1β  induces the expression of MHC II and co-stimulatory molecules on splenic NCR-
ILC3s. A) Expression of CD69, CD40, CD86 and MHC II on sort-purified ex vivo isolated splenic CD4+ 
NCR-ILC3s cultured for 48 h in the presence of IL-1β or medium alone as indicated in the figure. 
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Numbers in contour plots show the percentage of cells in each quadrant. Data are representative of 3 
independent experiments. 
 
5.4 Peripheral NCR-ILC3s are able to take up latex beads, to 
process protein Ag and to promote CD4+ T cell responses in 
vitro. 
 
 NCR-ILC3s can internalize latex beads.  5.4.1
 
Based on the notion that inflammatory stimulation of NCR-ILC3s induced the 
acquisition of an APC-like phenotype, I wondered whether ILC3s could function as 
APCs. Therefore, I asked whether NCR-ILC3s were able to internalize and process 
exogenous Ag in order to present it to naïve CD4+ T cells. First of all, I measured the 
capacity of NCR-ILC3s to take up exogenous Ag using red fluorescent latex beads 
with a size of 1 µm. Sort purified in vitro generated and ex vivo isolated splenic NCR-
ILC3s were cultured for 6 h in the presence of red fluorescent latex beads. Both in 
vitro generated and ex vivo isolated NCR-ILC3s were able to internalize red 
fluorescent latex beads at 37 °C (Fig. 11 A - C). Bead uptake was severely inhibited 
at 4 ºC or in the presence of 0.5 µM Cytochalasin D (CytD), an inhibitor of actin 
polymerization (Fig. 11 B and C). Those two controls showed the specificity of bead 
internalization by NCR-ILC3s. As previously described, in vitro generated NCR-ILC3s 
could be subdivided into CD4+ and CD4-NCR-ILC3 subsets (Fig. 6 A and B). Both 
CD4+ and CD4- NCR-ILC3 subsets were able to internalize latex beads, although 
CD4+ NCR-ILC3 were slightly more efficient in taking up Ag than their CD4- 
counterpart (Fig. 11 D). However, compared to BM-derived macrophages (BMMΦ), 
bead uptake by NCR-ILC3s occurred with slower kinetics (Fig. 11 E). Altogether, I 
could show that NCR-ILC3s were able to internalize exogenous Ags. 
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Figure 11:	   Naïve NCR-ILC3s can internalize latex beads. A) Representative immunofluorescence 
image of red fluorescent latex bead uptake by sort-purified in vitro generated NCR-ILC3s. Scale, 5 µm.   
B - C) Representative plots of sort-purified (B) in vitro generated or (C) ex vivo isolated splenic NCR-
ILC3s cultured with beads for 6 h at either 37 ºC or 4 ºC, or at 37 ºC in presence of 0.5 µM Cytochalasin 
D (CytD) as indicated in the figure. Histograms show bead+ cells. Data are representative of at least 3 
independent experiments (n = 3 - 5). D) Percentage of bead+ and bead- cells within in vitro generated 
CD4+ and CD4- NCR-ILC3s after 6 h incubation with beads (mean values + SD). Data shown are 
representative of at least 3 independent experiments (n = 3 - 5). E) Bead internalization by NCR-ILC3s 
and BMMΦ. Percentage of bead+ cells 2 and 24 h after addition of beads (mean values + SD; n = 3 - 5; 
n.s. = not significant; **P < 0.01). 
 
 Activated NCR-ILC3s can induce Ag-specific CD4+ T cell 5.4.2
activation and proliferation.  
 
To further investigate Ag processing and presentation by NCR-ILC3s as well as the 
induction of CD4+ T cell priming in vitro, I made use of a T cell transgenic mouse 
model, the OT-II transgenic (OT-IItg) mouse.247 All CD4+ T cells found in homozygous 
OT-IItg mice bear a transgenic T cell receptor (TCR) on their surface that specifically 
recognizes chicken Ovalbumin (OVA323-339) in the context of MHC II (H-2b). OT-II 
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transgenic CD4+ T cells were isolated from LNs and spleen of naïve OT-IItg mice, 
enriched with magnetically associated cell sorting and sort-purified before use for in 
vitro and in vivo experiments. Sort-purified OT-IItg CD4+ T cells showed a naïve 
phenotype displayed by the lack of CD69 expression and simultaneously high levels 
of CD62L expression (Fig. 12 A). CD44, a marker indicating an activated memory-
like phenotype for T cells was only expressed by a minority of sorted OT-IItg CD4+ T 
cells (Fig. 12 A). To test the ability of NCR-ILC3s to prime CD4+ T cells in vitro, sort-
purified NCR-ILC3s (H-2b) were first in vitro stimulated with IL-1β for 24 h and 
afterwards incubated for 72 h with sort-purified carboxyfluorescein succinimidyl ester 
(CFSE)-labeled OT-IItg CD4+ T cells in the presence of OVA peptide323-339 or whole 
OVA protein (Fig. 12 B). CFSE labeling of OT-IItg CD4+ T cells allowed me to monitor 
T cell proliferation under different co-culture conditions. BM-derived dendritic cells 
(BMDCs), known as professional APCs, were used as a positive control for efficient 
Ag presentation and CD4+ T cell activation. The activation of CD4+ T cells was 
monitored by surface CD69 expression and the CFSE proliferation profile. Ex vivo 
isolated and in vitro generated CD4+ and CD4- NCR-ILC3s were able to activate the 
majority of CD4+ T cells in the presence of OVA peptide considering surface CD69 
expression (Fig. 12 B). When naïve OT-IItg CD4+ T cells and IL-β-activated NCR-
ILC3s were co-cultured without Ag, neither CD4+ T cell activation (CD69 expression) 
nor proliferation could be observed (Fig. 12 B). In vitro generated FL-derived CD4+ 
and ex vivo isolated splenic NCR-ILC3s were able to induce several rounds of OVA-
specific CD4+ T cell proliferation when pulsed with OVA peptide or, to a lesser extent, 
with OVA protein (Fig. 12 B). CD4- NCR-ILC3s were considerably less efficient in 
inducing protein Ag-specific CD4+ T cell responses (Fig. 12 B).  
To further examine the effect of pre-activation of NCR-ILC3s on their capacity to elicit 
T cell responses, I stimulated ex vivo isolated splenic NCR-ILC3s with IL-1β for 24 h 
or left them untreated, and co-cultured them for additional 48 h with naïve OT-IItg 
CD4+ T cells in the presence or absence of whole OVA protein (Fig. 12 C - E). 30.2 
% of the CD4+ T cells in culture with untreated NCR-ILC3s and OVA protein 
expressed CD69 and only 4.3 % of the T cells proliferated (Fig 12 C). IL-1β-activated 
NCR-ILC3s increased the percentage of both CD69+ and proliferating T cells (Fig. 12 
C - E). Together, these results showed that NCR-ILC3s were able to induce CD4+ T 
cell activation and proliferation in vitro and that pre-activation of NCR-ILC3s with IL-
1β increased their efficiency to induce CD4+ T cell activation. 	  
	   82 
	  	  	  	  	  	  	  	  	  	  	   	  
	   83 
Figure 12:	   NCR-ILC3s can induce Ag-specific CD4+ T cell activation and proliferation. A) 
Representative dot plots of ex vivo isolated sort-purified OT-IItg CD4+ T cells. Live cells after isolation 
and sort-purification are represented in the first dot plot. Surface expression of CD69, CD62L and CD44 
is shown gated on CD3+CD4+ T cells. Numbers in dot plots show the percentage of cells in each gate. 
B) Naïve CFSE-labeled OT-IItg CD4+ T cells were cultured with either BMDCs, IL-1β-activated ex vivo 
isolated splenic NCR-ILC3s or in vitro generated CD4+ or CD4- NCR-ILC3s in the presence of OVA 
peptide, OVA protein or medium alone (w/o Ag) as indicated in the figure. Representative plots of CD69 
and CFSE expression by CD4+ T cells 72 h later. Bold black numbers: % of proliferating T cells. Bold 
red numbers: % of total CD69+ T cells.  C) Naïve CFSE-labeled OT-IItg CD4+ T cells were cultured with 
non- or IL-1β-activated splenic NCR-ILC3s in the presence of OVA peptide, OVA protein or medium 
alone (w/o Ag) for 72 h as indicated in the figure. Representative dot plots are shown. D) Percentage of 
CD69+ T cells upon co-culture with non- or IL-1β-activated splenic NCR-ILC3s in the presence or 
absence of Ag as indicated in the figure. Data are shown as mean values + SD (n = 3 - 7; *P < 0.05; 
***P < 0.001). E) Fold increase of percentage of CD69+ T cells upon co-culture with non- or IL-1β-
activated splenic NCR-ILC3s in the presence of OVA protein relative to co-culture of IL-1β- activated 
splenic NCR-ILC3s and T cells in the absence of Ag as indicated in the figure. Data are shown as mean 
values + SD (n = 3 - 7; *P < 0.05). D – E) Data are representative of at least 3 - 7 independent 
experiments. 
 
 Ag-dependent interaction of CD4+ T cells and splenic NCR-5.4.3
ILC3s induces de novo activation of splenic NCR-ILC3s. 
 
In co-cultures of naïve OT-IItg CD4+ T cells and untreated splenic NCR-ILC3s, the 
surface expression of CD69 on NCR-ILC3s was increased approximately 7-fold when 
Ag (OVA protein) was present compared to co-cultures without Ag (Fig. 13 A). This 
phenomenon was not further increased by previously activating NCR-ILC3s with IL-
1β (Fig. 13 A). It is important to note, that pre-activation of NCR-ILC3s (IL-1β, 24 h) 
induced CD69 expression, which peaked early after activation and later decreased in 
co-cultures, unless T cells and Ag were added. To exclude that the presence of 
whole OVA protein was responsible for CD69 up-regulation on NCR-ILC3s in co-
cultures with CD4+ T cells and OVA protein, I cultured sort-purified ex vivo isolated 
splenic NCR-ILC3s in the presence or absence of whole OVA protein for 48 h and 
examined their CD69 expression. The presence of whole OVA protein did not induce 
CD69 expression on NCR-ILC3s (Fig. 13 B). Thus, this experiment showed that Ag 
alone was not able to activate naïve NCR-ILC3s. 
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Figure 13: Ag-dependent CD4+ T cell activation induces activation of splenic NCR-ILC3s. A) Fold 
increase of mean fluorescent intensity (MFI) of CD69 expression on non- or IL-1β-activated (24 h) 
splenic NCR-ILC3s co-cultured with OT-IItg CD4+ T cells in the presence or absence of OVA protein (48 - 
72 h) relative to non-activated splenic NCR-ILC3s co-cultured with OT-IItg CD4+ T cells in the absence of 
Ag. Data are shown as mean values + SD (3 - 7 independent experiments). B) Representative 
histogram of CD69 expression on non-activated splenic NCR-ILC3s in presence of OVA protein or in 
medium alone. 
 
 Activation of NCR-ILC3s can be induced by soluble factors 5.4.4
produced in co-cultures of APCs and CD4+ T cells in the 
presence of cognate Ag.  
 
My previous observations showed that the presence of cognate Ag in co-cultures of 
OT-IItg CD4+ T cells with NCR-ILC3s induced and sustained activation of NCR-ILC3s 
(Fig. 13 A). This activation of NCR-ILC3s reached an equal level regardless of 
whether NCR-ILC3s were pre-activated with IL-1β or not (Fig. 13 A). Further, the 
presence of Ag alone was not able to induce activation of NCR-ILC3s in vitro (Fig. 13 
B). Thus, I assumed that OT-IItg CD4+ T cells produced some soluble factors after 
Ag-dependent interaction with NCR-ILC3s, which were able to activate NCR-ILC3s. 
However, one could not exclude that NCR-ILC3s themselves also secreted soluble 
factors upon Ag-dependent interaction with CD4+ T cells. To further test the effect of 
soluble factors produced by activated CD4+ T cells on the activation of NCR-ILC3s, 
cell culture supernatant (SN) of activated CD4+ T cells had to be produced. The 
following possibilities existed; i) co-cultures of NCR-ILC3s and CD4+ T cells with Ag, 
ii) co-cultures of BMDCs and CD4+ T cells with Ag, or iii) CD4+ T cell activation in 
presence of anti-CD3/anti CD28 Abs. In my previous in vitro assay, I could show that 
OT-IItg CD4+ T cells were fully activated in the presence of BMDCs and OVA protein 
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(Fig. 12 B). Therefore, I decided to use the SN of co-cultures of BMDCs with CD4+ T 
cells and Ag to further test soluble factor-mediated activation of splenic NCR-ILC3s.  
Sort-purified ex vivo isolated splenic NCR-ILC3s showed increased expression of 
CD69 when cultured for 48 h in the presence of SN collected from co-cultures of 
BMDCs and CD4+ T cells with Ag (Fig. 14 A). The CD69 expression level was 
compared to that of NCR-ILC3s, which were either cultured in cell culture medium 
alone or in SN collected from co-cultures of BMDCs and CD4+ T cells without Ag 
(Fig. 14 A). In addition to increased CD69 expression, only SN collected from co-
cultures of BMDCs and CD4+ T cells with Ag induced a slight up-regulation of CD80 
and CD40 on splenic NCR-ILC3s (Fig. 14 B). Together, these data showed that 
soluble factors secreted upon Ag-dependent interaction of CD4+ T cells and BMDCs 
were able to induce the activation of splenic NCR-ILC3s. Moreover, these soluble 
factors assumed to support the efficiency of Ag-dependent splenic NCR-ILC3-CD4+ T 
cell interaction by the induction of co-stimulatory molecule expression.  
CD4+ T cells are known to produce cytokines such as IFNγ upon encounter of Ag 
presented via MHC II on APCs.272 My previous data showed that in vitro generated 
NCR-ILC3s increased CD69 and MHC II expression upon exposure to IFNγ (Table 
1). Thus, IFNγ might be a potential soluble factor inducing and sustaining activation 
of NCR-ILC3s during Ag-dependent interaction with CD4+ T cells. In line with this, 
intracellular staining of OT-IItg CD4+ T cells revealed that CD4+ T cells produced IFNγ 
only in the presence of BMDCs and OVA protein (Ag) while IFNγ production was low 
or not detectable in CD4+ T cells co-cultured with BMDCs in the absence of Ag (Fig. 
14 C). The role for CD4+ T cell-derived IFNγ in NCR-ILC3 activation needs to be 
further explored.  
CD4+ T cells are known to produce IL-2 as a consequence of activation through their 
antigen receptor.211 IL-2 secreted by activated CD4+ T cells was shown to directly 
induce the proliferation of group 2 ILCs (ILC2s).51 Moreover it was reported that the 
presence of IL-2 in co-cultures of CD4+ T cells and ILC2s enhanced the ability of 
ILC2s to produce type 2 related cytokines.51 Although the interplay of IL-2 and ILC2s 
was well described, a role for IL-2 in ILC3-mediated CD4+ T cell responses was so 
far not known. Therefore, I examined whether naïve splenic NCR-ILC3s express the 
receptor for IL-2. CD25, the IL-2 receptor alpha chain (IL-2Rα), builds together with 
the IL-2Rβ and IL-2Rγ chain the high affinity receptor for IL-2.273 Analysis of naïve ex 
vivo isolated splenic NCR-ILC3s revealed that CD25 was highly expressed on the 
surface of these cells (Fig. 14 D).  The presence of SN collected from co-cultures of 
BMDCs and CD4+ T cells with Ag even increased expression of CD25 on splenic 
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NCR-ILC3s (Fig. 14 D). Thus, NCR-ILC3s expressed the high affinity receptor for IL-2 
providing the possibility to respond to IL-2. However, the effects of T cell-derived IL-2 
on NCR-ILC3s have to be explored in further experiments.  
The inducible T cell co-stimulator ICOS belongs to the CD28/CTLA-4 family and is 
mainly de novo expressed on T cells upon activation.274 ICOS acts, like CD28, as a 
co-stimulatory signal for T cell proliferation, however it is not able to induce IL-2 
production.275 Interestingly, whereas naïve splenic NCR-ILC3s expressed low levels, 
the expression of ICOS was increased in the presence of SN collected from co-
cultures of BMDCs and CD4+ T cells with Ag (Fig. 14 D). Furthermore, the ligand for 
ICOS (ICOSL) was also expressed on naïve ex vivo isolated splenic NCR-ILC3s but 
contrary to ICOS its expression was diminished in the presence of SN from co-
cultures with Ag (Fig. 14 D). The precise role for ICOS and its ligand expressed on 
NCR-ILC3s is completely unknown and requires further investigation. Collectively, 
these data showed that NCR-ILC3s underwent different phenotypical changes 
reflecting their activation in the presence of soluble factors produced by activated 
CD4+ T cells.  
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Figure 14:	  Splenic NCR-ILC3s show changes in the phenotype in the presence of soluble factors 
produced in co-cultures of BMDCs, CD4+ T cells and the cognate Ag. A) Representative 
histograms of CD69 expression on sort-purified ex vivo isolated splenic CD4+ NCR-ILC3s in the 
presence of co-culture SN (BMDCs and CD4+ T cells with or without Ag). B) Histograms of CD40 and 
CD80 expression on splenic NCR-ILC3s in the presence of co-culture SN. C) Representative histogram 
of IFNγ expression by OTIItg CD4+ T cells upon 48 h co-culture with BMDCs in the presence or absence 
of OVA protein. D) Representative dot plots of CD25, ICOS and ICOSL expression of naïve sort-purified 
ex vivo isolated splenic NCR-ILC3s upon 48 h culture in medium alone. Representative histograms of 
CD25, ICOS and ICOSL expression of CD4+ NCR-ILC3s upon 48 h culture in the presence of co-culture 
SN. Data shown are representative of at least 2 independent experiments. SN; supernatant.  
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5.5 NCR-ILC3s elicit CD4+ T cell immunity in vivo by promoting 
Ag-dependent CD4+ T cell proliferation and enhancing T-
dependent B cell responses. 
 
 I-abΔILC3 mice – a model to study Ag presentation by ILC3s in 5.5.1
vivo.  
 
I could show that NCR-ILC3s, either generated in vitro from a FL-derived precursor or 
isolated ex vivo from the spleen of adult mice, were able to elicit CD4+ T cell 
responses in vitro by processing and presenting Ag via MHC II as well as by 
providing co-stimulatory signals. To examine the role of NCR-ILC3s in CD4+ T cell 
responses in vivo, I generated a new mouse model in which MHC II expression was 
deleted exclusively in ILC3s. For this reason, I crossed mice expressing Cre 
recombinase under the control of the RORc promoter (RORc(gt)-Cretg)25 to mice 
carrying a floxed H2-Ab1 allele (I-abneo).248 Mice homozygous for the floxed H2-Ab1 
allele and carrying one copy of the Cre transgene are here referred as I-abΔILC3 mice. 
I-abΔILC3 mice were healthy, did not show signs of spontaneous inflammation and had 
a normal distribution of T and B lymphocytes, macrophages (MΦ), dendritic cells 
(DCs) and natural killer (NK) cells in the spleen (Fig. 15 A and B). Numbers of 
splenic ILC3s were also similar in WT and I-abΔILC3 mice (Fig. 15 B). Within the 
splenic B cell compartment, absolute numbers of splenic marginal zone B cells 
(MZB; CD19+CD21highCD23low) and follicular B cells (FolB; CD19+CD21lowCD23high) 
did not differ in I-abΔILC3 compared to WT mice (Fig. 15 C). I-abΔILC3 mice displayed a 
small reduction in absolute numbers of naïve CD4+ and CD8+ T cells 
(TCRβ+CD62LhighCD44-/low) compared to WT mice whereas numbers of central 
memory (TCRβ+CD62LhighCD44high) as well as effector memory (TCRβ+CD62L-
/lowCD44high) CD4+ and CD8+ T cells were comparable between I-abΔILC3 and WT mice 
(Fig. 15 D).  MHC II was highly expressed on splenic B cells, DCs and MΦ of I-abΔILC3 
and WT mice whereas splenic NCR-ILC3s of I-abΔILC3 mice completely lacked MHC II 
(Fig. 15 E).  
Furthermore, I tested splenic NCR-ILC3s isolated from adult I-abΔILC3 mice for their 
ability to respond to innate stimulation. Therefore, ex vivo isolated sort-purified 
splenic NCR-ILC3s of I-abΔILC3 mice were cultured in the presence of IL-1β or in 
medium alone. 48 h later, I-abΔILC3 derived splenic CD4+ NCR-ILC3s showed 
increased levels of CD69 expression (Fig. 15 F) and up-regulated the expression of 
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the co-stimulatory molecule CD86 on the surface (Fig. 15 F). Only a slight increase 
of CD40 expression (from 6.7 % to 10.0 %) on IL-1β-activated CD4+ NCR-ILC3s 
could be observed (Fig. 15 F). As expected, MHC II expression was absent on 
splenic CD4+ NCR-ILC3s isolated from I-abΔILC3 mice, however, 5 % of IL-1β-
activated splenic NCR-ILC3s were found to express MHC II at low levels (Fig. 15 F). 
It cannot be excluded, that blast formation induced by IL-1β activation was 
responsible for this slight shift in MHC II expression (from 0 % to 5.0 %). As a 
comparison, 55.9 % of naïve splenic CD4+ NCR-ILC3s of WT mice expressed MHC II 
and increased their MHC II expression to 69.5 % upon 48 h exposure to IL-1β (Fig. 
10 A). Therefore, one could assume that the 5 % of CD4+ NCR-ILC3s expressing low 
levels of MHC II in I-abΔILC3 mice were not relevant for Ag presentation. Altogether, I-
abΔILC3 mice displayed completely normal immune compartments, lacked the 
expression of MHC II only on ILC3s and IL-1β stimulation was able to induce 
activation of splenic NCR-ILC3s in vitro. 
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Figure 15: I-abΔILC3 mice show normal numbers of lymphocytes in the spleen and lack MHC II 
expression exclusively on RORγt+ ILC3s. A – C) Absolute numbers of (A) T cells (CD3+) and B cells 
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(CD19+), (B) DCs (CD11c+), MΦ (CD11b+F4/80+), NK cells (NK1.1+NKp46+) and NCR-ILC3s (lin-
RORγt+CD117+NCR-), and (C) marginal zone B cells (MZB; CD19+CD21highCD23low) and follicular B 
cells (FolB; CD19+CD21lowCD23high) in the spleen of WT and I-abΔILC3 mice. D) Absolute numbers of 
naïve (TCRβ+CD62LhighCD44-/low), central memory (TCRβ+CD62LhighCD44high) and effector memory 
(TCRβ+CD62L-/lowCD44high) CD4+ and CD8+ T cells in the spleen of WT and I-abΔILC3 mice. E) 
Representative histograms of MHC II expression on splenic B cells, DCs, MΦ and CD4+ NCR-ILC3s of 
WT and I-abΔILC3 mice. F) Expression of CD69, CD40, CD86 and MHC II on sort-purified ex vivo isolated 
splenic CD4+ NCR-ILC3s of I-abΔILC3 mice cultured for 48 h in the presence of IL-1β or medium alone. 
Numbers in contour plots show the percentage of cells in each quadrant. Data are representative of 2 
independent experiments. A – D) All data are shown as mean + SD (n = 9 - 12; 3 - 4 independent 
experiments; n.s. = not significant; *P < 0.05).	  
 
 ILC3s elicit Ag-specific T cell proliferation in vivo.  5.5.2
 
To examine the ability of NCR-ILC3s to act as APCs in vivo, I first tested whether 
NCR-ILC3s contribute to Ag-specific CD4+ T cell proliferation in vivo. In order to 
address this question, I compared the proliferation of adoptively transferred OT-IItg 
CD4+ T cells after in vivo immunization with the cognate Ag (OVA) in the following 
recipients; WT, I-abΔILC3 and I-ab-/- mice. I-ab-/- mice have a complete deficiency of all 
MHC II genes and were therefore used as negative controls unable to present Ag via 
MHC II to CD4+ T cells.245 I-ab-/- mice displayed a normal distribution of total CD3+ T 
and CD19+ B lymphocytes in the spleen compared to WT mice (Fig. 16 A). Absolute 
numbers of MZB cells (CD19+CD21highCD23low) and FolB cells 
(CD19+CD21lowCD23high) in I-ab-/- mice were similar to WT mice (Fig. 16 B). However, 
I-ab-/- mice showed significantly reduced relative and absolute numbers of CD4+ T 
cells compared to WT mice (Fig. 16 C). MHC II expression is involved in the 
selection process and maturation of CD4+ T cells in the thymus whereas T cell 
differentiation into the CD8+ lineage is not affected by the loss of MHC II genes in I-
ab-/- mice.245, 276 In line with this, I found significantly increased relative and absolute 
numbers of CD8+ T cells in I-ab-/- mice, probably as a result of expansion in the 
absence of CD4+ T cells (Fig. 16 C). Detailed characterization of the T cell subsets in 
I-ab-/- mice revealed that the remaining CD4+ T cells mainly showed an activated 
memory-like phenotype. Absolute and relative numbers of naïve CD4+ T cells (Tnaïve; 
TCRβ+CD62LhighCD44-/low) were significantly reduced whereas relative numbers of 
CD4+ T cells with an effector memory-like phenotype (TEM; TCRβ+CD62L-/lowCD44high) 
were significantly increased compared to WT mice (Fig. 16 D). However, absolute 
numbers of central memory (TCM; TCRβ+CD62LhighCD44high) and effector memory 
CD4+ T cells were both significantly lower in I-ab-/- compared to WT mice (Fig. 16 D). 
Analysis of the CD8+ T cell subsets in I-ab-/- mice revealed that relative and absolute 
numbers of naïve and central memory CD8+ T cells were comparable to WT mice 
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and only a significant increase in relative and absolute numbers of effector memory 
CD8+ T cells could be observed (Fig. 16 D). Altogether these data showed that 
although I-ab-/- mice had a normal distribution of CD8+ T cells they harbored a 
disrupted CD4+ T cell compartment with a severe reduction of naïve CD4+ T cells. 
Therefore, to proper compare CD4+ T cell responses in WT, I-abΔILC3 and I-ab-/- mice, 
adoptive transfer of Ag-specific OT-IItg CD4+ T cells was performed providing each 
recipient with the same amount of naïve CD4+ T cells capable to respond to OVA 
immunization.  
 
	  
 
Figure 16:	   I-ab-/- mice show reduced numbers of CD4+ T cells in the spleen. A - B) Absolute 
numbers of (A) T cells (CD3+), B cells (CD19+) and (B) marginal zone B cells (MZB; 
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CD19+CD21highCD23low) and follicular B cells (FolB; CD19+CD21lowCD23high) in the spleen of WT and I-
ab-/- mice.  C - D) Absolute and relative numbers of CD4+ and CD8+ T cell subsets in the spleen of WT 
and I-ab-/- mice as indicated in the figure. A – D) All data are shown as mean + SD (n = 5; n.s. = not 
significant; *P < 0.05; **P < 0.01). Tnaïve: naïve T cells; TCM; central memory T cells; TEM: effector 
memory T cells. 
 
To examine the contribution of NCR-ILC3s to CD4+ T cell proliferation in vivo, 3 x 106 
CFSE-labeled OT-IItg CD4+ T cells were adoptively transferred into WT, I-abΔILC3 or I-
ab-/- mice followed by an immunization with ovalbumin (OVA) peptide323-339 and OVA 
protein in combination with CpG (Fig. 17 A). CpG was additionally used for the 
immunization as an adjuvant since it induced activation of splenic NCR-ILC3s and an 
inflammatory milieu in the spleen of WT mice upon in vivo treatment (Fig. 9 B and C). 
The proliferation of adoptively transferred OT-IItg CD4+ T cells in the different 
recipient mice was examined 2 days later to uncover the contribution of NCR-ILC3s 
to transient CD4+ T cell responses.277 As expected, CFSE-labeled OT-IItg CD4+ T 
cells proliferated in WT, but not I-ab-/- mice (Fig. 17 B). In I-abΔILC3 mice, OT-IItg CD4+ 
T cell proliferation was significantly reduced demonstrating that ILC3s were able to 
present Ag and to meaningfully alter OVA-specific CD4+ T cell responses in vivo (Fig. 
17 B).  
 	  
	  	  	  	  	  	  	  	  	   	  
 
Figure 17:	   ILC3s elicit Ag-specific T cell proliferation in vivo. A) Schematic representation of the 
experimental performance of the in vivo experiment. t = time (h). B) Sort-purified CFSE-labeled OT-IItg 
CD4+ T cells were injected i.v. into WT (), I-abΔILC3 (§) and I-ab-/- () mice immunized with OVA peptide, 
OVA protein and CpG. Absolute numbers of proliferating OT-IItg CD4+ T cells recovered from the spleen 
2 days later (mean values + SD; 4 independent experiments; n = 6 – 7; *P < 0.05; **P < 0.01). 	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 ILC3s support Ag-specific T-dependent B cell responses in 5.5.3
vivo.  
 
My data could demonstrate that ILC3s were able to elicit Ag-dependent CD4+ T cell 
proliferation in vivo. However, whether ILC3s contribute to T dependent (TD) B cell 
responses was not yet investigated. To study the role of ILC3s in TD B cell 
responses, I compared B cell responses in WT, I-abΔILC3 and RORγ-/- mice. RORγ-/- 
mice are described to completely lack ILC3s and consequently LNs and PPs the 
places where immune responses can be generated.25, 70 Therefore, the spleen, which 
develops independently of ILC3s, serves as the main place to generate adaptive 
immune responses in RORγ-/- mice. Further, RORγ-/- mice show a diminished T cell 
pool.70 It has been reported that RORγt regulates the survival of double positive 
(CD4+CD8+) thymocytes during T cell development in the thymus by enhancing the 
expression of the anti-apoptotic factor Bcl-xL.70 In line with this, analysis of RORγ-/- 
mice revealed significantly reduced relative numbers of CD3+ T cells compared to 
WT mice (Fig, 18 A). This reduction could not be reflected in absolute cell numbers, 
probably due to the fact that T cells in RORγ-/- mice only have the possibility to 
accumulate in the spleen while T cells in WT mice can be distributed within other 
secondary lymphoid organs (Fig. 18 A). The development of B cells was not affected 
by RORγt deficiency shown by increased relative and absolute numbers of total 
CD19+ B cells in the spleen of RORγ-/- mice compared to WT mice (Fig. 18 A). Within 
the splenic B cell compartment, a normal distribution of MZB cells 
(CD19+CD21highCD23low) and FolB cells (CD19+CD21lowCD23high) was observed (Fig. 
18 B). The significant increased in B cell numbers in RORγ-/- mice might be the 
consequence of accumulation of these cells in the spleen. Furthermore, RORγ-/- mice 
showed a decrease in relative numbers of CD4+ but not CD8+ T cells compared to 
WT mice (Fig. 18 C). This reduction was probably induced by the lack of a subset of 
CD4+ T cells, the Th17 cells, whose differentiation is known to be regulated by RORγt 
expression.231 However, the decreased relative numbers of CD4+ T cells in RORγ-/- 
mice could not be reflected in absolute cell numbers (Fig. 18 C). The majority of 
CD4+ and CD8+ T cells found in the spleen of RORγ-/- mice showed a memory-like 
phenotype (Fig. 18 D - E).  Relative and absolute numbers of naïve CD4+ T cells 
(Tnaïve; TCRβ+CD62LhighCD44-/low) were significantly reduced in RORγ-/- mice whereas 
effector memory CD4+ T cells (TEM; TCRβ+CD62L-/lowCD44high) were increased 
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compared to WT mice. Collectively, these data showed that RORγ-/- mice harbored a 
diminished T cell pool.  
 
	  
 
Figure 18:	  RORγ -/- mice show a diminished T cell repertoire with a bias to memory-like phenotype 
T cells. A - C) Relative and absolute numbers of (A) T cells (CD3+) and B cells (CD19+), (B) marginal 
zone B cells (MZB; CD19+CD21highCD23low) and follicular B cells (FolB; CD19+CD21lowCD23high), and 
(C) CD4+ and CD8+ T cells in the spleen of WT and RORγ-/- mice. D - E) Relative (D) and absolute (E) 
numbers of CD4+ and CD8+ T cell subsets in the spleen of WT and RORγ-/- mice. A – E) All data are 
shown as mean + SD (n = 5; n.s. = not significant; *P < 0.05). Tnaïve: naïve T cells; TCM; central memory 
T cells; TEM: effector memory T cells. 
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Since RORγ-/- mice only showed low numbers of naïve T cells, adoptive transfer of 
OT-IItg CD4+ T cells was required to provide a pool of naïve CD4+ T cells able to 
achieve CD4+ T cell help to B cells. Hereby, RORγ-/- mice could be used to study TD 
B cell responses in the complete absence of ILC3s.  
To examine the contribution of ILC3s to TD B cell responses, 2 x 106 OT-IItg CD4+ T 
cells were adoptively transferred into WT, I-abΔILC3 and RORγ-/- mice at day 0. 
Subsequently, all mice were immunized i.p. with a single dose of Alum-precipitated 
4-hydroxy-3-nitrophenyl-acetyl (NP)-OVA (100 µg per mouse) plus CpG at day 0. 
Mice were bleed one day before adoptive transfer and immunization (day -1; naïve), 
and 5 (day 5) as well as 14 (day 14) days after adoptive transfer and immunization 
(Fig. 19 A). Each time the serum was collected to measure immunoglobulin (Ig) 
levels in the different recipients.  
Naïve WT and I-abΔILC3 mice showed similar levels of total IgM measured in the 
serum at day -1 whereas total IgM levels in naïve RORγ-/- mice were slightly higher 
(Fig. 19 B). Furthermore, IgG3, the Ig subtype often produced in response to T 
independent (TI) Ags, could be detected in I-abΔILC3 and RORγ-/- mice at day -1 at 
slightly higher levels than in WT mice (Fig. 19 C). These findings indicated that naïve 
I-abΔILC3 and RORγ-/- mice were able to mount immune responses against TI Ags and 
to secrete normal or even higher levels of IgG3 than WT mice.  
The establishment of a humoral immune response to TD Ags includes isotype class 
switch, a process that takes place within germinal centers (GC), which are especially 
formed in response to the encountered Ag.278, 279 Therefore it was not surprising that 
the level of total IgG produced against nitrophenylacetyl (NP)-OVA was low in the 
serum of mice only 5 days upon immunization and CD4+ T cell transfer (Fig. 19 D). 
14 days after immunization, NP-OVA-specific total IgG was increased in all three 
different recipient mouse strains (Fig. 19 E). The loss of MHC II on ILC3s (I-abΔILC3) 
resulted in a significant reduction of NP-OVA-specific IgG titers compared to IgG 
titers measured in WT mice (Fig. 19 E). In RORγ-/- mice, which lack ILC3s, Th17 
cells, LNs and PPs, NP-OVA-specific IgG titers were even more reduced (Fig. 19 E). 
Additionally, a more detailed analysis of IgG subtypes revealed that NP-OVA specific 
IgG1, IgG2a, IgG2b and IgG3 levels were all low or not detectable 5 days after 
immunization (Fig. 19 F). However, the IgG subtypes IgG1, IgG2a, IgG2b and IgG3 
were found to be produced against NP-OVA 14 days after immunization (Fig. 19 G). 
MHC II deficiency on ILC3s in I-abΔILC3 mice resulted in a significant reduction of all 
NP-OVA-specific IgG subtypes compared to WT mice (Fig. 19 G).  RORγ-/- mice 
showed again an even higher reduction of NP-OVA specific IgG subtypes (Fig. 19 
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G). Collectively, these data showed that Ag-presentation by ILC3s contributed to T 
cell priming in vivo, and that TD B cell responses were impaired when Ag-
presentation was abolished in ILC3s. 	  
	  
 
Figure 19:	   ILC3s support Ag-specific TD B cell responses in vivo. A) Schematic representation of 
the experimental performance of the in vivo experiment. t = time (days). B - C) Total IgM (B) and total 
IgG3 (C) levels in naïve WT, I-abΔILC3 and RORγ-/- mice measured 1 day before immunization (day -1). 
Data are shown as mean values + SD (n = 9 – 10, n.s. = not significant; *P < 0.05; **P < 0.01; ***P < 
0.001). D - E) WT, I-abΔILC3 and RORγ-/- mice were i.p. immunized with 100 µg Alum-precipitated NP-
OVA after i.v. injection of OT-IItg CD4+ T cells plus CpG. NP-OVA-specific total IgG level 5 days (D) and 
14 days (E) after immunization are shown. Data are representative as mean values + SD (n = 9 – 10) 
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from 3 independent experiments (**P < 0.01; ***P < 0.001; ****P < 0.0001). F - G) NP-OVA-specific 
IgG1, IgG2a, IgG2b and IgG3 levels in WT, I-abΔILC3 and RORγ-/- mice measured 5 days (F) or 14 days 
(G) after i.p. immunization with 100 µg NP-OVA in Alum and i.v. injection of OT-IItg CD4+ T cells plus 
CpG. Data are depicted as mean values + SD (n = 9 – 10; n.d. = not detectable; n.s. = not significant; *P 
< 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001).	  
 
 CD4+ T cell - NCR-ILC3 interaction in vivo. 5.5.4
 
My previous data showed that NCR-ILC3s contribute to CD4+ T cell responses in 
vitro as well as in vivo by direct interaction with CD4+ T cells in an Ag-dependent 
manner. For the in vivo experiments I made use of the I-abΔILC3 mouse model, in 
which ILC3s lacked MHC II expression and were therefore not able to contribute with 
Ag-presentation to CD4+ T cell responses. 
To gain more insight into the interaction of NCR-ILC3s and CD4+ T cells in vivo, the 
next approach was to monitor Ag-dependent interaction of CD4+ T cells and NCR-
ILC3s directly in vivo. Adoptive transfer of Ag-specific OTIItg CD4+ T cells and NCR-
ILC3s into I-ab-/- mice followed by immunization with the cognate Ag should allow the 
monitoring of CD4+ T cell - NCR-ILC3 interaction in vivo.  Therefore, I started to 
establish a protocol for adoptive transfer of OTIItg CD4+ T cells in combination with 
APCs (BMDCs or NCR-ILC3s) into I-ab-/- recipients. 
First, I adoptively transferred 3 x 106 naïve CFSE-labeled OTIItg CD4+ T cells i.v. at 
time point 0 h into I-ab-/- mice to allow the migration of transferred cells into 
secondary lymphoid tissues. 24 h later, 1 x 106 APCs were additionally injected i.v. 
and the recipient mice were immunized with the cognate Ag. The proliferation of 
adoptively transferred OTIItg CD4+ T cells was examined 48 h later as a first 
indication for Ag-dependent CD4+ T cell – NCR-ILC3 interaction (Fig. 20 A).280 
According to my previous in vivo experiments, the following different immunization 
strategies were tested; i) alum precipitated NP-OVA, ii) OVA peptide/OVA protein or 
iii) OVA peptide/OVA protein plus CpG. These immunization strategies should 
provide the cognate Ag as well as additional stimulation of recipient mice. 
Analysis of I-ab-/- mice 72 h after the start of the in vivo experiment revealed that i.v 
injected OTIItg CD4+ T cells were detectable in the spleen as well as in the inguinal 
and mesenteric LNs (mLNs; Fig. 20 B and C). However, independent of the 
immunization strategy, the recovered OTIItg CD4+ T cells did not proliferate in the 
recipient mice (Fig. 20 B and C). No differences in CD4+ T cell proliferation in I-ab-/- 
recipients were observed by injection of either BMDCs or NCR-ILC3s as APCs (Fig. 
20 C and D). The absence of CD4+ T cell proliferation could be due to the inability of 
APCs to reach the areas where interaction with CD4+ T cells would take place within 
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the secondary lymphoid organ. Thus, further experiments are required to examine 
whether transferred APCs were localized in close proximity to adoptively transferred 
CD4+ T cells.  
CXCR5 was shown to be crucial for B cell homing to peripheral LNs.281 Since NCR-
ILC3s express high levels of CXCR5 (Fig. 6 B) I assumed that these cells were able 
to reach LNs upon adoptive transfer in order to interact with CD4+ T cells in such 
organized structures. Therefore, in a second approach, I tried to limit the migration of 
NCR-ILC3s and CD4+ T cells to the popliteal LNs in order to increase the possibility 
of interaction of these two cell types (Fig. 20 E). The popliteal LNs are the draining 
LNs upon injection into the foot pad of mice. Thus, I first injected different amounts (3 
x 105 – 1 x 106 cells) of in vitro generated NCR-ILC3s into the foot pad of I-ab-/- mice 
and screened for the presence of transferred NCR-ILC3s after different time points by 
flow cytometry. NCR-ILC3s were only detectable in very low numbers 3 h after 
injection. At later time points after injection, I could not detect NCR-ILC3s in the 
draining LNs indicating that these cells either migrate further or die. Since, with this 
approach it was not possible to provide the popliteal LN of I-ab-/- mice with MHC II-
expressing NCR-ILC3s, there was no need for further transfer of CD4+ T cells and 
immunization of recipient mice in this experimental approach. Thus, by the use of the 
different approaches described before it was not possible to monitor CD4+ T cell – 
NCR-ILC3 interaction directly in vivo. 
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Figure 20:	   Establishment of adoptive transfer of APCs and OTIItg CD4+ T cells in vivo. A) 
Schematic representation of the experimental performance. B) Summary of the outcome of different 
approaches carried out to establish a protocol for adoptive transfer of APCs and OTIItg CD4+ T cells in 
order to monitor NCR-ILC3s-CD4+ T cell interactions in vivo. ✔ = yes; OTIItg CD4+ T cells could be 
recovered, ✖ = no; recovered OTIItg CD4+ T cells did not proliferate. C) Representative dot plots of 
adoptively transferred CFSE-labeled CD4+ T cells (blue gate) recovered in the inguinal LNs of I-ab-/- 
mice 72 h after adoptive transfer either alone or in combination with BMDCs (DCs) and immunization as 
indicated in the figure. D) Representative dot plot of adoptively transferred CFSE-labeled CD4+ T cells 
recovered in the inguinal LNs of I-ab-/- mouse, which received in vitro generated NCR-ILC3s followed by 
immunization indicated in the figure. E) Schematic representation of the experimental performance of 
the second approach. i.v.: intravenous; f.p.: foot pad.  
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5.6 Small intestinal NCR-ILC3s differ from splenic NCR-ILC3s in 
regard to their phenotype, response to innate stimulation and 
ability to induce CD4+ T cell responses. 
 
 The phenotype of small intestinal lamina propria-derived NCR-5.6.1
ILC3s differs from that of splenic NCR-ILC3s. 
 
In vivo, ILC3s are predominantly found in mucosa-associated tissues such as the 
gastrointestinal tract.108, 109, 110, 266 How intestinal NCR-ILC3s contribute to innate and 
adaptive immune responses was not fully understood. Therefore, I focused more 
detailed on NCR-ILC3s found in the lamina propria (LP) of the small intestine of adult 
mice. First of all, I examined the phenotype of ex vivo isolated small intestinal LP 
NCR-ILC3s of adult WT mice. LP NCR-ILC3s could be identified as lin-
CD90.2+CD117+RORγt+ cells (Fig. 21 A). Within this cell population, both CD4+ and 
CD4- subpopulations could be found (Fig. 21 A). The CD4+ population represented 
approximately 10 % of total LP NCR-ILC3s whereas 90 % of the cells were CD4- (Fig. 
21 A). Both CD4+ and CD4- LP NCR-ILC3s expressed comparable high levels of 
RORγt (Fig. 21 A). The expression profile of the chemokine receptor CCR6 differed 
in CD4+ and CD4- LP NCR-ILC3s. Whereas all CD4+ LP NCR-ILC3s expressed 
CCR6, within the CD4- LP NCR-ILC3s subset 60 % of the cells was CCR6- (counting 
for 70 % of total CD4- LP NCR-ILC3s; Fig. 21 B). This indicated that the CD4- LP 
NCR-ILC3 subset represented a more heterogeneous population. MHC II expression 
could be observed on both CD4+ and CD4- LP NCR-ILC3s (Fig. 21 B). Whereas 
around 40 % of all CD4+ LP NCR-ILC3s expressed MHC II only approximately 20 % 
of all CD4- LP NCR-ILC3s were MHC II+. 
The intestine contains a large number of commensal bacteria as well as potential 
pathogens,282 which might have an influence on the activation state of LP NCR-
ILC3s. Therefore, I investigated the expression of co-stimulatory molecules CD40 
and CD86 as well as the early activation marker CD69 on the surface of LP NCR-
ILC3s ex vivo isolated from naïve WT mice. Both subsets of LP NCR-ILC3s lacked 
the expression of CD40 and CD86 (Fig. 21 C). CD69 was highly expressed on both 
CD4+ and CD4- LP NCR-ILC3 subsets isolated from naïve WT mice (Fig. 21 D). LP 
NCR-ILC3s expressed CD69 two to three fold higher compared to ex vivo isolated 
splenic NCR-ILC3s, which lack CD69 expression (Fig. 21 E). It was possible that 
either bacteria, endogenous IL-1 or IL-23 present in the small intestine induced the 
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expression of CD69 on LP NCR-ILC3s of naïve WT mice. Therefore, I investigated 
IL-1R1-/- mice, which lack the receptor for IL-1 and hence are unresponsive to IL-1.  
LP NCR-ILC3s isolated from naïve IL-1R1-/- mice showed CD69 expression at similar 
levels to WT mice (Fig. 21 F). Thus, signaling via IL-1R1 was not responsible for the 
high expression of CD69 on LP NCR-ILC3s. Microbial products and components of 
bacteria are mainly sensed through TLRs. Therefore, I investigated CD69 expression 
on LP NCR-ILC3s ex vivo isolated from MyD88ΔILC3/T mice, which lack the expression 
of MyD88 on RORγt-expressing cells. MyD88 is an adaptor molecule used by almost 
all TLRs for activation of NFκB downstream signaling transmitting the recognized 
stimulus.163 However, CD69 was highly expressed on LP NCR-ILC3s lacking MyD88. 
Furthermore, ex vivo isolated LP NCR-ILC3s of mice with a complete deficiency of 
MyD88 (MyD88-/-) also showed high expression of CD69 (Fig. 21 F). These findings 
indicated that the absence of MyD88-mediated TLR signaling in ILC3s as well as in 
all other immune cells did not influence CD69 expression on LP NCR-ILC3s. TLR3 
and TLR4 are known to signal independent of MyD88 by the use of another adaptor 
molecule, named TRIF.283, 284 Therefore, I tested mice with a deficiency in both 
MyD88 and TRIF (MyD88-/-Trif-/-) for the expression of CD69 on LP NCR-ILC3s. 
Naïve MyD88-/-Trif-/- mice showed as well high levels of CD69 expression on LP 
NCR-ILC3s (Fig. 21 F).  Thus, bacteria and microbial products sensed through TLRs 
were not responsible for CD69 expression by LP NCR-ILC3s. My previous in vitro 
stimulation data suggested IL-23 as a potential activator of ILC3s (Fig. 7 A and Table 
1). Furthermore, IL-22 production by ILC3s in a model of C. rodentium infection, an 
intestinal pathogen, has been reported to be IL-23 dependent.106 Thus, I investigated 
the phenotype of LP NCR-ILC3s ex vivo isolated from IL-23p19-/- mice. However, LP 
NCR-ILC3s isolated from IL-23p19-/- mice showed CD69 expression similar to WT 
(Fig. 21 F). Additionally, LP NCR-ILC3s isolated from germfree mice expressed 
CD69 excluding the microbiota to be responsible for this phenomenon (Fig. 21 F). 
CD69 expression on LP NCR-ILC3s was also not the consequence of the presence 
of T and B lymphocytes, as Rag2-/- mice contained LP NCR-ILC3s expressing CD69 
at levels comparable to WT (Fig. 21 F). Altogether, compared to splenic NCR-ILC3s, 
LP NCR-ILC3s continuously expressed CD69 independent of IL-1R1- and TLR 
signaling, the presence of T and B cells, as well as the microbiota or the availability 
of IL-23.  
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Figure 21:	   Naïve LP NCR-ILC3s express CD69 independent on IL-1R1 and TLR signaling, IL-23, 
the microbiota and the presence of T and B lymphocytes. A) Phenotype of ex vivo isolated LP NCR-
ILC3s of WT mice. RORγt expression of LP CD4+ and CD4- NCR-ILC3s is shown. RORγt expression of 
total LP NCR-ILC3s (black line) is displayed in the histogram. Grey solid line corresponds to lin+ cells. 
Numbers in dot plots show the percentage of cells in each gate. Representative dot plots and histogram 
are illustrated. B - C) Expression of (B) CCR6 and MHC II, and (C) CD40 and CD86 on naïve ex vivo 
isolated LP NCR-ILC3s of adult WT mice. Numbers in dot plots show the percentage of cells in each 
gate. Representative dot plots are shown. D) Representative dot plot of CD69 expression of LP NCR-
ILC3s. E) Representative histogram of CD69 expression of LP compared to splenic NCR-ILC3s. F) 
Representative dot plots of CD69 expression on CD4+ and CD4- LP NCR-ILC3s isolated from different 
mouse strains as indicated in the figure. 
 
 Small intestinal LP NCR-ILC3s do not express co-stimulatory 5.6.2
molecules upon IL-1β stimulation.  
 
It has been previously reported that mucosa-associated intestinal ILC3s rather limit 
CD4+ T cell responses to commensal bacteria than promote CD4+ T cell responses 
due to the lack of co-stimulatory molecules.132 However, whether these cells express 
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co-stimulatory molecules under inflammatory condition similar to splenic NCR-ILC3s 
has never been investigated. Therefore, I isolated LP NCR-ILC3s from adult Rag2-/- 
mice as these mice harbor increased numbers of ILC3s and simultaneously lack T 
and B cells facilitating the enrichment of high numbers of ILC3s without 
contaminating T or B cells. Similar to WT derived LP NCR-ILC3s (Fig. 21 A and B) 
Rag2-/- derived LP NCR-ILC3s could be identified as lin-CD90.2+CD117+ cells 
expressing high levels of the transcription factor RORγt (Fig. 22 A). Sort-purified ex 
vivo isolated NCR-ILC3s were then cultured for 48 h in the presence of IL-1β or in 
medium alone. In vitro exposure to IL-1β induced blast formation of LP NCR-ILC3s 
(Fig. 22 B). However, despite increasing amount of IL-1β in the in vitro cultures, 
neither the expression of the co-stimulatory molecules CD40 and CD86 nor the up-
regulation of MHC II could be detected on LP NCR-ILC3s (Fig. 22 C). Furthermore, 
LP NCR-ILC3s showed high levels of IL-22 production in the absence of IL-1β, and 
IL-22 secretion was increased in the presence of IL-1β (Fig. 22 D). IL-22 secretion by 
IL-1β-activated LP NCR-ILC3s exceeded those of IL-1β-activated splenic NCR-ILC3s. 
In contrast to LP NCR-ILC3s, splenic NCR-ILC3s did not secrete IL-22 in the absence 
of innate stimulation (Fig. 22 D). Therefore, the response of LP NCR-ILC3s to innate 
stimulation differed from that of splenic NCR-ILC3s as such as LP NCR-ILC3s 
predominantly produced IL-22 and did not up-regulate expression of MHC II and co-
stimulatory molecules upon IL-1β exposure. 
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Figure 22:	   Small intestinal LP NCR-ILC3s do not express co-stimulatory molecules upon 
stimulation with IL-1β . A) Phenotype of NCR-ILC3s ex vivo isolated from the lamina propria (LP) of the 
small intestine of Rag2-/- mice. Numbers in dot plots show the percentage of cells in each gate. 
Representative dot plots and histogram are depicted. B) Representative histogram of forward scatter 
(FSC) level in LP NCR-ILC3s cultured for 48 h in the presence of IL-1β or in medium alone. C) 
Expression of MHC II, CD40 and CD86 by LP NCR-ILC3s cultured for 48 h in the presence of different 
concentrations of IL-1β or in medium alone as indicated in the figure. Data are representative of 4 
independent experiments. Numbers in dot plots show the percentage of cells in each quadrant. D) IL-22 
secretion by either ex vivo isolated LP or splenic NCR-ILC3s upon 48 h exposure to IL-1β or medium 
alone. Data are shown as mean values + SD (n = 3 - 6, at least 3 independent experiments; *P < 0.05; 
**P < 0.01).  
 
 Small intestinal LP NCR-ILC3s are able to internalize 5.6.3
exogenous Ag.  
 
Naïve LP NCR-ILC3s showed MHC II expression on their surface (Fig. 21 B and Fig. 
22 C). Therefore, I tested the capacity of LP NCR-ILC3s to take up exogenous Ag. 
Sort-purified ex vivo isolated LP NCR-ILC3s were cultured for 6 h in the presence of 
red fluorescent latex beads at 37 °C and 4 °C. Whereas LP NCR-ILC3s were able to 
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internalize latex beads at 37 °C, bead uptake was severely impaired at 4 °C as 
expected (Fig. 23 A). Thus, naïve ex vivo isolated LP NCR-ILC3s, similar to splenic 
NCR-ILC3s, were capable to internalize exogenous Ag.  
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
 
Figure 23: LP NCR-ILC3s are able to take up exogenous Ag. A) Representative plots and histograms 
of sort-purified ex vivo isolated LP NCR-ILC3s incubated for 6 h with red fluorescent latex beads at 37 
ºC or 4 ºC. Number in the dot plots shows percentage of bead+ cells (4 independent experiments).  
 
 Small intestinal LP NCR-ILC3s are unable to efficiently induce 5.6.4
CD4+ T cell activation. 
 
Upon IL-1β exposure, LP NCR-ILC3s were unable to express co-stimulatory 
molecules (Fig. 22 C). Interaction of T cells with APCs lacking co-stimulatory 
molecules rather limits T cell responses and induces T cell anergy.133, 218 Whether LP 
NCR-ILC3s were able to either elicit CD4+ T cell responses or limit them was not fully 
understood. Therefore, I tested the ability of pre-activated LP NCR-ILC3s to induce 
CD4+ T cell responses in vitro by the use of so-called BW-OTII cells. BW-OTII cells 
were generated by the fusion of activated OT-IItg T cells (activated in the presence of 
soluble anti-CD3 Ab) with TCRαβ- BW-5147 NFAT-EGFP fusion partner (see 4.2.6 
Generation of BW-OTII cells).256 TCRαβ- BW-5147 NFAT-EGFP hybridoma cells 
contain nuclear factor of activated T cells (NFAT)-binding sites inserted upstream of 
the enhanced green fluorescent protein (EGFP) coding sequence. Thus, TCRαβ- 
BW-5147 NFAT-EGFP hybridoma cells fused to OT-IItg CD4+ T cells (BW-OTII cells) 
provide a tool to study Ovalbumin-MHC II dependent TCR engagement (Fig. 24 A 
and B). Ex vivo isolated sort-purified LP or splenic NCR-ILC3s were activated with IL-
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1β for 24 h and subsequently co-cultured with BW-OTII cells in the presence or 
absence of OVA peptide (Fig. 24 A and B). The percentage of GFP+ BW-OTII cells in 
the co-culture reflected the efficiency of Ag presentation by NCR-ILC3s. IL-1β-
activated LP NCR-ILC3s were less efficient in BW-OTII activation in the presence of 
OVA peptide compared to splenic NCR-ILC3s (Fig. 24 A and B). GFP+ BW-OTII cells 
were almost not detectable in co-cultures in the absence of Ag (Fig. 24 A and B). To 
test whether LP NCR-ILC3s were able to process also whole OVA protein in order to 
interact with CD4+ T cells, IL-1β-activated LP NCR-ILC3s were co-cultured with sort-
purified ex vivo isolated OT-IItg CD4+ T cells either in the presence or absence of 
whole OVA protein (Fig. 24 C and D). LP NCR-ILC3s were 3 times less efficient to 
induce cognate T cell activation in vitro compared to splenic NCR-ILC3s (Fig. 24 C 
and D). Thus, these data demonstrated that although NCR-ILC3s were able to 
process exogenous Ag and to interact with CD4+ T cells, they showed only low CD4+ 
T cell activation efficiency. Collectively, these data showed that LP NCR-ILC3s 
responded differentially than splenic NCR-ILC3s to innate simulation and were less 
efficient in triggering CD4+ T cell responses.  
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Figure 24:	   Activated LP NCR-ILC3s do not induce efficient CD4+ T cell activation. A) 
Schematic representation of naïve GFP- BW-OTII cells (fusion of TCRαβ- BW5147 NFAT-
EGFP cells with OT-IItg CD4+ T cells) and activated GFP+ BW-OTII cells upon TCR 
engagement. B) Percentage of GFP+ BW-OTII cells upon co-culture with IL-1β-activated LP 
or splenic NCR-ILC3s in the presence or absence of OVA peptide. Data are shown as mean 
values (n= 2-3). C) Naïve sort-purified OT-IItg CD4+ T cells were cultured with IL-1β-activated 
LP or splenic NCR-ILC3s in presence of OVA protein or medium alone (w/o Ag) as indicated 
in the figure. Representative plots of CD69 expression by OT-IItg CD4+ T cells 48 h later. Data 
are representative of 4 independent experiments. D) Percentage of CD69+ OT-IItg CD4+ T 
cells upon co-culture with IL-1β-activated LP or splenic NCR-ILC3s in the presence or 
absence of OVA protein. Data are shown as mean values + SD (4 independent experiments). 	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6 Discussion 
 
 
Beside the role as key players in the induction of lymphoid tissue formation and 
organization during embryogenesis, ILC3s are found after birth, mainly accumulating 
in the intestine and are as well present in peripheral organs. So far, the immune 
functions described for NCR- and NCR+ILC3s in the adult immune system are based 
on their ability to secrete effector cytokines in response to soluble factors derived 
from other immune cells. I show here that NCR-ILC3s were able to directly sense and 
respond to microbial products and pro-inflammatory cytokines. Upon IL-1β exposure, 
peripheral NCR-ILC3s expressed MHC II and co-stimulatory molecules and became 
bona fide APCs, as they were able to take up exogenous Ag, to process it and 
consequently promoted OVA-specific CD4+ T cell proliferation in vitro and in vivo. In 
addition, activated NCR-ILC3s expressed an unexpected repertoire of cytokines 
known to alter T cell responses. Ag-specific T cell proliferation and IgG-mediated 
humoral immunity were impaired in animals in which Ag-presentation was abolished 
exclusively in ILC3s. Moreover, in the presence of Ag, the T cell priming led to an 
extended activation of ILC3s suggesting a reciprocal crosstalk between NCR-ILC3s 
and CD4+ T cells. Indeed, soluble factors most likely produced by CD4+ T cells upon 
Ag encounter were able to induce de novo activation of NCR-ILC3s. These novel 
data suggest that under inflammatory conditions the cognate interaction of NCR-
ILC3s and CD4+ T cells contributes to adaptive immunity. Furthermore, I show here 
that small intestinal NCR-ILC3s differed phenotypically and functionally from 
peripheral NCR-ILC3s. Small intestinal NCR-ILC3s produced high amounts of IL-22 
upon exposure to IL-1β, but were not able to up-regulate MHC II molecule 
expression or to express co-stimulatory molecules. Moreover, although they were 
able to take up, process and present exogenous Ag, the induction of CD4+ T cell 
responses was less efficient compared to peripheral NCR-ILC3s. These data suggest 
that NCR-ILC3 immune function might be tissue-specific and depend on 
environmental signals that are differentially active under homeostatic and 
inflammatory conditions.  
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Innate stimulation of NCR-ILC3s induces cytokine production and 
changes in the phenotype. 
 
The FL harbors a population of α4β7+ cells, which were described to give rise to 
ILC3s lacking the expression of the natural cytotoxicity receptor (NCR) NKp46 in 
vitro.60, 61 I line with this, I was able to generate NCR-ILC3s from the α4β7+ ILC3 
precursor population isolated from the FL of 14.5 dpc WT embryos. These in vitro 
generated NCR-ILC3s showed a phenotype (Fig. 6 A - B), which is similar to the 
classical phenotype described for NCR-ILC3s.57 The existence of a CD4+ and a CD4- 
NCR-ILC3 subpopulation in embryonic tissues was reported in several studies61, 63, 93 
and CD4+ and CD4- NCR-ILC3s showed nearly identical phenotype and gene 
expression patterns.285 In line with this, I could demonstrate that in vitro generated 
NCR-ILC3s can be subdivided into CD4+ and CD4- NCR-ILC3s possessing an 
identical phenotype except the surface expression of CD4 (Fig. 6 A - B). Altogether, 
the in vitro generation of NCR-ILC3s provided me with sufficient numbers of cells to 
study the function of CD4+ and CD4- NCR-ILC3s in innate and adaptive immune 
responses. 
NCR-ILC3s were reported to produce IL-17 and IL-22 upon in vivo challenge with 
zymosan, a yeast cell wall product.105 Furthermore, NCR-ILC3s could be shown to 
provide protective immunity during fungal infection with Candida albicans265 or 
bacterial infection with Citrobacter rodentium106 by massive production of IL-17 and 
IL-22, respectively. The secretion of IL-17 and/or IL-22 was dependent on the 
presence of IL-23 produced by other immune cells in response to the pathogens or 
microbial products.105, 106 Consistent with these findings, I could show that in vitro 
generated NCR-ILC3s were able to produce high amounts of IL-22 in response to IL-
23 stimulation in vitro. In addition, I could demonstrate that NCR-ILC3s secreted IL-
22 upon exposure to several TLR ligands whereby Poly I:C induced the production of 
significantly high levels of IL-22 (Fig. 7 A and C). Thus, NCR-ILC3s are as well 
capable to directly sense and respond to the presence of microbial products without 
the involvement of other immune cells suggesting a rapid and independent cytokine-
mediated role for NCR-ILC3s in protective immunity. Only few studies reported the 
expression of TLRs on ILC3s.286, 287, 288 TLR4 was shown to be expressed on murine 
ILC3s whereas TLR2 expression was reported on murine and human ILC3s.287, 288 
Nevertheless, my data suggest, that NCR-ILC3s express at least some TLRs 
allowing the direct response to microbial products.  
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IL-17 secretion could not be observed in the presence of the tested TLR ligands (Fig. 
7 C). Whether the exposure of NCR-ILC3s to a combination of several TLR ligands is 
required and sufficient to induce IL-17 secretion remains to be investigated. 
Moreover, whether ligands for the aryl hydrocarbon receptor (AhR), which are 
reported to be crucial for the secretion of IL-17 and IL-22 by Th17 cells,289 are 
potential inducer of IL-17 and/or IL-22 production by NCR-ILC3s remains to be 
explored. In contrast to other studies, which reported IL-23-dependent IL-17 
production by NCR-ILC3s,105, 265 I could not observe IL-17 secretion of in vitro 
generated NCR-ILC3s in response to IL-23 stimulation in vitro. However, the 
presence of the pro-inflammatory cytokine IL-1β induced IL-17 secretion (Fig. 7 B). 
Considering IL-17 production by ILC3s in different in vivo infection models, my in 
vitro data hence suggest that NCR-ILC3s might require IL-23 and additional factors, 
such as IL-1β, to secrete IL-17.  
The pro-inflammatory cytokine IL-1β was able to induce remarkably high levels of IL-
22 secretion by NCR-ILC3s even exceeding those induced by IL-23 (Fig. 7 A). Both 
CD4+ and CD4- NCR-ILC3 subsets were capable to secrete IL-22 at similar levels, 
indicating that in addition to similarities in their phenotype they shared the capacity to 
secrete typical ILC3 cytokines. In line with the responsiveness to IL-1β, ILC3s were 
reported to express the appropriate receptor, IL-1R1 and MyD88 allowing IL-1R1 
downstream signaling.266, 267, 268, 288 In addition, it was shown that basal and IL-23- as 
well as IL-1β-induced production of IL-22 by ILC3s was dependent on IL-1R1.266, 267, 
268 Blockade of IL-1β in vivo resulted in a decreased production of IL-17 and IFNγ by 
ex vivo isolated ILC3s upon IL-23 stimulation consistent with the fact that levels of IL-
23R expression by ILC3s were reduced.290 Similarly, the production of IL-17, IL-22 
and IFNγ by ILC3s, their expansion in vitro and their accumulation at sites of infection 
in vivo was partially triggered through IL-1R signaling.262, 291 Altogether, these data 
suggest that IL-1β triggers ILC3 responses. IL-1β and/or IL-23 are produced by DCs 
and MΦ under steady state and upon microbial challenge.126, 164, 165, 166, 167, 170, 292 
Considering my findings that NCR-ILC3s are responsive to both, microbial products 
and cytokines, one could assume that their full activation might be reached by a 
combination of direct pathogen recognition and indirect sense of a cytokine milieu 
provided by other immune cells. Further, it could be shown that IL-1β is able to 
increase IL-23R expression on NCR-ILC3s,290 a fact, which might enhance their 
responsiveness to IL-23 and therefore suggests a role for IL-1β in orchestrating IL-
23-dependent NCR-ILC3 responses. Several TLR ligands such as Poly I:C and LPS 
were previously reported to induce pro-IL1β.293 However, Poly I:C-induced direct 
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NCR-ILC3 activation was not mediated through IL-1β secretion of NCR-ILC3s as 
addition of neutralizing IL-1β Ab was not able to reduce activation in the presence of 
Poly I:C (data not shown). This suggests, that TLR ligand-induced NCR-ILC3 
activation was at least not mediated through IL-1β secretion of NCR-ILC3s.  
Moreover, I could show that the exposure of in vitro generated NCR-ILC3s to IL-1β 
induced the secretion of an unexpected broad repertoire of different cytokines, such 
as IL-2, IL-6, MIP-1α, IP-10, IFNγ, TNFα and GMCSF, all known for their capacity to 
alter T cell responses (Fig. 7 D). Whereas IL-2 and IL-6 are involved in T cell 
activation and proliferation,211, 294, 295, 296 MIP-1α and IP-10 can act as 
chemoattractants for mononuclear cells and effector T cells.297, 298 IFNγ has been 
shown to induce Th1 cell differentiation,299 whereas GMCSF plays an important role 
in the induction and maintenance of intestinal tissue resident DCs,121 which are in 
turn crucial for the induction of regulatory T cells (Tregs) responsible for the regulation 
of intestinal tolerance.122, 123, 124 In line with this, it could recently be shown that IL-1β-
induced secretion of GMCSF by ILC3s in the intestine indirectly regulates the 
differentiation and number of Tregs suggesting a cytokine-mediated regulatory role for 
ILC3s in the intestinal immune system.126 However, the role of the different cytokines 
released by NCR-ILC3s in response to IL-1β stimulation needs to be further explored. 
T cell activation, proliferation, survival, differentiation or migration could be examined 
in the presence of soluble factors produced by IL-1β - exposed NCR-ILC3s in vitro. 
Further, one has to consider that most likely not each cell of the in vitro generated 
NCR-ILC3 population was able to produce the entire repertoire of cytokines. It might 
be possible that this population is functionally heterogeneous containing several 
different cell clones capable of producing one or more cytokines. In response to IL-
1β, or to other pro-inflammatory cytokines and microbial products, those different cell 
clones might be able to secrete one single or even several effector cytokines as 
described for human ILC and CD4+ T cell clones.20, 287, 300, 301 Altogether, these data 
suggested that activation-induced and stimuli-dependent cytokine production by 
NCR-ILC3s might play different roles in immunity. 
Beside cytokine production upon direct exposure to microbial products and pro-
inflammatory cytokines, I examined whether one can phenotypically distinguish naïve 
and “experienced” NCR-ILC3s. In order to answer this question, I measured the 
surface expression of CD69, which is reported to be the earliest inducible 
glycoprotein during lymphocyte activation.202 In vitro generated NCR-ILC3s 
expressed low to negligible levels of CD69, indicating their naïve phenotype obtained 
upon differentiation from α4β7+ ILC3 precursors residing in the sterile environment of 
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the FL (Fig. 6 B and Fig. 8 B). However, in vitro exposure to TLR ligands Poly I:C 
and CpG, as well as the pro-inflammatory cytokine IL-1β, increased the expression of 
CD69 indicating the activation of NCR-ILC3s (Fig. 8 A). Further, I could demonstrate 
that in vivo challenge with CpG or LPS induced activation of NCR-ILC3s residing in 
the spleen of adult mice. Splenic NCR-ILC3s up-regulated the expression of CD69 
and MHC II (Fig. 9 C and D). It has been reported, that CpG is able to induce 
activation and maturation of DCs resulting in the up-regulation of the expression of 
certain surface molecules, such as MHC I and II, and co-stimulatory molecules.302, 303 
In line with the finding that CpG stimulates APCs to secrete cytokines like IL-1, 
TNFα, IL-12 and IFNγ,302, 303, 304, 305 I could demonstrate that in vivo administration of 
CpG induced an inflammatory milieu in the spleen with significantly increased levels 
of the pro-inflammatory cytokines IL-1β, TNFα and IFNγ (Fig. 9 B). Similar to CpG, it 
has been reported that in vivo challenge of mice with LPS induces the production of 
IL-1β.167 Regarding the fact that the pro-inflammatory cytokine IL-1β appeared to be 
a strong activator of NCR-ILC3s in vitro able to induce the production of various 
cytokines and the up-regulation of CD69 expression, one can assume that the 
activation of splenic NCR-ILC3s observed upon in vivo challenge of adult mice with 
microbial products was at least partially mediated by the induction of a pro-
inflammatory milieu.  
Altogether, my data showed that direct recognition of certain microbial products and 
sensing of pro-inflammatory cytokines induced activation of NCR-ILC3s in vitro and in 
vivo. Activation and cytokine production of NCR-ILC3s was dependent on the nature 
of the present stimuli suggesting that NCR-ILC3s might be able to differentially 
regulate and adapt their responses to innate stimulation.  
 
Activated NCR-ILC3s acquire an APC-like phenotype.  
 
In addition to CD69 up-regulation, I could demonstrate that in vitro generated and ex 
vivo isolated splenic NCR-ILC3s increased the expression of MHC II molecules and 
acquired the expression of co-stimulatory molecules CD80/86 and CD40 upon IL-1β 
exposure in vitro (Fig. 8 B and 10 A). These data showed that peripheral NCR-ILC3s 
were able to acquire an APC-like phenotype upon exposure to inflammation-
associated signals. This phenomenon was already well documented for DCs, which 
were able to mature into professional APCs fully capable of initiating efficient CD4+ T 
cell immunity.173 Expression of MHC II by a fraction of fetal/neonatal ILC3s was 
already reported.57 Here, I could show that whereas naïve splenic NCR-ILC3s 
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already expressed MHC II molecules on their surface, naïve in vitro generated NCR-
ILC3s only showed low levels of MHC II expression. This low expression level might 
arise due to the fact that these cells differentiated from α4β7+ ILC3 precursors 
residing in the sterile environment of the FL whereas splenic NCR-ILC3s of adult 
mice might have already been exposed to factors able to induce MHC II expression. 
The determination of the gene expression profile of in vitro generated CD4+ and CD4- 
NCR-ILC3 subsets revealed the expression of gene-transcripts related to MHC II 
expression and Ag presentation at high levels under steady state (Fig. 8 C). This 
suggests that already naïve NCR-ILC3s possess the machinery for MHC II-
dependent Ag presentation. Surprisingly, no differences in the transcript levels of 
these genes could be observed upon exposure to IL-1β in vitro for 1 h suggesting 
that this short stimulation might not be sufficient to induce substantial changes. 
Hence, these data might imply that NCR-ILC3s require a prolonged exposure to 
inflammatory signals to acquire an APC-like phenotype.  
 
NCR-ILC3s take up latex beads, process protein Ag and promote CD4+ T 
cell responses in vitro.  
 
Having demonstrated that peripheral NCR-ILC3s were able to acquire an APC-like 
phenotype upon innate stimulation, I intended to examine their ability to take up 
exogenous Ag and to induce CD4+ T cell responses. Indeed, I could show that 
peripheral NCR-ILC3s were capable to internalize latex beads although with slower 
kinetics than MΦ (Fig. 11 A - E). This could be either due to less efficient 
internalization of beads by or due to limitations in the experimental technique. In fact, 
MΦ were adherent in in vitro cultures facilitating the uptake of soluble beads 
compared to NCR-ILC3s, which were in suspension. Moreover, I could demonstrate 
the specificity of bead internalization by peripheral NCR-ILC3s as bead uptake was 
severely inhibited in the presence of Cytochalasin D, reported to inhibit 
phagocytosis,257, 306 and when bead uptake was performed at 4 °C, a condition 
shown to prevent ingestion of targets.307  
In addition, I could show that peripheral NCR-ILC3s were able to prime naïve Ag-
specific CD4+ T cells. CD4+ T cell proliferation could be observed in the presence of 
activated peripheral NCR-ILC3s and peptide-Ag, and to a lesser extent with entire 
protein-Ag (Fig. 12 A - E). Not surprisingly, peripheral NCR-ILC3s were less potent in 
priming naïve T cells than BMDCs, probably because DCs were more efficient in 
processing of protein Ag and expressed higher levels of co-stimulatory and MHC II 
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molecules. Despite their similarities in phenotype (Fig. 6 B), cytokine production (Fig. 
7 A) and gene expression (Fig. 8 C),285 in vitro generated CD4+ NCR-ILC3s had a 
greater potential to induce protein Ag-specific T cell proliferation than CD4- NCR-
ILC3s (Fig. 12 B). These data were in line with a previous finding that embryonic 
CD4+ NCR-ILC3s were more differentiated than their CD4- counterpart308 and my data 
showing that CD4+ NCR-ILC3s were slightly more efficient in bead uptake (Fig. 11 D).  
Although activation of splenic NCR-ILC3s led to significantly increased CD4+ T cell 
activation, I unexpectedly observed that naïve splenic NCR-ILC3s without prior 
activation were able to induce CD4+ T cell responses (Fig. 12 C - E). However, I 
could show that Ag-dependent interaction of NCR-ILC3s and CD4+ T cells resulted in 
NCR-ILC3 activation (Fig. 13 A), which might explain why naïve NCR-ILC3s could 
trigger T cell priming in the absence of previous activation by IL-1β. These data 
suggested that T cell-derived signals might be able to enhance and/or prolong NCR-
ILC3-mediated T cell activation. A similar crosstalk has been reported for ILC2-T cell 
interactions whereby CD4+ T cells activated through TCR engagement produced 
cytokines able to reciprocally induce ILC2 proliferation and to increase their Th2 type 
cytokine production.51 Another study suggested an additional reciprocal effect in 
which ILC2s induced T cell proliferation and increased Th2 cytokine production in a 
cell-cell contact-dependent manner via OX40L.53 Collectively, this illustrates a 
multifaceted crosstalk between ILCs and T cells, which most likely acts on T as well 
as ILC responses. A role for OX40L expressed on adult ILC3s in CD4+ T cell 
responses was already proposed a decade ago.94, 95 It could be shown that adult 
ILC3s expressed OX40L and CD30L providing the possibility to interact within 
secondary lymphoid organs with primed CD4+ T cells expressing CD30 and OX40.94, 
95 Thereby, it was suggested that ILC3s promoted the survival of CD4+ memory T 
cells by providing accessory signals, at least via OX40L.94, 95, 309 The expression of 
CD30L and OX40L on adult ILC3s was reported to be the only difference between 
fetal and adult ILC3s,102 which otherwise were shown to share phenotypic and 
functional properties.96, 103 In line with this, I found that splenic NCR-ILC3s were 
phenotypically similar to FL-derived NCR-ILC3s (Fig. 6 A - B and Fig. 9 A).  
Having demonstrated that the presence of Ag could not be responsible for NCR-ILC3 
activation upon Ag-dependent interaction with CD4+ T cells (Fig. 13 B), I assumed 
that a positive feedback loop based on secreted cytokines from T cells to ILC3s 
might exist as it was already demonstrated for ILC2-T cell interactions.51 Therefore, I 
examined the ability of soluble factors produced by CD4+ T cells upon cognate Ag-
encounter to reciprocally induce NCR-ILC3 activation. The following approaches 
were used to generate cell culture supernatant (SN) containing CD4+ T cell-derived 
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cytokines; i) co-culture of NCR-ILC3s and CD4+ T cells with Ag, ii) co-culture of 
BMDCs and CD4+ T cells with Ag, or iii) CD4+ T cell activation in presence of anti-
CD3/anti-CD28 Abs coated on a plate. Indeed, I could show that naïve splenic NCR-
ILC3s up-regulated the expression of CD69 and slightly increased the expression 
levels of CD40 and CD80 in response to soluble factors produced in the co-culture of 
BMDCs and CD4+ T cells with Ag (Fig. 14 A and B) suggesting that these soluble 
factors induced activation of NCR-ILC3s, which might increase their efficiency to 
promote CD4+ T cell responses. In line with the previous finding that CD4+ T cells 
secrete IFNγ upon Ag encounter,272 I could show that CD4+ T cells in in vitro cultures 
with BMDCs and Ag produced IFNγ (Fig. 14 C). IFNγ was previously reported to 
enhance MHC II expression either on cells constitutively expressing MHC II 
molecules, such as B cells and DCs310 or on cells, which do not constitutively 
express MHC II.311 In addition, IFNγ was shown to increase the expression of other 
genes involved in the class II Ag presentation pathway overall suggesting that IFNγ 
indirectly promotes peptide-specific activation of CD4+ T cells.312, 313, 314 As I could 
demonstrate that NCR-ILC3s up-regulated MHC II expression in response to IFNγ 
stimulation in vitro (Table 1), IFNγ might mediate NCR-ILC3 activation observed 
during Ag-dependent NCR-ILC3-CD4+ T cell interactions. To further test the 
involvement of IFNγ during ILC3-CD4+ T cell interactions one could examine NCR-
ILC3 activation in the presence of neutralizing IFNγ Ab. IL-2, another cytokine 
produced by CD4+ T cells upon Ag encounter,211 was previously reported to promote 
survival, proliferation and type 2 cytokine secretion by ILC2s.51 Furthermore, 
treatment of Rag2-/- mice with IL-2/anti-IL-2 complexes upon infection with 
Nippostrongylus brasiliensis was reported to increase the ILC2 numbers and the 
production of Th2 type cytokines in absence of CD4+ T cells sufficient to overcome 
the infection.54 I could show that CD25, the high affinity receptor for IL-2, was 
expressed at high levels on naïve NCR-ILC3s and was even more increased upon 
their activation (Fig. 14 D). Moreover, I found that NCR-ILC3s were able to secrete 
IL-2 upon IL-1β exposure in vitro (Fig. 7 D). These data suggest a role for IL-2, either 
NCR-ILC3- or T cell-derived, on the survival, proliferation or cytokine production of 
both cell types. I could show that the ligand for ICOS, ICOSL, was expressed on 
naïve NCR-ILC3s (Fig. 14 D). ICOSL binding to ICOS, which is de novo expressed 
on CD4+ T cells upon activation,274 has previously been reported to be involved in the 
induction CD40L expression on T cells allowing the interaction with CD40+ B cells.315 
This is crucial for the induction of T-dependent B cell responses.316, 317 This finding 
suggested that NCR-ILC3s can provide an additional co-stimulatory signal promoting 
	   117 
CD4+ T cell-mediated immunity. In line with a previous finding, that ICOS is able to 
down-regulate ICOSL expression,318 I observed decreased levels of ICOSL 
expression on NCR-ILC3s in the presence of soluble factors produced by CD4+ T 
cells upon Ag-encounter. At the same time ICOS expression on NCR-ILC3s was 
increased in vitro (Fig. 14 D). It is possible that the level of ICOS expression on NCR-
ILC3s induced by the integration of signals from CD4+ T cells regulates ICOSL 
expression and thereby NCR-ILC3 immune function. However, the precise role for 
ICOS-ICOSL interactions of NCR-ILC3s with CD4+ T cells in vivo remains to be 
explored.  
The data regarding the positive feedback loop from CD4+ T cells to NCR-ILC3s were 
based on in vitro experiments transferring the SN of co-cultures from BMDCs and 
CD4+ T cells with Ag to naïve NCR-ILC3s. It could not be excluded that in addition to 
CD4+ T cells, BMDCs produced soluble factors upon Ag-dependent interaction with 
CD4+ T cells leading to NCR-ILC3 activation. Therefore, the SN of CD4+ T cells, 
which are activated by anti-CD3/anti-CD28 Abs should be used to confirm these 
findings. Secondly, it is possible that NCR-ILC3s secrete cytokines itself in response 
to Ag-dependent interaction with CD4+ T cells, which might further affect NCR-ILC3 
activation in an autocrine manner. Finally, one has to consider that the in vitro 
findings of Ag-dependent NCR-ILC3-T cell crosstalk might not fully reflect the in vivo 
situation.  
 
The disruption of Ag-dependent interaction of NCR-ILC3s and CD4+ T 
cells impairs CD4+ T cell and T-dependent B cell responses in vivo. 
 
By using I-abΔILC3 mice, I studied the role of MHC II-mediated Ag presentation by 
ILC3s in T cell responses in vivo. In contrast to a previous study in which the I-abΔILC3 
mouse strain has been reported to spontaneously develop signs of systemic 
inflammation,132 our I-abΔILC3 mouse colony kept under strict specific pathogen free 
conditions did not show any pathology or abnormal lymphocyte numbers (Fig. 15 A - 
D). In the study mentioned above, I-abΔILC3 mice developed intestinal inflammation at 
12 weeks of age, which could be attenuated by antibiotic treatment demonstrating 
the dependence on intestinal pathogens.132 Thus, the discrepancy between our mice 
and the mice reported by Hepworth et al., might be due to exposure to local intestinal 
pathogens in different animal facilities. This assumption was in line with another 
study, reporting as well the absence of intestinal inflammation in the same mouse 
strain up to the age of 30 weeks.319 In contrast to the finding of Hepworth et al. that T 
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cells in I-abΔILC3 mice preferentially possess an activated memory-like phenotype,132 I 
could show that our I-abΔILC3 mice had normal numbers of CD4+ and CD8+ memory T 
cells and only a slight reduction in the naïve T cell compartment (Fig. 15 D) 
suggesting that these mice were overall comparable to naïve WT mice. Using these 
mice, I could demonstrate that the specific lack of MHC II on ILC3s drastically 
impaired CD4+ T cell responses in the spleen. The proliferation of adoptively 
transferred CD4+ T cells upon immunization was significantly reduced in I-abΔILC3 
mice when compared to WT mice demonstrating the crucial role of MHC II-mediated 
Ag presentation of ILC3s in vivo (Fig. 17 B). This substantial reduction in CD4+ T cell 
proliferation in I-abΔILC3 mice was not expected, as these mice showed normal 
numbers of DCs with high expression of MHC II (Fig. 15 B and E). Moreover, my in 
vitro data demonstrated that BMDCs were more efficient in the induction of CD4+ T 
cell activation than NCR-ILC3s in vitro (Fig. 12 B). Despite this, the in vivo data 
suggested that the ability of NCR-ILC3s to present Ag might be increased in the 
splenic microenvironment. It is possible that the splenic cytokine milieu or the 
positioning of ILC3s within the spleen increases their efficiency in CD4+ T cell 
activation. In line with this, NCR-ILC3s were previously reported to reside at the 
interface between B and T cell zones and it was shown that they were placed in the 
spleen around blood vessels and in LNs around high endothelial venules (HEVs), 
providing the possibility to directly capture Ag or to interact with incoming 
lymphocytes.94, 98, 102 Thus, NCR-ILC3s were located strategically within the lymphoid 
microenvironment to efficiently promote immune responses in vivo. Another 
possibility would be that splenic NCR-ILC3s are able to crosstalk with other APCs 
within the splenic compartment. They might for example provide cytokine- or cell-cell 
contact-dependent signals to DCs thereby enhancing DC immune function. This 
might explain the discrepancy between the data observed in vitro and in vivo. My 
data showed that MHC II-mediated Ag presentation by peripheral ILC3s was crucial 
for the induction of CD4+ T cell activation and proliferation within transient T cell 
responses (2 days). The expected peak of T cell proliferation is around day 8 upon 
immunization.277 Therefore, one should additionally examine the contribution of 
peripheral ILC3s to persisting CD4+ T cell responses (day 8) in comparison to DCs. 
I also investigated the role of peripheral ILC3s in the induction of TD B cell responses 
in vivo. I could show that immunization of I-abΔILC3 mice with a TD Ag (NP-OVA in 
Alum) after adoptive transfer of Ag-specific CD4+ T cells resulted in drastically 
impaired TD B cell responses compared to WT mice. NP-OVA-specific IgG levels 
were significantly reduced in I-abΔILC3 mice (Fig. 19 E and G). The overall decrease in 
NP-OVA-specific Ab isotypes suggested that cognate ILC3-T cell interactions did not 
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significantly affect T helper cell polarization. RORγ-/- mice, completely lacking ILC3s, 
Th17 cells, LNs and PPs,25, 70, 231 showed even more reduced NP-OVA-specific IgG 
levels (Fig. 19 E and G). This might either be due to the absence of LNs, normally 
providing a site for germinal center formation required for isotype class switch, or due 
to the absence of NCR-ILC3s, which were reported to promote the survival of 
memory T cells within the spleen.309 T-independent (TI) Ags, which do not require the 
help of primed T cells, stimulate marginal zone B (MZB) cells to produce IgM and 
IgG3 class Abs.320, 321 In line with increased numbers of MZB cells, RORγ-/- mice 
showed the highest levels of total IgM and IgG3 compared to WT and I-abΔILC3 mice 
measured before immunization (Fig. 19 B and C). In contrast, another study 
suggested that elevated levels of IgM observed in RORγ-/- mice were caused by an 
increase in B1 B cells migrating from the peritoneal cavity to the spleen due to the 
lack of gut-associated lymphoid tissues,127 a fact, which cannot be exclude as I did 
not examine B1 B cell numbers. The role of ILC3s in TI immune responses is not 
fully understood, as splenic ILC3s could also be shown to enhance Ab production of 
MZB cells through GMCSF secretion.127 Further, IgA production in the gut was 
reported to indirectly depend on ILC3s.100, 129 
Collectively, my in vivo data demonstrated that peripheral NCR-ILC3s were able to 
support Ag-specific CD4+ T cell and TD B cell responses. One has to consider that in 
I-abΔILC3 mice MHC II expression was deleted not only on NCR-ILC3s but also on 
ILC3s expressing the natural cytotoxicity receptor NKp46 (NCR+ILC3s). However, 
MHC II was reported to be substantially expressed on NCR-ILC3s when comparing 
MHC II expression on the different ILC3 subsets suggesting that NCR-ILC3s were 
mainly affected by the deficiency of MHC II in the I-abΔILC3 mouse model.132, 319 
 
Small intestinal NCR-ILC3s differ from splenic NCR-ILC3s in regard to 
their phenotype, response to innate stimulation and ability to induce 
CD4+ T cell responses.  
 
ILC3s predominantly accumulate in gut-associated lymphoid tissues, such as the 
lamina propria (LP) of the small and large intestine, ILFs, PPs and mLNs.108, 266 
Having demonstrated that activated peripheral ILC3s expressed both MHC II and co-
stimulatory molecules and were fully capable of inducing T cell responses in vitro and 
in vivo, I intended to examine the role of NCR-ILC3s residing in the LP of the small 
intestine of adult mice in CD4+ T cell responses. Small intestinal NCR-ILC3s could be 
identified based on the expression of classical ILC3 markers (Fig. 21 A). However, 
	   120 
they differed in the expression of the early activation marker CD69. Whereas naïve 
splenic NCR-ILC3s did not express CD69, its expression was high on naïve small 
intestinal NCR-ILC3s (Fig. 21 D - E). It could be excluded that the slightly different 
experimental procedure used to isolate splenic and small intestinal NCR-ILC3s (see 
4.2.5 Cell isolation and culture) was responsible for the expression of CD69 on small 
intestinal NCR-ILC3s (data not shown). A recent study associated the function of 
intestinal ILC3s to an inhibition of CD4+ T cell responses.132 The fact that small 
intestinal NCR-ILC3s were highly positive for CD69 let me ask the question whether 
intestinal CD69+ NCR-ILC3s have a repressive immune function. None of the tested 
mouse strains contained CD69- NCR-ILC3s in the gut. CD69 expression appeared to 
be independent of TLR- and IL-1R signaling as well as the presence of the 
microbiota or IL-23 (Fig. 21 F). Thus, these findings excluded that commensal 
bacteria, microbial products, or IL-1 and IL-23 secreted by intestinal DCs or MΦ at 
steady state or upon microbial stimulation,126, 165, 292, 322 led to activation-induced up-
regulation of CD69. Which other factors, not investigated in this thesis, were 
responsible for CD69 expression on small intestinal NCR-ILC3s remains to be 
explored. Previous reports demonstrated that CD69 regulates lymphocyte egress 
from lymphoid organs.323, 324 Therefore CD69 expression might retain Ag-loaded 
NCR-ILC3s in the lamina propria and prevent T cell priming in other lymphoid organs. 
In addition, CD69 deficiency was previously reported to be associated with increased 
production of pro-inflammatory cytokines by intestinal CD4+ T cells and reduced 
induction of Tregs suggesting an important role for CD69 expression in the regulation 
of mucosal immune responses.325 Furthermore, a recent study demonstrated that a 
fraction of Tregs expressed CD69 at steady state enhancing their expression of 
suppression-associated markers (e.g. CTLA-4) and their suppressive function 
compared to Tregs lacking CD69.326 However, the precise function of CD69 
expression by small intestinal NCR-ILC3s remains to be explored. Preliminary data of 
adoptive transfer experiments showed that NCR-ILC3s were able to regulate their 
CD69 expression dependent on the lymphoid tissue they have colonized suggesting 
as well an organ-dependent regulation of CD69. 
The regulatory role of ILC3s in CD4+ T cell immunity in the intestine was supported 
by the idea that ILC3s limit T cell responses to commensal bacteria in the intestine at 
steady state through Ag presentation in the absence of co-stimulation.132 However, 
the role of small intestinal NCR-ILC3s in CD4+ T cell immunity under inflammatory 
conditions was not known. I could show that small intestinal NCR-ILC3s were fully 
capable to internalize latex beads (Fig. 23 A) and expressed MHC II molecules on 
their surface (Fig. 21 B and Fig. 22 C) suggesting that they were able to present 
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exogenous Ag to CD4+ T cells. However, in contrast to peripheral NCR-ILC3s, I found 
that small intestinal NCR-ILC3s were unable to express co-stimulatory molecules 
after in vitro stimulation with IL-1β (Fig. 22 C). In addition, I could show that in 
contrast to peripheral NCR-ILC3s, small intestinal NCR-ILC3s were far less efficient 
in promoting peptide- or protein-specific CD4+ T cell responses (Fig. 24 A - D). 
Preliminary data suggested that CD4+ and CD4- NCR-ILC3 subsets of either splenic 
or small intestinal NCR-ILC3s did not differ in their ability to induce CD4+ T cell 
activation, as it was shown for FL-derived in vitro generated NCR-ILC3s (Fig. 12 B), 
ruling out that the relatively high ratio of CD4+ NCR-ILC3s in the spleen (Fig. 9 A) 
compared to the small intestine (Fig. 21 A) accounts for the higher efficiency in CD4+ 
T cell activation. Hence, it appeared that while splenic NCR-ILC3s were capable of 
priming T cell responses, mucosal NCR-ILC3s might rather prevent T cell responses 
through the absence of co-stimulation. It remains to be investigated whether small 
intestinal NCR-ILC3s can become efficient APCs when they were ex vivo cultured for 
several days before co-culture with Ag and T cells. Long-term ex vivo culture of small 
intestinal NCR-ILC3s might lead to the loss of their organ-dependent phenotype, 
activation state and function. It has to be noted that the exposure of small intestinal 
NCR-ILC3s to IL-1β indeed induced further activation of these cells. For example, 
small intestinal NCR-ILC3s produced high levels of IL-22, a cytokine involved in 
intestinal homeostasis, in response to IL-1β (Fig. 22 D). Altogether, my findings 
supported the idea that IL-1β is a strong activator of ILC3s, and that the outcome of 
ILC3 effector functions depends on additional tissue-specific cells and cytokines. 
Hence, the microenvironments in which ILC3s reside might profoundly alter their 
function and responsiveness to stimulatory factors, as suggested by the different 
expression signature profiles displayed by ILC3s isolated from various tissues.327, 328  
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7 Conclusion  
 
 
Innate lymphoid cells are crucial for tissue formation and remodeling, protective 
innate immunity and immune regulation. The data of my PhD thesis work shown here 
demonstrate that mouse ILC3s are able to directly sense and recognize pathogen-
derived products and pro-inflammatory cytokines. Naïve ILC3s can be generated 
from fetal liver progenitors. Upon challenge with TLR ligands or cytokines such as IL-
1β, they show an activated phenotype. Moreover, in response to innate challenge 
ILC3s produce different cytokines dependent on the nature of the stimuli. My findings 
further show that innate stimulation induces ILC3s to acquire an APC-like phenotype. 
Thereby, I could demonstrate that ILC3s meaningfully regulate CD4+ T cell 
responses in vitro and in vivo. ILC3s are able to take up, process and present Ag to 
CD4+ T cells. Results of several in vivo models reveal that ILC3s are able to 
contribute to T cell and TD B cell responses ascribing to them a novel function in 
adaptive immunity. Furthermore, I could show that during Ag-dependent interaction 
of ILC3s and CD4+ T cells a positive feedback loop exists inducing further activation 
of ILC3s. Finally, my data point out tissue-specific immune functions of ILC3s, 
namely peripheral ILC3s differ from small intestinal ILC3s with respect of their 
phenotype, response to innate stimulation and induction of CD4+ T cell immunity. 
Intestinal ILC3s release cytokines in response to innate activation but lack co-
stimulatory molecules and are less efficient in T cell stimulation. 
Altogether, my findings show that ILC3s are capable to contribute to innate and 
adaptive immunity by the production of cytokines and the ability to present Ag and to 
directly interact with CD4+ T cells. Not only the response of ILC3s to innate challenge 
seems to be fine-tuned dependent on the stimuli, but also the tissue in which ILC3s 
reside appears to alter their immune function.  
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9 Appendix 
 
9.1 Abbreviations and symbols 
 
 Abbreviations 9.1.1
 
Ab  antibody 
Ag  antigen 
AhR  aryl hydrocarbon receptor 
AHR  airway hyper-reactivity 
AKP  alkaline phosphatase 
Alum   aluminium potassium 
APC   antigen presenting cell 
APC  allophycocyanin 
APC Cy7  allophycocyanin cyanine 7 
BCR  B cell receptor 
BFA  Brefeldin A 
BM  bone marrow 
BMDCs bone marrow derived dendritic cells 
BMMΦ  bone marrow derived macrophages 
bp  base pair 
BSA   bovine serum albumin  
BV  brilliant violet 
CCL  chemokine (C-C motif) ligand 
CCR  chemokine (C-C motif) receptor 
CD  cluster of differentiation 
CFSE  carboxyfluorescein succinimidyl ester 
CHILP  common helper innate lymphoid progenitor 
CIITA  class II transactivator 
CLIP  class II associated invariant chain peptide 
CLP  common lymphoid progenitor 
CP  cryptopatch 
CpG  cytosine phosphatidyl guanine 
CXCL  chemokine (C-X-C motif) ligand 
CXCR  chemokine (C-X-C motif) receptor 
CytD  cytochalasin D 
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DAMP  danger associated molecular pattern 
DC  dendritic cell 
DMEM  Dulbecco`s modified eagle minimal essential medium 
DNA  deoxyribonucleic acid 
dNPP  dinitrophenyl phosphate 
dpc  days post coitum 
DSS  dextran sodium sulfate  
E  embryonic day 
EDTA  ethylenediamine-tetraacetic acid (disodium salt dehydrate) 
e.g.  [exempli gratia], for example 
EGFP  enhanced green fluorescent protein 
ELISA  enzyme linked immunosorbent assay 
ER  endoplasmic reticulum 
ERK  extracellular signal regulated kinase 
et al.  [et alii], and others 
EYFP  enhanced yellow fluorescent protein 
FACS  fluorescence-activated cell sorting 
FALC  fat associated lymphoid cluster 
FcγR  Fc gamma receptor chain 
FCS  fetal calf serum 
FITC  fluorescein isothiocyanate  
FL  fetal liver 
Flag  flagellin 
Flt3  fms-like tyrosine kinase 3 
FLT3L  fms-like tyrosine kinase 3 ligand 
fm  fate map 
FolB  follicular B cell 
FoxP  forkhead box protein P3 
f.p.  foot pad 
FRC  fibroblastic reticular cell 
Fwd  forward 
GALT  gut-associcated lymphoid tissue 
GATA3 gata binding protein 3 
GC  germinal center 
γc  common cytokine gamma chain 
GFP  green fluorescent protein 
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GMCSF granulocyte macrophage colony stimulating factor 
HAT  hypoxanthine-aminopterin-thymidine 
HEV  high endothelial venule 
IBD  inflammatory bowel disease 
IC  intracellular 
ICAM-1 intracellular adhesion molecule 1 
ICOS  inducible T cell co-stimulator 
ICOSL  inducible T cell co-stimulator ligand 
Id2  inhibitor of DNA binding 2 
IFNγ  interferon gamma 
IFNβ  interferon beta  
Ig  immunoglobulin 
Ii  invariant chain 
iILC2  immature group 2 innate lymphoid cell 
IL  interleukin 
IL-1R1  interleukin 1 receptor type 1 
IL-7R  interleukin 7 receptor 
IL-23R  interleukin 23 receptor 
ILC  innate lymphoid cell 
ILF  isolated lymphoid follicle 
IMDM  Iscove`s modified Dulbecco`s medium 
Imiqui  Imiquimod 
iNOS  inducible nitric oxide synthase 
i.p.   intraperitoneal 
IP-10  IFNγ-induced protein 10 
IRF3  interferon regulatory transcription factor 3 
i.v.  intravenous 
JNK  c-Jun N-terminal kinase 
LCMV  lymphocytic choriomeningitis virus 
lin  lineage 
LN  lymph node 
LP  lamina propria 
LPS  lipopolysaccharide 
LTαβ  lymphotoxin αβ 
LTβR  lymphotoxin β receptor 
LTi   lymphoid tissue inducer  
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LTin  lymphoid tissue initiating  
mAb  monoclonal antibody 
MACS® magnetic associated cell sorting 
MadCam-1 mucosal addressin cell adhesion molecule 1 
MAPK  mitogen associated protein kinase 
MFI  mean fluorescent intensity 
MHC  major histocompatibility complex 
MHC I  major histocompatibility complex class I 
MHC II  major histocompatibility complex class II 
MIIC  major histocompatibility complex class II compartment 
MIP-1α macrophage inflammatory protein 1 alpha  
mLN  mesenteric lymph node 
MRC  marginal reticular cell 
Myd88  myeloid differentiation primary response gene 88 
MZ  marginal zone 
MZB  marginal zone B cell 
MΦ  macrophage 
NALT  nasal-associated lymphoid tissue 
NCR  natural cytotoxicity receptor 
NEAA  non-essential amino acid 
NFAT  nuclear factor of activated T cells 
NFκB  nuclear factor-kappa B 
NIK  nuclear factor-kappa B inducing kinase 
NK  natural killer 
NODR  nucleotide binding oligomerization domain-like receptor 
NP  4-hydroxy-3-nitrophenyl-acetyl 
OD  optical density 
OVA  Ovalbumin 
o/n  over night 
PAMP  pathogen associated molecular pattern 
PBS   phosphate buffer saline 
PCR   polymerase chain reaction 
PE  phycoerythrin 
PECy7  phycoerythrin cyanine 7 
PEG  polyethylene glycol 
PerCP  peridinin chlorophyll 
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pH  [pondus hydrogenii], potential hydrogen 
PI  propidium iodide 
Poly I:C polyinosinic:polycytidylic acid 
PP  Peyer`s patch 
Prox1  prospero homeobox gene 1 
PRR  pattern recognition receptor 
P3C  Pam3Cys 
RAG  recombination activating genes 
RegIIIβ regenerating islet-derived protein III beta  
RegIIIγ  regenerating islet-derived protein III gamma   
Rev  reverse 
RNA  ribonucleic acid 
RORα  retinoic acid related orphan receptor alpha  
RORγt  retinoic acid related orphan receptor gamma  
RT  room temperature 
RT qPCR real time quantitative PCR 
SCF  stem cell factor 
SD  standard deviation 
SF  serum free 
sg  staggerer 
SI  small intestine 
SN  supernatant 
SPF  specific pathogen free 
TCF-1  T cell factor 1 
TCM  central memory T cell 
TCR  T cell receptor 
TD  thymus dependent 
TEM  effector memory T cell 
Tfh  T follicular helper 
Tg  transgenic 
TGF  tumor growth factor 
Th  T helper 
Th1  T helper type 1 
Th2  T helper type 2 
Th17  T helper type 17 
TI  thymus independent 
	   153 
TIR  Toll/Interleukin-1 receptor homology 
TIRAP  TIR-domain containing adaptor protein 
TLR  Toll-like receptor 
Tnaïve   naïve T cell 
TNF  tumor necrosis factor  
TRAF  TNF receptor associated factor 
TRAIL  TNF related apoptosis inducing ligand 
TRAM  TRIF-related adaptor molecule 
TRANCE TNF related activation induced cytokine  
TRANCER TNF related activation induced cytokine receptor 
Treg  regulatory T cell 
TRIF  TIR-domain containing adaptor inducing interferon beta  
TRUC  Tbx21-/- Rag2-/- ulcerative colitis mouse model 
TSLP  thymic stromal lymphopoietin 
UC  ulcerative colitis 
VCAM-1 vascular cell adhesion molecule 1 
WT  wild type 
w/o  without 
Zym  zymosan 
 
 Symbols 9.1.2
 
%  percent 
°C  degree Celsius 
#  number 
cm  centimeter 
g  gram 
h  hour 
kDA  kilo dalton 
l  liter 
m  meter 
M  molar 
mg  milligram 
min  minutes 
ml  milliliter 
mM  millimolar 
	   154 
ng  nanogram 
nm  nanometer 
pg  picogram 
rpm  rounds per minute 
sec  seconds 
U  Unit 
µg  microgram 
µl  microliter 
µm  micrometer 
µM  micromolar 
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Group 3 innate lymphoid cells (ILC3s) have emerged as important
cellular players in tissue repair and innate immunity. Whether
these cells meaningfully regulate adaptive immune responses
upon activation has yet to be explored. Here we show that
upon IL-1β stimulation, peripheral ILC3s become activated, secrete
cytokines, up-regulate surface MHC class II molecules, and express
costimulatory molecules. ILC3s can take up latex beads, process
protein antigen, and consequently prime CD4+ T-cell responses
in vitro. The cognate interaction of ILC3s and CD4+ T cells leads
to T-cell proliferation both in vitro and in vivo, whereas its disrup-
tion impairs specific T-cell and T-dependent B-cell responses in
vivo. In addition, the ILC3–CD4+ T-cell interaction is bidirectional
and leads to the activation of ILC3s. Taken together, our data re-
veal a novel activation-dependent function of peripheral ILC3s in
eliciting cognate CD4+ T-cell immune responses.
T-cell activation | antigen presentation
Innate lymphoid cells (ILCs) are a group of lymphocytes thatplay a critical role in immediate immune host defense as well
as mucosal and lymphoid tissue homeostasis. Although they lack
somatically rearranged antigen (Ag) receptors, they exhibit
a transcription factor and cytokine profile similar to T helper
(Th) cells. Therefore, ILCs are classified into three major fam-
ilies (1). Reminiscent of Th1 cells, ILC1s are characterized by
Interferon (IFN)γ production and developmental regulation by
T-bet. ILC2s secrete interleukin (IL)-5, IL-9, and IL-13 and,
analogous to Th2 cells, depend on Gata3. ILC3s produce IL-22
and IL-17A and together with Th17 cells express the retinoic acid
receptor-related orphan receptor RORγt (2, 3). ILC3s can be frac-
tioned into NKp46+ and NKp46− subsets including lymphoid tissue
inducer (LTi) cells. Here, lin−NKp46−CD4+/−RORγt+ ILCs are re-
ferred to as natural cytotoxicity receptor (NCR)−ILC3s. ILCs express
Toll-like receptors (TLRs) (4) and IL-1R, indicating that they can
directly sensemicrobial products and inflammatory signals (5–7).The
ability to rapidly release cytokines upon microbial challenge fostered
the idea that ILCs may bias the outcome of T-cell responses. In ad-
dition, both ILC2 and ILC3s were recently shown tomodulate CD4+
T-cell responses throughAg-peptidepresentationbyMHCclass II (8,
9). In line with this, it was proposed a decade ago that ILC3s interact
withTcells in secondary lymphoidorgansand therebypromoteCD4+
T-cell memory responses (10, 11). Whether peripheral ILC3s can
mature into Ag-presenting cells (APCs) providing costimulation for
T-cell–mediated immunity has never been explored. In the present
study, we show that inmicewhereMHCclass II is specifically deleted
in ILC3s, Ag-specific T-cell and T-dependent (TD) B-cell responses
are impaired, demonstrating that ILC3spresentAg toCD4+Tcells in
vivo. IL-1β strongly activates fetal liver (FL)-derived and splenic
NCR−ILC3s and induces both the expression of costimulatory
molecules and the up-regulation of MHC class II molecules,
thereby enhancing their T-cell priming potential. Finally, we show
that in thepresenceofAg, the cognate interactionbetweenCD4+T
cells and NCR−ILC3s leads to the activation of the latter,
suggesting an unexpected crosstalk between these two cell types.
Altogether, we show that peripheral ILC3s can mature upon
activation into bona fide APCs shaping T-cell–mediated immune
responses.
Results
ILC3s Elicit Ag-Specific T-Cell Proliferation and TD B-Cell Responses in
Vivo. To investigate whether ILC3s can initiate CD4+ T-cell
responses in vivo, we generated mice with a deletion of Iab ex-
clusively in ILC3s by crossing mice expressing Cre recombinase
under the control of the RORc promoter [RORc(γt)-Cretg] (12)
to mice with a floxed H2-Ab1 allele (I-abneo) (13). Mice homo-
zygous for the floxed H2-Ab1 allele and carrying one copy of the
Cre transgene, here referred to as I-abΔILC3 mice, were healthy,
did not show signs of spontaneous inflammation, and had
a normal distribution of lymphocytes, macrophages (MΦ), and
dendritic cells (DCs) (Fig. 1A). Numbers of ILC3s were also
similar in WT and I-abΔILC3 mice (Fig. 1A). MHC class II ex-
pression was normal on splenic B cells, DCs, and MΦ, whereas
NCR−ILC3s completely lacked MHC class II (Fig. 1B). To ex-
amine Ag-specific CD4+ T-cell proliferation in vivo, 3 × 106
carboxyfluorescein succinimidyl ester (CFSE)-labeled CD4+ T
cells from OT-II (H-2b) T-cell receptor transgenic mice (OT-IItg)
were adoptively transferred into WT, I-abΔILC3, or I-ab−/− mice.
Following immunization with ovalbumin (OVA) peptide323–339
and OVA protein plus CpG, labeled OT-IItg T cells proliferated
inWT, but not in I-ab−/−mice (Fig. 1C). In I-abΔILC3 mice, OT-IItg
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T-cell proliferation was significantly reduced, demonstrating
that ILC3s were able to present Ag and to meaningfully alter
OVA-specific T-cell responses in vivo. To study the role of ILC3s
in TD B-cell responses, we immunized WT, I-abΔILC3, and
RORγ−/− mice intraperitoneally (i.p.) with a single dose of Alum-
precipitated nitrophenylated-OVA (100 μg) and adoptively
transferred 2 × 106 OT-IItg CD4+ T cells plus CpG. The loss of
MHC class II on ILC3s (I-abΔILC3) resulted in a significant re-
duction of 4-hydroxy-3-nitrophenyl-acetyl (NP)-OVA–specific
IgG 14 d after immunization (Fig. 1D). Additionally, a more
detailed analysis of IgG subtypes revealed that specific IgG1,
IgG2a, IgG2b, and IgG3 levels were significantly reduced (Fig. 1
E–H). In RORγ−/− mice, where ILC3s, Th17 cells, lymph nodes,
and Peyer’s patches were completely absent, NP-OVA–specific
IgG titers were even more reduced. Collectively, these data un-
ambiguously show that Ag presentation by ILC3s contributes to
T-cell priming in vivo and that CD4+ T-cell proliferation and TD
B-cell responses were impaired when Ag presentation was
abolished in ILC3s.
NCR−ILC3s Can Internalize Latex Beads. Based on the in vivo finding
that the lack of MHC class II molecules by ILC3s impaired
T-cell–mediated immune responses, we tested the capacity of
NCR−ILC3s generated from α4β7+ FL progenitor cells in vitro
(14) or ex vivo isolated from the spleen of adult mice to take up
red fluorescent latex beads. We and others have previously
shown that FL-derived and adult ILC3s share phenotypic and
functional properties such as lymphotoxin β-dependent induction
of lymphoid tissue formation (15, 16). Both in vitro-generated
and ex vivo-isolated NCR−ILC3s were capable of internalizing
red fluorescent latex beads, although with slower kinetics than
bone marrow (BM)-derived MΦ (BMMΦ) (Fig. 2 A and B and
Fig. S1). Bead uptake was severely inhibited at 4 °C or in the
presence of 0.5 μM Cytochalasin D (CytD), an inhibitor of actin
polymerization, showing the specificity of internalization (Fig.
2C). In vitro-generated NCR−ILC3s could be subdivided into
CD4+ and CD4−NCR−ILC3 subsets (Fig. S2 A and B). Both
subsets had a CD69− naïve phenotype and expressed compa-
rable levels of RORγt, LTαβ, common gamma chain (γc),
CD117, integrins, and chemokine receptors (Fig. S2C). CD4+
NCR−ILC3s were slightly more efficient in taking up Ag than
their CD4− counterpart (Fig. S2D). Thus, NCR−ILC3s can in-
ternalize and process exogenous Ags.
Upon Proinflammatory Stimulation NCR−ILC3s Become Activated and
Secrete Cytokines. How DCs undergo maturation and activation
upon exposure to signals associated with infection and inflammation
is well documented (17). We therefore tested proinflammatory
cytokines and TLR ligands for their ability to activate NCR−ILC3s.
IL-1β, Poly I:C, and CpG up-regulated the expression of surface
CD69 on NCR−ILC3 (Fig. 3A). Similar results were obtained from
ex vivo-isolated splenic NCR−ILC3s of WT mice 6 h after i.p. in-
jection with CpG (Fig. S3). Upon stimulation with IL-1β, in vitro-
generated NCR−ILC3s produced high levels of IL-22, exceeding
those induced upon IL-23 stimulation (Fig. 3B). In vitro stimulation
with TLR ligands revealed that Poly I:C could induce IL-22 pro-
duction by NCR−ILC3s (Fig. 3C). Thus, these data show that
ligands for TLR 3 and 9 have the ability to directly activate
NCR−ILC3s and that IL-1β is a remarkably strong inducer of IL-22
secretion. In addition, IL-1β–exposed NCR−ILC3s secreted IL-2,
IL-6, macrophage inflammatory protein 1 (MIP-1)α, IFNγ, and
tumor necrosis factor (TNF)α, all known for their capacity to pro-
mote T-cell responses (Fig. 3D). IL-1β also induced the secretion of
IFN-induced protein of 10 kDa (IP-10), a chemoattractant for
mononuclear cells and CXCR3+ effector T cells (18). Collectively,
these data demonstrate that IL-1β and TLR ligands can activate
NCR−ILC3s, remarkably altering the repertoire of cytokines
they produce.
Fig. 1. ILC3s elicit Ag-specific T-cell proliferation and TD B-cell responses in vivo.
(A) Absolute numbers of T cells (CD3+), B cells (CD19+), DCs (CD11c+), MΦ (CD11b+
F4/80+), natural killer (NK) cells (NK1.1+NKp46+), and NCR−ILC3s (lin−RORγt+
CD117+NCR−) in the spleenofWTand I-abΔILC3mice.Data are shownasmean±SD
(n = 9; three independent experiments). (B) Representative histograms of MHC
class II expression on splenic B cells, DCs, MΦ, and CD4+NCR−ILC3s of WT and
I-abΔILC3 mice (three independent experiments). (C) Sort-purified CFSE-labeled
OT-IItg CD4+ T cells were injected i.v. intoWT (filled circle), I-abΔILC3 (filled square),
and I-ab−/− (filled triangle) mice immunized with OVA peptide, OVA protein, and
CpG. Absolute numbers of proliferating OT-IItg CD4+ T cells recovered from the
spleen 2 d later (mean values ±SD; four independent experiments; n = 6–7; *P ≤
0.05; **P ≤ 0.01). (D–H)WT, I-abΔILC3, and RORγ−/−mice were i.p. immunized with
100 μg alum-precipitated NP-OVA after i.v. injection of OT-IItg CD4+ T cells plus
CpG. NP-OVA–specific IgG (D), IgG1 (E), IgG2a (F), IgG2b (G), and IgG3 (H) levels
14 d after immunization. Data are presented asmean values± SD (n= 9–10) from
three independent experiments (n.s., not significant; *P≤ 0.05; **P≤ 0.01; ***P≤
0.001; ****P ≤ 0.0001).
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IL-1β Induces the Expression of MHC Class II and Costimulatory
Molecules on Peripheral NCR−ILC3s. We further asked whether,
analogous to DCs, activated NCR−ILC3s express costimulatory
molecules and up-regulate MHC class II molecules. Both
in vitro-generated and ex vivo-isolated CD4+NCR−ILC3s
had a naïve phenotype shown by the absence of CD69 and
costimulatory molecules (Fig. 4 A and B). Upon stimulation with
IL-1β for 48 h, both sort-purified in vitro-generated CD4+
NCR−ILC3s and ex vivo-isolated CD4+NCR−ILC3s expressed
the costimulatory molecules CD80 and CD86 and up-regulated
the expression of CD40, CD69, and MHC class II (Fig. 4 A and
B). Hence, upon IL-1β stimulation, NCR−ILC3s acquire an
APC-like phenotype, reminiscent of activated DCs. It has been
reported that mucosa-associated ILC3s were unable to express
costimulatory molecules (9). Whether these cells could respond
to inflammatory stimulation has never been investigated.
Therefore, we stimulated ex vivo-isolated small intestinal lamina
propria (LP)-derived NCR−ILC3s with IL-1β for 48 h. In-
terestingly, although IL-1β stimulation resulted in blast forma-
tion, even with high concentrations of IL-1β, we were unable to
detect up-regulation of MHC class II or expression of CD40 and
CD86 (Fig. S4 A and B). These data unambiguously show that
peripheral but not LP NCR−ILC3s express costimulatory mole-
cules upon innate activation.
Activated NCR−ILC3s Can Induce Ag-Specific CD4+ T-Cell Activation
and Proliferation. We next examined whether peripheral
NCR−ILC3s could trigger naïve T-cell priming in vitro.
NCR−ILC3s (H-2b) were in vitro stimulated with IL-1β and in-
cubated with CFSE-labeled OT-IItg CD4+ T cells in the presence
of OVA peptide323–339 or OVA protein. Ex vivo-isolated and in
vitro-generated CD4+ and CD4− NCR−ILC3s were able to ac-
tivate the majority of CD4+ T cells in the presence of OVA
peptide monitored by CD69 expression (Fig. 5A). In vitro-gen-
erated CD4+ and ex vivo-isolated NCR−ILC3s were able to in-
duce several rounds of OVA-specific CD4+ T-cell proliferation
when pulsed with OVA peptide or, to a lesser extent, with OVA
protein. CD4−NCR−ILC3s were considerably less efficient in
inducing protein Ag-specific CD4+ T-cell responses (Fig. 5A). To
further examine the effect of activation of NCR−ILC3s on the
capacity to elicit T-cell responses, we stimulated ex vivo-isolated
splenic NCR−ILC3s with IL-1β or left them untreated and
cocultured them with OT-IItg CD4+ T cells and OVA protein
(Fig. 5 B–D). A total of 30.2% of the T cells in culture with
untreated NCR−ILC3s and OVA protein expressed CD69, and
only 4.3% of the T cells proliferated (Fig. 5B). IL-1β–activated
NCR−ILC3s increased the percentage of both CD69+ and pro-
liferating T cells (Fig. 5 B–D). Compared with splenic
NCR−ILC3s, LP NCR−ILC3s were three times less efficient to
induce cognate T-cell activation in vitro (Fig. S5 A and B). In-
terestingly, we noted that the CD69 surface expression level of
NCR−ILC3s increased approximately sevenfold in the presence
of OT-IItg CD4+ T cells and OVA protein, compared with
cocultures without Ag and without previous IL-1β stimulation.
This phenomenon was not further increased by previously acti-
vating NCR−ILC3s with IL-1β (Fig. S6A). It is important to note
that CD69 expression on NCR−ILC3s peaked early after acti-
vation and decreased in cocultures, unless T cells and Ag were
added. Ag alone was not able to sustain CD69 expression (Fig.
S6B). Together, these results show that IL-1β increased the ca-
pacity of NCR−ILC3s to induce CD4+ T-cell activation and that
the cognate ILC3–CD4+ T-cell interaction led to the activation
of NCR−ILC3s.
Discussion
We show here that upon IL-1β stimulation NCR−ILC3s ex-
pressed MHC class II and costimulatory molecules and became
bona fide APCs as they were able to promote OVA-specific
CD4+ T-cell proliferation in mice. In addition, activated
NCR−ILC3s expressed an unexpected repertoire of cytokines
known to alter T-cell responses. Ag-specific T-cell proliferation
and IgG-mediated humoral immunity were impaired in animals
in which Ag presentation was abolished exclusively in ILC3s.
Finally, in the presence of Ag, the T-cell priming led to an ex-
tended activation of ILC3s. These novel data suggest that upon
Fig. 2. Naïve NCR−ILC3s can internalize latex beads. (A) Representative
immunofluorescence image of red fluorescent latex bead uptake by sort-
purified in vitro-generated NCR−ILC3s. (Scale bar, 5 μm.) (B) Bead in-
ternalization by NCR−ILC3s and BMMΦ. Percentage of bead+ cells 2 and 24 h
after addition of beads (mean values ± SD; n.s., not significant; **P ≤ 0.01).
(C) Representative plots of NCR−ILC3s cultured with beads for 6 h at either
37 °C or 4 °C, or at 37 °C in the presence of 0.5 μM CytD. Data are repre-
sentative of at least three independent experiments (n = 3–5).
Fig. 3. Cytokine secretion of activated NCR−ILC3s. (A) Representative his-
tograms of CD69 expression on in vitro-generated NCR−ILC3s after 48 h
stimulation with IL-1β, Poly I:C, CpG, or in medium alone (four independent
experiments). IL-22 secretion by in vitro-generated NCR−ILC3s upon 48 h
exposure to IL-1β, IL-23 (B), TLR ligands (C), or medium alone (mean values ±
SD, n = 6–7, three independent experiments; *P ≤ 0.05; **P ≤ 0.01). (D)
Cytokine production by in vitro-generated NCR−ILC3s after 48 h culture with
IL-1β or medium alone. Results are shown as mean values ± SD.
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inflammation the cognate interaction of NCR−ILC3s and CD4+
T cells contributes to adaptive immunity.
Our in vivo data demonstrate that peripheral NCR−ILC3s
process protein Ags and stimulate Ag-specific CD4+ T-cell
responses. Whether the cognate interaction between NCR−ILC3s
and CD4+ T cell leads directly to the priming of T cells or
whether this interaction rather polarizes or enhances the T-cell
response has yet to be established. In either case, the cytokines
that are secreted by NCR−ILC3s upon activation are likely to
decisively impact the outcome of T-cell responses. Because
NCR−ILC3s reside at the interface between B- and T-cell zones
(10, 19), they are located strategically within the lymphoid mi-
croenvironment to efficiently promote immune responses in vivo.
Considering their 10 times lower numbers compared with DCs in
the spleen of WT mice, our in vivo data emphasize the potential
of ILC3s to induce CD4+ T-cell proliferation. The immunization
of I-abΔILC3 mice indeed showed that the specific lack of MHC
class II on NCR−ILC3s drastically impaired T and TD B-cell
responses in the spleen. The overall decrease in Ag-specific Ab
isotypes suggests that cognate ILC3–T cell interactions did not
significantly affect Th cell polarization. In vitro, NCR−ILC3s
were less potent than BM-derived DCs in priming naïve T cells,
probably because DCs expressed higher levels of costimulation
and MHC class II molecules. Despite this, our data show that
ILC3s are crucial for mounting adaptive immune responses in
vivo, suggesting that their ability to present Ag is increased in the
splenic microenvironment. This could be either due to the splenic
cytokine milieu or the crosstalk between ILC3s and other im-
mune cells. In line with the finding that CD4+NCR−ILC3s are
more differentiated than their CD4− counterpart (20), CD4+
NCR−ILC3s had a greater potential of inducing Ag protein-
specific T-cell proliferation.
The I-abΔILC3 mouse strain generated by others has been
reported to spontaneously develop signs of systemic inflammation
(9). In our I-abΔILC3 mouse colony that we kept under strict
specific pathogen-free conditions, we did not observe any pa-
thology or abnormal lymphocyte numbers. The discrepancy
between our mice and the mice reported by Hepworth et al.
might be due to microbial exposure in different animal facilities.
Fig. 4. IL-1β induces the expression of MHC class II and costimulatory mol-
ecules on peripheral NCR−ILC3s. Expression of CD69, CD40, CD80, CD86, and
MHC class II on sort-purified in vitro-generated CD4+NCR−ILC3s (A) and ex
vivo-isolated splenic CD4+NCR−ILC3s (B) cultured for 48 h with IL-1β or me-
dium alone. Numbers in contour plots show the percentage of cells in each
quadrant. Data are representative of three independent experiments.
Fig. 5. NCR−ILC3s can induce Ag-specific CD4+ T-cell activation and pro-
liferation. (A) Naïve CFSE-labeled OT-IItg CD4+ T cells were cultured with
either BMDCs, IL-1β–activated ex vivo-isolated splenic NCR−ILC3s, or in vitro-
generated sorted CD4+ or CD4−NCR− ILC3s in the presence of OVA peptide,
OVA protein, or medium alone (without Ag). Representative plots of CD69
and CFSE expression by CD4+ T cells 72 h later. Bold black numbers, per-
centage of proliferating T cells; bold red numbers, percentage of total CD69+
T cells. (B) Naïve CFSE-labeled OT-IItg CD4+ T cells were cultured with non- or
IL-1β–activated splenic NCR−ILC3s in the presence of OVA peptide, OVA
protein, or medium alone (without Ag) for 72 h. (C) Percentage of CD69+
CD4+ T cells upon coculture with non- or IL-1β–activated splenic NCR−ILC3s in
the presence or absence of Ag. Data are shown as mean values ± SD (n = 3–7;
*P ≤ 0.05; ***P ≤ 0.001). (D) Fold increase of percentage of CD69+ CD4+ T cells
upon coculture with non- or IL-1β–activated splenic NCR−ILC3s in the presence
of OVA protein relative to coculture of IL-1β–activated NCR−ILC3s and T cells
in the absence of Ag. Data are shown as mean values ± SD (n = 3–7; *P ≤
0.05). Data are representative of at least three independent experiments.
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Whereas ILC3s appear to limit T-cell responses to commensal
bacteria in the intestine through Ag presentation in the absence
of costimulation (9), we show here that splenic NCR−ILC3s have
the ability to promote T- and B-cell responses in the periphery.
Interestingly, we were unable to detect costimulatory molecules
on LP NCR−ILC3s ex vivo or after in vitro stimulation with IL-1β.
Hence, it appears that the microenvironments in which ILC3s
reside profoundly alter their function, as suggested by the dif-
ferent expression signature profiles displayed by ILC3s isolated
from various tissues (21, 22). We observed that ex vivo-isolated
splenic ILC3s from naïve mice lacked costimulatory molecules
but a substantial fraction expressed MHC class II. Activated
NCR−ILC3s, however, expressed both MHC class II and cos-
timulatory molecules and were fully capable of inducing T-cell
responses in vitro and in vivo. In the mucosa, the microbiota-
driven release of IL-1β promotes the production of granulocyte
macrophage colony-stimulating factor (GM-CSF) by ILC3s. This
triggers the release of retinoic acid and IL-10 by mucosal DCs
and MΦ, leading to the expansion of regulatory T cells (23).
These data together with our findings support the idea that IL-1β
is a strong activator of ILC3s and that the outcome of ILC3 ef-
fector functions depends on additional tissue-specific cells and
regulatory cytokines. Hence, splenic ILC3s are fully capable of
priming T-cell responses, whereas mucosal ILC3s may prevent
T-cell responses through absence of costimulation and induction
of tolerogenic cytokine responses by other cells. Because of their
remarkable ability to secrete cytokines, ILCs are emerging
as important cellular players, actively modulating immune re-
sponses. For instance, human splenic ILC3s enhance the survival
of marginal zone B cells through the release of B-cell activating
factor (BAFF) and stimulate perifollicular neutrophils through
GM-CSF (24). In humans, IL-1R signaling was shown to induce
NCR−ILC3s to produce IL-17, IL-22, and IFNγ (25, 26). We
show here that IL-1β increased the secretion of IL-2, IL-6, MIP-
1α, IP-10, IFNγ, TNFα, and GM-CSF in vitro. Although our in
vitro data suggest that IL-1β is likely to play an important role in
ILC activation and immunity, the actual molecular and cellular
events leading to NCR−ILC3 activation in vivo are still un-
known. Ag-dependent cognate interaction between ILC3s and
T cells also led to NCR−ILC3 activation reflected by the up-
regulation of CD69 (Fig. S6A). This result may explain why naïve
NCR−ILC3 could trigger T-cell priming in the absence of pre-
vious activation by IL-1β (Fig. 5B). A similar TCR-dependent
crosstalk occurs during ILC2–T cell interactions (8), illustrating
that T cells or T-cell–derived cytokines may reciprocally act on
ILC responses. Collectively, our data reveal an important func-
tion for group 3 ILCs in promoting peripheral T-cell–mediated
responses and improve our understanding of how these cells may
link innate and adaptive immune responses.
Materials and Methods
Mice. C57BL/6 were purchased from Janvier (Saint Berthevin). RORγ−/− (3)
and MHCIIΔ/Δ (here referred to as I-ab−/−) (27) were described elsewhere.
OT-IItg mice were kindly provided by A. Rolink, Rag2−/−mice by G. Hollaender
(UniversityofBasel, Basel, and JesusCollege,Oxford), I-abneo (13)micebyE. Palmer
(University of Basel, Basel), and RORc(γt)-Cretg mice (12) by A. Diefenbach
(University of Freiburg, Freiburg im Breisgau, Germany). All mice were bred
and maintained under specific pathogen-free conditions. I-abΔILC3 mice
were generated by crossing I-abneo mice, which contain a floxed H2-Ab1
allele, with RORc(γt)-Cretg mice. F1 generations were backcrossed to I-abneo
mice. The animal experiments received the approval of the Cantonal Veterinary
Office of the city of Basel.
Antibodies. FITC, Phycoerythrin (PE), PerCP–eFluor 710, PE–Cy7, Allophy-
cocyanin (APC), APC–Cy7, BV421 or biotin-conjugated anti-CD3 (17A2),
anti-CD4 (RM4-5), anti-CD11b (M1/70), anti-CD11c (117310, N418), anti-
CD19 (6D5), anti-CD29 (HMb1-1), anti-CD40 (1C10), anti-CD45R (RA3-6B2,
B220), anti-CD69 (H1.2F3), anti-CD90.2 (30-H12), anti-CD117 (2B8), anti-
CD196 (29-2L17), anti-CD197 (4B12), anti–Gr-1 (RB6-8C5, Ly-6G), anti-TCRβ
(H57-597), anti-TCRγδ (UC7-13D5), anti-MHC II (M5/114.15.2), anti-α4β7
(DATK32), and anti-NKp46 (29A1.4) antibodies (Abs) were purchased from
BioLegend; anti-CD54 (3E2), anti-CD132 (TUGm2, γc chain), anti-CD184
(2B11, CXCR4), anti-CD185 (2G8, CXCR5), and anti-MHC II (25-9-17) Abs from
BD Bioscience; and anti-CD3 (145-2C11), anti-CD8α (53-6.7), anti-CD11c
(N418), anti-CD80 (16-10A1), anti-CD86 (GL1), anti-F4/80 (BM8), anti-NK1.1
(PK136), NKp46 (29A1.4), and anti-RORγt (AFKJS-9, B2D) Abs from eBioscience.
As secondary reagent, fluorochrome-conjugated streptavidin (BioLegend)
was used.
Flow Cytometry and Cell Sorting. Flow cytometry stainings were performed
using standard protocols (28). Intracellular RORγt staining was performed
using a fixation/permeabilization kit (FoxP3 staining buffer kit, eBioscience).
Dead cells were identified using fixable Aqua Live/Dead cell staining kit
(Molecular Probes, Life Technologies) or propidium iodide solution (Sigma-
Aldrich). Lymphotoxin staining was performed as previously described (29).
Data acquisition was performed with a FACSCalibur or FACSCanto II (BD
Bioscience), and data were analyzed using FlowJo software (Tree Star). Cell
sorting was done using a FACS Aria (BD Bioscience, >98% purity).
Cell Isolation and Culture. BMDCs and BMMΦ were generated as described
elsewhere (30, 31). Cells were harvested after 7 d in culture at 37 °C, 10%
CO2. NCR
−ILC3s were generated in vitro from α4β7+ precursors as described
before (14) and sorted based on CD90.2, CD117, and CD4 expression. Splenic
and small intestinal LP NCR−ILC3s were isolated from the spleen and small
intestine of adult Rag2−/− mice. The small intestine was opened longitudi-
nally, cut into pieces, incubated in 1× PBS containing 30 mM EDTA (30 min,
4 °C), washed several times in 1× PBS, and then incubated in DMEM con-
taining 0.025 mg/mL DNaseI (Roche) and 1 mg/mL Collagenase D (Roche) for
1 h at 37 °C. Every 15 min, the supernatant was collected, and tissue pieces
were washed and reincubated with medium containing DNaseI and Colla-
genase D. Cell suspension was pelleted, resuspended in 5 mL 40% Percoll (GE
Healthcare), underlayed with 3 mL 80% Percoll, and centrifuged at 20 °C and
630 × g for 30 min. Cells of the interphase were collected. Spleens were also
cut into pieces, washed in 1× PBS, and digested with DNaseI and Collagenase
D as described above. After digestion, spleen cells were washed and eryth-
rolysis was performed. Ex vivo-isolated splenic or LP NCR−ILC3s were sorted
based on the expression of CD117 and the lack of the lineage marker CD3,
CD8α, CD11c, CD19, B220, Gr-1, TCRβ, TCRγδ, NK1.1, and NKp46. CD4+ T cells
from the spleen and lymph nodes of OT-IItg mice were magnetically purified
by using CD4 beads (LTR4, Miltenyi Biotec) following the manufacturer’s
instruction. MACS-enriched CD4+ T cells were sorted to reach >98% purity
and labeled with 7.5 μM CFSE (Molecular Probes) in 1× PBS (8 min,
room temperature).
NCR−ILC3 Stimulation and Ag Presentation Assay. Sort-purified in vitro-gen-
erated NCR−ILC3s or ex vivo-isolated splenic or LP NCR−ILC3s were cultured
in a 96-well plate (Costar, Corning, Inc.) in the presence of either TLR ligands
[100 ng/mL Pam3Cys, 25 μg/mL Poly I:C, 1 μg/mL Flagellin, 1 μg/mL Imiquimod
(InvivoGen), 10 μg/mL Zymosan, 1 μg/mL lipopolysaccharide (LPS) (Sigma-
Aldrich), 1 μM CpG (Trilink Biotechnologies, ODN1826 sequence InvivoGen)],
proinflammatory cytokines [20, 100 ng/mL IL-1β (Biovision, Inc.), 20 ng/mL
IL-23 (eBioscience)], or in medium alone for 48 h. To test Ag presentation
and T-cell activation, sort-purified stimulated (20 ng/mL IL-1β, 24 h) NCR−ILC3s
were cocultured in the presence of OT-IItg CD4+ T cells and either OVA323–339
peptide (5 μg/mL, AnaSpec), OVA protein (100 μg/mL, Imject Ovalbumin,
Thermo Fisher Scientific, Inc.), or medium alone (without Ag) for 48–72 h.
Fluorescent Latex Bead Uptake. Fluorescent latex bead uptake was performed
as previously described (32) with some adaptations. Briefly, in vitro-gener-
ated or ex vivo-isolated splenic NCR−ILC3s were cultured in a 96-well plate,
and latex beads [FluoSpheres carboxylate-modified microspheres, 1 μm, red
fluorescent (580/605), Molecular Probes, Life Technologies] were added for
6 h at 37 °C, 4 °C, or 37 °C in the presence of 0.5 μM CytD (Applichem). To
compare bead uptake of BMMΦ and NCR−ILC3s, cells were harvested after
2 h or 24 h. Bead internalization was analyzed by flow cytometry. For im-
munofluorescence microscopy, in vitro-generated NCR−ILC3s were stained
with FITC-conjugated anti-CD90.2 (30-H12, 30 min at 4 °C) and HOECHST dye
(Hoechst 33342, Invitrogen, 30 min at 37 °C) after incubation with beads.
Bead uptake was monitored using a confocal laser-scanning microscope
(Zeiss LSM 510 Meta). Images were analyzed with ImageJ (W. Rasband,
National Institutes of Health, Bethesda). An adjustment of brightness and
contrast was performed.
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Adoptive Cell Transfer and Immunization. We injected 3 × 106 OT-IItg CD4+ T cells
(CFSE+) intravenously (i.v.) into WT, I-abΔILC3, and I-ab−/− recipient mice i.v. im-
munized with OVA323–339 peptide (20 μg/mL), OVA protein (100 μg/mL), and CpG
(50 μM). Forty-eight hours later,OT-IItg CD4+ T-cell proliferation was examined in
the spleen. We i.v. injected 2 × 106 OT-IItg CD4+ T cells plus CpG (25 μM) intoWT,
I-abΔILC3, and RORγ−/− mice. Mice were immunized i.p. with 100 μg alum-pre-
cipitated NP-OVA [NP (18)-OVAL, Biosearch Technologies, Inc.]. Sera were col-
lected 14 d after NP-OVA immunization.
Ab and Cytokine Detection by ELISA and Luminex Assay. To detect NP-OVA–
specific Abs in the serum of immunized mice, NUNC immunoplate Maxisorb
F96 plates (Thermo Scientifics) were coated with 5 μg/mL NP-OVA (Bio-
search Technologies, Inc.) in 1× PBS at 4 °C overnight. Sera were incubated
for 1.5 h at room temperature, and after washing [H2O 0.1% Tween-20
(AppliChem)] biotin-conjugated goat anti-mouse IgG, IgG1, IgG2a, IgG2b, or
IgG3 (Caltag Laboratories) was added, incubated for 1.5 h at room temper-
ature, and detected by alkaline-phosphatase–conjugated Steptavidin (Roche,
45 min, room temperature). Plates were developed with dinitrophenyl
phosphate (1 mg/mL, Sigma) in substrate buffer [0.1 g MgCl2 × 6 H2O
(Merck), 10 mM NaN3 (Sigma), and 10% diethanolamine (Sigma) at pH 9.8
filled up to 1 L]. The reaction was stopped with 1 M NaOH (Fluka). OD was
determined at 405 nm with an ELISA reader (ASYS Expert plus). IL-22 was
determined in the supernatant of NCR−ILC3s cultures by using mouse/rat
ELISA MAX Deluxe Set (Biolegend) according to the manufacturer’s
instructions. OD was determined at 450 nm with an ELISA reader (ASYS
Expert Plus). In addition, cytokines were quantified using a multiplex-
bead–based Luminex assay (mouse cytokine 20-plex panel, Invitrogen,
Life Technologies) according to the manufacturer’s protocol. Analysis
was performed with a Luminex 100 (LX100) analyzer (Invitrogen, Life
Technologies).
Statistical Analysis. Statistical analysis was performed using Mann–Whitney U
test, unpaired Student t test, and Wilcoxon test with Prism software (GraphPad
Software, Inc.).
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Fig. S1. Sort-purified ex vivo-isolated splenic NCR−group 3 innate lymphoid cells (ILC3s) incubated for 6 h with red fluorescent latex beads at 37 °C or 4 °C.
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Fig. S2. (A and B) Phenotype of in vitro-generated NCR−ILC3s derived from α4β7+ fetal liver (FL) precursors. Representative plots are shown. (C) Representative
histograms of RORγt, LTαβ, γc chain, CD117, α4β7, β1, ICAM1, CD69, CXCR4, CXCR5, CCR6, and CCR7 expression by CD4+ and CD4−NCR−ILC3 subsets. (D) Per-
centage of bead+ and bead− cells within CD4+ and CD4−NCR−ILC3s after 6 h incubation with beads (mean values ± SD). Data shown are representative of at
least three independent experiments (n = 3–5).
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Key points: 
1. Flt3L controls intestinal ILCs in fetal and adult mice by regulating the 
progenitor pool in the fetal liver and bone marrow. 
2. Development of ILC2s and ILC3s is independent of the presence of dendritic 
cells. 
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Abstract 
 
Fms-like tyrosine kinase 3 ligand (Flt3L) promotes survival of lymphoid progenitors 
in the bone marrow (BM) and differentiation of dendritic cells (DCs), but its role in 
regulating innate lymphoid cells (ILCs) during fetal and adult life is not understood. 
By using Flt3L knockout and transgenic mice we could demonstrate that Flt3L 
controlled ILC numbers by regulating the pool of α4β7- and α4β7+ lymphoid tissue 
inducer (LTi) cell progenitors in the fetal liver (FL) and common lymphoid 
progenitors in the BM. Deletion of flt3l severely reduced the number of FL 
progenitors and LTi cells in the neonatal intestine resulting in impaired development 
of Peyer’s patches (PPs). In the adult intestine, natural killer cells and group 2 and 3 
ILCs were severely reduced. This effect occurred independently of DCs as ILC 
numbers were normal in mice in which DCs were constitutively deleted. Finally, we 
could show that administration of recombinant Flt3L increased the number of NKp46- 
ILC3s in WT and even in Il7-/- mice, which generally have reduced numbers of ILCs. 
Taken together, Flt3L is essential for ILC and PP development by targeting lymphoid 
progenitor cells during fetal and adult life. 
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Introduction 
Innate lymphoid cells (ILCs) are a family of immune cells that participate in the early 
response to infections at mucosal surfaces.1,2 Beside their abundance in mucosa-
associated tissues like gastrointestinal tract, skin and lung,2-5 ILCs are found in 
lymphoid organs such as spleen, lymph nodes (LNs), Peyer’s patches (PPs) and 
tonsils.6,7 Recently, ILCs were categorized into three groups due to their 
transcriptional regulation of development and cytokine production.8 Group 1 ILCs 
consist of natural killer (NK) cells and ILC1s. They are characterized by the 
expression of NK1.1 and NKp46,2,9 require the transcription factor T-bet 10,11 and 
produce interferon gamma.12,13 Group 2 ILCs (ILC2) are identified by the expression 
of Sca1, CD25 and CD127.14 They depend on the transcription factors Gata3 15 and 
RORα 14,16  and produce T helper cell type 2 cytokines like interleukin (IL)-5 and IL-
13.14,17 Group 3 ILCs (ILC3s) include lymphoid tissue inducer (LTi) cells that are 
important for the development of LNs and PPs 7,18-20 and adult ILC3s. The latter are 
divided into several subsets according to their expression of CD4 and NKp46.21,22 
They depend on the expression of RAR-related orphan receptor gamma (RORγt) 20 
and produce IL-17 and/or IL-22.23-25 
Cytokines play an important role during hematopoietic development, either by 
supporting proliferation, survival or lineage commitment.26 Only few cytokines are 
described that are required for the development and maintenance of ILCs under 
steady state conditions. NK cell development depends on IL-15 but not on IL-7,27 
which instead is crucial for ILC3s 13,28-30 and ILC2s.15,17 In addition, we have shown 
that stem cell factor (SCF) 29 and thymic stromal lymphopoietin 31 are important for 
LTi cell development. During fetal development, LTi cells arise from α4β7+ CD127+ 
fetal liver (FL) progenitors.32 In adults, ILCs develop from common lymphoid 
progenitors (CLPs) in the bone marrow (BM).16,33,34 Fetal and adult ILC progenitor 
express receptors for cytokines that are important for ILC development, like the 
receptors for IL-7 (CD127) and SCF (CD117).32,35,36 Additionally, they express the 
cytokine receptor fms-like tyrosine kinase 3 (flt3 or CD135).33,37,38 Evidence for a role 
of flt3 ligand (Flt3L) for ILC development came from a study of Yang and colleges, 
who reported a diminished development of lung ILC2s after transfer of BM cells from 
flt3-/- mice into irradiated WT mice.39 Another study, however, reported normal ILC 
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numbers in the small intestine (SI) of flt3l-/- mice.40 In order to clarify the effect of 
Flt3L on ILC development, we analyzed flt3l-/- and flt3l-tg mice as well as mice 
treated with recombinant Flt3L. In addition, we compared fetal and adult ILC 
development in flt3l-/- and Il7-/- mice. We show that Flt3L controls intestinal LTi cell 
numbers in neonatal mice and ILC numbers in the SI of adult mice by regulating the 
ILC progenitor pool in FL and BM. 
 
Materials and Methods 
 
Mice 
C57BL/6 mice were obtained from Janvier. Rag2-/-Il2rg-/-,31 Il7-/-,41 flt3l-/-,42 flt3l-tg,43 
CD11c-Cre44 and R-DTA45 mice were on a C57BL/6 background. All mice were bred 
and maintained under SPF conditions according to the guidelines of the cantonal 
veterinarian office of Basel or the animal care and use committees of Lower 
Franconia, Germany. LN numbers of mice were determined by injection of 1% 
Chicago sky Blue 6B ink (Sigma-Aldrich) subcutaneously into the footpads of mice 2 
days before analysis. For Flt3L treatment mice were injected intraperitoneally (i.p.) 
for 10 days with 20µg recombinant Flt3L per day and sacrificed 1 day after the last 
treatment.  
 
Antibodies, intracellular staining, flow cytometry and cell sorting 
The following antibodies (Abs) used for flow cytometry were purchased from 
Biolegend: FITC-conjugated anti-CD3 (145-2C11), anti-CD8 (53-6.7), anti-CD11c 
(M1/70), anti-CD19 (6D5), anti-Gr-1 (RB6-8C5), anti-TCRβ (h57-597), anti-TCRγδ 
(UC7-13D5); Alexa-488 conjugated anti-CD103 (2E7); PE-conjugated anti-CD3 
(145-2C11), anti I-A (MHC II) (M5/114.15.2); PE-Cy7-conjugated anti-CD11b 
(M1/70); APC-conjugated anti-CD11c (N418), anti-CD25 (PC61); anti-CD117 (2B8), 
anti-KLRG1 (2F1/KLRG1); Alexa-647 conjugated anti-CD45.2 (104); APC-Cy7-
conjugated anti-CD4 (GK1.5) and streptavidin; Brilliant Violet 510 conjugated anti-
Thy1 (53-2.1) and anti-Sca1 (D7). The following Abs used for flow cytometry were 
purchased from eBioscience: FITC-conjugated anti-B220 (RA3-6B2), anti-NK1.1 
(PK136); PE-conjugated anti-CD135 (A2F10); PE-Cy7-conjugated anti-CD45.1 
(A20), anti-CD127 (A7R34); eFluor660-conjugated anti-NKp46 (29A1.4); 
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biotinylated anti-Sca-1 (D7). Brilliant Violet 421-conjugated anti-CD117 (2B6) was 
purchased from Biolegend or BD Biosciences. PE-conjugated anti-α4β7 (DATK32) 
was purchased from BD Biosciences. 
The lineage cocktail used for the identification of ILCs consisted of: anti-CD3, anti-
CD8, anti-CD11c, anti-CD19, anti-B220, anti-NK1.1, anti-Gr-1, anti-TCRβ and anti-
TCRγδ. For intracellular staining of RORγt and Gata3, the FoxP3 staining buffer kit 
with PE-conjugated anti-RORγt (AFKJS-9) and eFluor660-conjugated anti-Gata3 
(TWAJ) (eBioscience) was used. Cells were acquired using a FACS Canto II or LSR 
Fortessa (BD Biosciences) and analyzed with Flow Jo software (Tree star). Cell 
sorting was done using a FACS Aria II. 
 
Whole mount immunohistochemistry 
Whole mount VCAM staining of small intestines (SIs) from 1-2 day old mice was 
performed as described before.18 Briefly, after removing the serosa, intestines were 
fixed with 4% paraformaldehyde. Free aldehyde groups were quenched with 4% 
glycin in phosphate-buffered saline (PBS) and tissue was rehydrated using 50%, 70% 
and 100% methanol. Endogenous peroxidase was blocked by incubation with 30% 
H2O2 in methanol. After blocking with PBS, 1.5% skim milk, 0.1% Triton X-100 
(PBSMT), intestines were incubated with biotinylated anti-VCAM Abs (eBioscience, 
clone 429) over night at 4ºC. After extensive washing with PBSMT, intestines were 
incubated with horseradish peroxidase-conjugated streptavidin (Biolegend) for 3h at 
RT. After washing with PBS and tris-buffered saline, 3,3’-Diaminobenzidine 
substrate (Sigma) was added to visualize Ab binding.  
 
Cell isolation 
BM cells were obtained by crushing bones in a mortar. Cells from the spleen, 
mesentery and FL were obtained by gently pressing the organs between two glass 
slides. Lamina propria (LP) preparation from SI of adult mice was done as described 
before.21 Briefly, SIs were collected, PPs were removed, SIs were opened 
longitudinally, cut into 1-2cm pieces and incubated in Ca2+- and Mg2+- free PBS 
containing 30mM EDTA (Ethylenediaminetetraacetic acid) for 30 min on ice. 
Epithelial cells and intra-epithelial cells were removed by shaking vigorously and 
repeated washing of the tissue with PBS. Intestinal pieces were incubated 4 times 
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with DMEM containing 1mg/ml Collagenase D (Roche) and 0,025mg/ml DNAse I 
(Roche) for 15 min at 37ºC. After each digestion, supernatant was collected in 
DMEM, 5% FCS, 2mM EDTA. LP cells were purified using a Percoll (GE 
Healthcare) gradient at 20ºC and 1800rpm for 30min. Cells of the interphase were 
collected. 
SI from 0.5 days old mice were collected and mesenteric tissue was removed under 
the microscope. Intestines were opened longitudinally and washed with PBS by 
vigorous shaking. E15.5 intestines were collected under the microscope and 3 
intestines were pooled. For digestion of fetal and neonatal tissue, intestines were cut 
into small pieces and digested 2 times with DMEM containing 1mg/ml Collagenase D 
(Roche) and 0,025mg/ml DNAse I (Roche) for 30 min at 37ºC. Supernatant was 
collected in DMEM, 5% FCS, 2mM EDTA. 
 
Statistical analysis 
Statistical analysis was performed with GraphPad Prism 6 for Macintosh OS X. All 
data were tested for normal distribution using the Shapiro-Wilk test. If data were 
normal distributed, differences between groups were calculated using a two-tailed 
unpaired Student’s T-Test. If data were not normal distributed differences between 
groups were calculated using the Mann-Whitney-U test. Statistical significant 
differences are depicted as follows: *p<0.05, **p<0.01, ***p<0.001. 
 
Results 
 
Flt3L controls LTi cell and Peyer’s patch development  
During fetal development LTi cells arise from FL progenitors.32,35 They can be 
derived either from CD117+ CD127+ α4β7- or from CD117+ CD127+ α4β7+ 
progenitors,33,46 which were reported to express CD135.33,37 In line with this, we 
found that the majority of both α4β7- and α4β7+ Thy1- progenitors in the FL were 
CD135+ (Figure 1A). We have previously shown that IL-7 is crucial for LTi cell and 
LN development and that in addition to IL-7 other cytokines promote intestinal LTi 
cell and PP development.29,31,47 To understand the influence of Flt3L on LTi cell 
development we analyzed fetal and neonatal flt3l-/- mice. Absolute numbers of α4β7- 
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and α4β7+ progenitors were reduced in the FL of E14.5 flt3l-/- mice as compared to 
WT and Il7-/- mice (Figure 1B). PP development was significantly impaired in flt3l-/- 
mice (Figure 1C). Accordingly, we detected a 3-fold reduction of LTi cells in the SI 
of day 0.5 flt3l-/- mice (Figure 1D). It was reported that a CD11c+ lymphoid cell 
population called lymphoid tissue initiating cell (LTin) contributes to PP 
development.48 We found that the number of LTin cells (gating see Figure S1B) was 
reduced in the intestine of E15.5 flt3l-/- embryos (Figure 1E). In contrast to Il7-/- mice, 
almost all LNs were present in flt3l-/- mice (Figure 1F). Accordingly, LTi cell 
numbers in the mesenteries of 0.5 days old neonatal mice (see gating in Figure S1A) 
were slightly reduced in Il7-/- mice but normal in flt3l-/- mice (Figure 1G). Since LTi 
cells were negative for flt3 (Figure S2A), we conclude that Flt3L deficiency mainly 
affected LTi progenitors in the FL. Together, these data show that Flt3L regulates PP 
development by controlling the number of intestinal LTi and LTin cells.  
 
Flt3L controls ILC3 numbers in the lamina propria of adult mice 
To investigate the role of Flt3L for adult ILCs, we compared the number of NK cells, 
ILC2s and ILC3s (see gating in Figure S1C-E) in the SI of WT, Il7-/-, flt3l-/- and flt3l-
tg mice. As already reported, NK cell numbers were normal in the SI of Il7-/- mice, 
while ILC2s and ILC3s were reduced (Figure 2A).13,15 In contrast, loss of Flt3L led to 
a significant reduction of NK cell, ILC2 and ILC3 numbers in the SI compared to WT 
controls (Figure 2A). While ILC2 reduction was comparable in Il7-/- and flt3l-/- mice, 
ILC3 numbers were lower in flt3l-/- mice compared to Il7-/- mice (Figure 2A). 
Transgenic over-expression of Flt3L under the control of the human β-actin promoter 
led to increased numbers of NK cells, ILC2s and ILC3s (Figure 2A). To further 
characterize the influence of Flt3L on ILC3s in the SI, we analyzed the different ILC3 
subsets, namely CD4+ ILC3s, NKp46+ ILC3s and CD4- NKp46- (DN) ILC3s (gating 
see Figure S1E). In flt3l-/- mice, we detected a 4-fold reduction of DN and NKp46+ 
ILC3 and a 8-fold reduction of CD4+ ILC3 numbers compared to WT mice (Figure 
2B). CD4+ and DN ILC3 numbers were significantly lower as in Il7-/- mice. In flt3l-tg 
mice CD4+ ILC3s were 20-fold, DN ILC3s were 16-fold and NKp46+ ILC3s were 9-
fold increased as compared to WT controls. Together, these data show that Flt3L 
controls the number of ILCs in the adult gut, preferentially targeting CD4+ and DN 
ILC3s.  
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Administration of recombinant Flt3L increases ILC numbers in WT and Il7-/- 
mice 
The results obtained from flt3l-tg mice prompted us to ask whether the treatment of 
adult mice with recombinant Flt3L could increase SI ILC numbers in WT mice and 
restore SI ILCs in Il7-/- and flt3l-/- mice. Therefore, we injected recombinant Flt3L 
over a period of 10 days into adult mice. As a control, we determined the number of 
CD11c+ DCs that are known to expand during Flt3L administration.49 DCs in the SI 
were highly increased after Flt3L treatment in all three strains (Figure 3A). In WT 
mice, the number of NK cells and ILC2s was significantly higher in Flt3L-treated 
mice compared to PBS-treated controls (Figure 3B). Amongst ILC3s, the CD4+ and 
DN subsets were mainly responding to Flt3L treatment in WT mice (Figure 3C), 
confirming our previous data. In Il7-/- mice, NK cells and ILC3s expanded upon Flt3L 
treatment while ILC2s were not changed in numbers (Figure 3B-C). Flt3L treatment 
was unable to expand the number of NK cells, ILC2s and ILC3 in flt3l-/- mice (Figure 
3B-C). These data show that short-term administration of Flt3L increases the number 
of several ILCs in the SI of WT and Il7-/- mice. However, ILC numbers could not be 
restored in flt3l-/- mice.  
 
CD103+ DCs are not required for ILC development 
Flt3L is an important cytokine for the development of DCs.42,50 In the intestine, three 
subsets of DCs can be discriminated by their expression of CD103 and CD11b.51 
CD103+ DCs were described to be responsive to Flt3L.51 Indeed, CD11chigh DCs, 
which contain mainly CD103+ DCs, were dramatically reduced in the SI of flt3l-/- 
mice, while numbers of CD11clow cell including CD103- DCs and monocytes were 
comparable to WT mice (Figure 4A-B). Recently, it has been reported that CX3CR1+ 
DCs can regulate ILC3 numbers in the SI.52 To investigate whether the effect of Flt3L 
on ILCs was indirectly mediated by DCs, we analyzed mice in which DCs were 
constitutively ablated by crossing CD11c-Cre mice with mice expressing Diphtheria 
toxin A (DTA) under the control of a loxP flanked stop cassette in the Rosa26 locus 
(R-DTA). The resulting CD11c-Cre/R-DTA (ΔDC) mice 53 lack more than 90% of 
conventional DCs including myeloid, lymphoid and plasmacytoid DCs in thymus, 
spleen and LNs.53 In the SI, ΔDC mice showed a severe reduction of CD11chigh DCs 
with an almost complete absence of CD103+ DCs (Figure 4C-D).  In contrast, 
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CD11clow macrophages (MΦ) showed a moderate reduction (Figure 4C-D). Despite 
the notion that ΔDC mice and flt3l-/- mice had reduced DC numbers in the SI, ΔDC 
mice had normal numbers of PPs (Figure 4E) suggesting that CD103+ DCs are not 
required for LTi cell development. While NK cell numbers were normal in the SI of 
ΔDC mice, ILC2 numbers were increased (Figure 4F). Analysis of the different ILC3 
subsets revealed that the number of NKp46+ ILC3s but not CD4+ or DN ILC3s was 
elevated (Figure 4G). Thus, we could show that ILCs in the SI were not dependent on 
CD103+ DCs.  
 
Flt3L affects CLP numbers but not their differentiation into ILC3s 
Since we neither found Flt3 protein nor transcript expression in ILC2s or ILC3s 
(Figure S2B-C), we focused on ILC progenitors in the BM. Therefore, we analyzed 
the number of CLPs and immature ILC2s (iILC2s) in the BM, which are progenitors 
for all ILCs and for ILC2s, respectively.15,33 Previous studies have shown that CLP 
numbers are reduced in flt3l-/- mice.54 In line with this, we found a 4.5-fold reduction 
of CLPs in the BM of flt3l-/- mice while CLP numbers were normal in the BM of Il7-/- 
mice as compared to WT controls (Figure 5A). In contrast to CLPs, iILC2s were only 
reduces 2-fold in flt3l-/- mice (Figure 5B), while Il7-/- mice showed a severe loss of 
these cells. 
Although CLP numbers are reduced in flt3l-/- mice, not all CLP-derived lymphocytes 
were affected to the same degree in the periphery. In the spleen, NK cells were 
severely reduced, while B cells were only diminished 2-fold and T-cells did not differ 
from WT numbers (Figure 5C). In the SI no difference in IgM+ B cell and T cell 
numbers was detectable in WT and flt3l-/- mice (Figure 5D). This prompted us to ask 
whether the loss of Flt3L might impair the ability of CLPs to generate ILCs. 
Therefore, we adoptively transferred FACS sorted Lin
-
 CD117low CD127+ Sca1low 
CD135+ CLPs (gating see Figure S1F) from WT mice (CD45.1) and from flt3l-/- mice 
(CD45.2) in a 1:1 ratio into Rag2-/-Il2rg-/- mice (CD45.2). As controls, we 
reconstituted Rag2-/-Il2rg-/- mice with CD45.1 and CD45.2 WT CLPs and analyzed the 
mice 6 weeks later. The frequency of ILC3s derived from WT and flt3l-/- CLPs was 
comparable (Figure 5E-F) indicating that flt3l-/- CLPs had no intrinsic defect in ILC 
lineage commitment. 
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Discussion 
Flt3L plays an essential role in survival of lymphoid progenitors in the BM 54 and 
differentiation of DCs.42,50 In this study we show that Flt3L is important to control 
ILC numbers in the SI during fetal and adult life and the ILC progenitor pool in the 
FL and BM. 
During fetal development, LTi cells are crucial for the development of LNs and PPs. 
Both organs are differently regulated by cytokines such as IL-7, SCF and tumor 
necrosis factor-family members like receptor activator of NFκB ligand 
(RANKL).29,55-57 Our data demonstrate that in the absence of Flt3L, PP development 
was impaired while LN development was normal. This was reflected by normal LTi 
cell numbers in the mesenteries and highly reduced LTi cell numbers in the SI of 
neonatal mice. In addition, the reduced number of LTin cells in flt3l-/- mice probably 
contributed to the almost complete abrogation of PP development. Since FL 
progenitors expressed CD135 and were severely reduced in flt3l-/- mice, Flt3L 
controls the size of the fetal ILC progenitor pool. Why Flt3L is dispensable for LN 
anlagen remains to be investigated. 
In the adult system, we could show that Flt3L controls the number of NK cells, ILC2s 
and ILC3s. A former study by Kinnebrew and colleges postulated that ILCs are not 
diminished in flt3l-/- mice.40 In their study the frequency of CD3- CD4- Thy1+ cells 
amongst CD45+ cells was equal in WT and flt3l-/- mice. Since a change in the number 
of other cell types influences the frequency of the analyzed population, it is possible 
that the loss of DCs led to normal ILCs frequencies in flt3l-/- mice although total cell 
numbers may be reduced.  In contrast, we determined the absolute number of the 
different ILC groups in flt3l-/- mice. We observed a significant reduction of NK cells 
in the SI of flt3l-/- mice. This is in line with the observation of reduced NK cell 
numbers in the spleen of flt3l-/- mice.42 ILC2s were reduced in the SI of adult flt3l-/- 
mice, which is in agreement with previous data showing that Flt3L is important for 
ILC2 development.39 CD4+ and DN ILC3s were mainly affected by the loss of Flt3L. 
This was also obvious in flt3l-tg mice as well as in WT and Il7-/- mice treated with 
recombinant Flt3L, in which the CD4+ and DN ILC3s were the main ILC3 subsets 
responding to Flt3L.  
Administration of recombinant Flt3L was previously shown to increases the number 
of DCs.49 In addition, NK cells and regulatory T cells were reported to expand after 
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Flt3L treatment.58-62 The increase of these two cell types was shown to be a result of 
the Flt3L-driven expansion of DCs and their secretion of IL-2 and IL-15. 59-62 As the 
expansion of DCs could be responsible for the increase of ILC2s and ILC3s after 
Flt3L treatment we analyzed ΔDC mice, which mainly lack the Flt3L-responsive 
CD103+ DCs in the SI. ILC numbers were normal or even increased in ΔDC mice, 
strongly arguing against the hypothesis that ILC expansion is driven by DCs. The 
inability of Flt3L treatment to increase ILCs in flt3l-/- mice, albeit increasing DC 
numbers, also supports our conclusion. It was recently shown that the number of 
NKp46+ ILC3s depends on CX3CR1+ cells, which contain CD103- DCs and resident 
MΦ.52 In ΔDC mice, NKp46+ ILC3s were even increased, which might be explained 
by the relative enrichment of CD11clow CD103- MΦ.  
As ILCs are negative for CD135, the effect of Flt3L on ILC numbers was most likely 
mediated by regulating the CD135+ progenitor pool (CLPs) of ILCs in the BM. In 
agreement with this hypothesis, we found a strong reduction of CLP numbers in flt3l-/- 
mice, which was comparable to the reduction of ILC3s in the SI (Figure 2A and 5A). 
The reduction of ILC2s and iILC2s was less severe in the absence of Flt3L (Figure 
2A and 5F) probably because other cytokines such as IL-7 can rescue ILC2 
development. The important role of IL-7 for ILC2 development is also reflected by 
the finding that Flt3L treatment did not increase ILC2 numbers in Il7-/- mice. 
Despite reduced CLP numbers in flt3l-/- mice, competitive transfer experiments 
showed that CLPs from flt3l-/- mice have the same ability as WT CLP to give rise to 
ILC3s if transferred at the same number into Flt3L-sufficient hosts. Considering the 
clear dependence of CLP numbers on Flt3L, the unequal number of CLPs in WT and 
in flt3l-/- mice might explain why Flt3L-treatment in flt3l-/- mice was not able to 
increase ILC numbers as seen in WT mice. Thus, it is likely that an extended 
treatment with recombinant Flt3L can compensate for low CLP numbers and can 
increase ILC numbers in flt3l-/- mice. In addition, we cannot exclude that flt3l-/- mice 
mounted an immune response against the recombinant protein, which led to the 
neutralization and subsequently lower abundance of Flt3L.  
Taken together, our study demonstrates that the presence of Flt3L is important to 
generate ILCs during fetal development as well as during adult life. Our data offer the 
possibility to use Flt3L as therapeutic approach for restoring intestinal ILCs in 
patients with severe combined immunodeficiency and for immune protection of 
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mucosal surfaces. Since Flt3L treatment is already approved for treatment of cancer 
patients 63 beneficial effects of this cytokine for mucosal immunity could be tested in 
human trials. 
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Figure legends 
 
Figure 1. Flt3L controls Peyer’s patch development. (A-B) Analysis of α4β7- and 
α4β7+ progenitors in the fetal liver (FL) of E14.5 embryos. (A) Surface expression of 
flt3 (CD135) on WT cells (black), grey shaded: unstained. (B) Number of progenitors 
(n=10-12). (C) Analysis of PP anlagen in the SI of 0.5 days old mice by VCAM-1 
whole mount staining. left: Representative pictures. VCAM+ spots are indicated by 
arrows. Right: Quantification of PP anlagen. (D) LTi cell number in the SI of 0.5 days 
old mice (n=14-16). (E) LTin cell numbers in the gut of E15.5 embryos (n=6). (F) 
Presence of lymph nodes (LN) in adult Il7-/- and flt3l-/- mice compared to WT set as 
100% (n=6-8). (G) LTi cell number in the mesenteric region of 0.5 days old mice 
(n=17-28). *P < .05; ** P < .01; *** P < .001 
 
Figure 2. Flt3L controls ILC numbers in the intestine. (A-B) Number of NK cells, 
ILC2s and ILC3s (A) as well as ILC3 subsets (B) in the SI of indicated mice. DN: 
CD4- NKp46- (double negative) (n=6-18). Bars show the mean with SEM. *P < .05; 
** P < .01; *** P < .001 
  
Figure 3. Flt3L treatment increases ILC numbers in the adult intestine. Mice 
were treated with 20µg recombinant Flt3L for 10 days (grey bars). Controls were 
injected with PBS (white bars). Numbers of CD11chigh DCs (A), NK cells and ILC2s 
(B) as well as ILC3 subsets (C) in the SI are shown (n=5-6). Bars show the mean with 
SEM. *P < .05; ** P < .01; *** P < .001 
 
Figure 4. Loss of DCs does not reduce ILCs in the intestine. (A-D) Analysis of 
macrophages (MΦ) and DC subsets in the SI of adult mice. (A and C) Representative 
FACS plots of MΦ and DC subsets in WT and flt3l-/- mice (A) and ΔDC mice with 
littermate controls (litters) (C). (B and D) Number of CD11chigh DCs and CD11clow 
MΦ in WT and flt3l-/- mice (n=6) (B) and in ΔDC mice and litters (n=4-8) (D). (E) 
Number of PPs in adult ΔDC mice and litters. Lines show the mean. (F-G) Number of 
NK cells, ILC2 (F) and ILC3 subsets (G) in the SI of ΔDC mice and litters (n=4-8). 
Bars show the mean with SEM. *P < .05; ** P < .01 
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Figure 5. Flt3L affects CLP numbers but not their differentiation into ILC3s. (A) 
Number of CD135+ CLP per 1 Mio. lineage- (Lin-) BM cells (n=6-8). (B) Number of 
iILC2s per 1 Mio. Lin- BM cells (n=6-8). (C) Number of NK cells, CD19+ B cells and 
CD3+ T cells in the spleen (n=6). (D) Number of CD19+ IgM+ B cells and CD3+ T 
cells in the SI (n=6-12). (E-F) Rag2-/- Il2rg-/- mice were injected with a 1:1 mixture of 
Ly5.1 WT CLPs and Ly5.2 Flt3l-/- (n=8) or Ly5.2 WT CLPs (n=4). Frequency of 
CD45.1+ and CD45.2+ ILC3s (lineage- Thy1+ RORγt+) in the SI was analyzed 6 
weeks later. Representative FACS plots (E) and pie charts for all mice (F) are shown. 
Bars and pie charts show the mean with SEM. *P < .05; ** P < .01; *** P < .001 
 
Supplementary figure legends 
 
Figure S1. Gating strategies. Gating strategy for: (A) LTi cells from the mesentery 
of 0.5 days old mice. (B) LTin cells in the gut of E15.5 embryos. (C-E) NK cells (C), 
ILC2s (D) and ILC3s with their subsets (E) in the SI of adult mice. (F-G) CLPs (F) 
and iILC2s (G) in the BM.  
 
Figure S2. CD135 expression on ILCs. (A) CD135 expression on LTi cells (CD117+ 
CD3- Thy1+ CD127+) in the mesentery of 0.5 days old mice (gray). As control 
CD117+ CD3- Thy1- cells were used (black). Light grey: unstained. CD135+ cells are 
marked with an arrow. (B) CD135 expression on lineage- CD117+ KLRG1+ RORγt- 
ILC2s (light gray) and lineage- CD117+ KLRG1- RORγt+ ILC3s (dark gray) from the 
SI of WT mice in comparison to lineage+ CD117+ DCs (black). (C) qRT-PCR of flt3 
transcripts in FACS sorted ILC3s from the SI of WT mice compared to WT 
splenocytes. Bars show characteristic data from 1 of 2 independent experiments. 
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